Some aspects of the metabolism and disposition of tiquinamide in several animal species. by Pierce, David M.
SOME ASPECTS OF THE METABOLISM AND DISPOSITION 
OF TIQUINAMIDE 'IN SEVERAL ANIMAL SPECIES
Being a Thesis Presented for the Award 
of a Degree of Doctor of Philosophy in 
the University of Surrey 
4 by
David M. Pierce, B.Sc.
Wyeth Laboratories 
Taplow 
Maidenhead 
Berkshire August
ProQuest Number: 10804366
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 10804366
Published by ProQuest LLC(2018). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
CONTENTS
ABSTRACT OF THESIS 
ACKNOWLEDGEMENTS 
CHAPTER I: INTRODUCTION
Section 1: Peptic ulcer disease'and its treatment:
The history and general background to peptic 
ulcer disease.
A brief summary of gastric physiology relevant 
to peptic ulcer disease.
The etiology of peptic ulcer disease.
Drug treatment of peptic ulcer.
Section 2: An introduction to tiquinamide:
The sequence of events leading,to the 
development of tiquinamide.
The gastric anti-secretory and anti-ulcer 
pharmacology of tiquinamide.
Mechanism of anti-secretory activity of tiquinamide 
Other pharmacological properties of tiquinamide 
Some chemical properties of tiquinamide.
Potential consequences of the physical chemistry 
of tiquinamide for its absorption, distribution 
and excretion.
Potential routes of metabolism of tiquinamide. 
Section 3 ‘ Objectives of the present study:
Some aspects of the metabolism and disposition 
of tiquinamide potentially relevant to its 
development as a gastric anti-secretory agent. 
CHAPTER II: MATERIALS AND METHODS 
MATERIALS: Chemicals
Thin-layer chromatography: plates and
solvents
Animals
CHAPTER II (contd) Page
METHODS: Drug administration ^2
Sample collection ^2
Sample preparation ^3
Determination of radioactivity ^5
Yvhole body autoradiography ^7
Pharmacokinetic analysis ^7
CHAPTER III: ABSORPTION OF TIQUINAMIDE IN THE PATAS MONKEY ^9 
Summary of chapter ^ a
Introduction 50
Materials and Methods 52
Experimental 53
(a) Absorption of tiquinamide in anaesthetized, 53
pylorus-ligated and sham-operated patas monkeys
(b) Gastric absorption of tiquinamide in conscious 53
0
patas monkeys
(c) Effect of tiquinamide on gastric emptying in 55
conscious patas monkeys
Results 5&
(a) Absorption of tiquinamide in anaesthetized 5^
pylorus-ligated and sham-operated patas monkeys
(b) Gastric absorption of tiquinamide in conscious 
patas monkeys
(c) Effect of tiquinamide on gastric emptying in 
conscious patas monkeys
Discussion
CHAPTER IV: METABOLISM OF TIQUINAMIDE IN THE RAT
Summary of chapter
Introduction
Experimental
(a) The chromatographic pattern of drug-related 
products in urine .
(b) The stability of the thioamide group under the 
conditions of urine collection and determination 
of the chromatographic pattern
(c) Hydrolysis of conjugated material
(d) Isolation of drug-?related products from urine
57
58
60
70
71
72
73 
73
CHAPTER IV (contd)
(e) Characterization of urinary end-products
(f) The chromatographic pattern of drug-related
products in bile
Results
(a) The chromatographic pattern of drug-related 
products in urine
(b) The stability of the thioamide group under 
the conditions of urine collection and 
determination of the chromatographic pattern
(c) Hydrolysis of conjugated material
(d) Characterization of urinary end-products
(e) The chromatographic pattern of drug-related
products in bile
Discussion
CHAPTER V: METABOLISM OF TIQUINAMIDE IN THE .PATAS MONKEY
Summary of chapter
Introduction
Experimental
(a) The chromatographic pattern of drug-related 
products in urine
(b) The stability of the thioamide group under 
the conditions of urine collection and 
determination of the chromatographic pattern
(c) Hydrolysis of conjugated material
(d) Isolation of drug-related products from urine
(e) Characterization of urinary end-products 
..Results
(a) Chromatographic pattern of drug-related 
products in urine
(b) The stability of the thioamide group under 
the conditions of urine collection arid 
determination of the chromatographic pattern
(c) Hydrolysis of conjugated material
(d) Characterisation of urinary end-products
Discussion
Page
77
77
78 
78
78
79
79
84-
85- 
110 
111 
112 
113 
113
113
114
115
116
117
117
118
118
121
CHAPTER VI: METABOLISM OF TIQUINAMIDE IN MAN iff2"
Summary of chapter 138
Introduction 139
Experimental 1^0
(a) Chromatographic pattern of drug-related products 1^ +0
in urine
(b) Comparative t.leC. of ether-soluble acidic 1^0 
compounds with those in rat urine
(c) Hydrolysis of conjugated material 1^0
Results 1^2
(a) Chromatographic pattern of drug-related products 1^2 
in urine
(b) Comparative t.l.c. of ether-soluble acidic 1^2 
compounds v/ith those in rat urine
(c) Hydrolysis of conjugated material 1^2
Discussion * 1^3
CHAPTER VII: PLASMA KINETICS OF TIQUINAMIDE AND ITS 150
METABOLITES IN RAT, PATAS MONKEY AND MAN
Summary of chapter 151
Introduction 152
Experimental 153
(a) Plasma kinetics 153
(b) Plasma protein-binding 15**
(c) Characterization of drug-related products in ^55 
25 h rat plasma
(d) Partition coefficients of tiquinamide between -^5& 
toluene and pH 7«*+ phosphate buffer
Results 157
(a) Plasma kinetics 157
(b) Plasma protein-binding IPO
(c) Characterization of drug-related products in l6l 
25 h rat plasma
(d) Partition coefficients of tiquinamide between 1°1 
toluene and pH 7»** phosphate buffer
Discussion , -1&2.
CHAPTER VIII: TISSUE DISTRIBUTION OF TIQUINAMIDE AND ITS 185
METABOLITES IN RAT AND PATAS MONKEY
Summary of chapter
Introduction
Experimental
187
188 
l89
CHAPTER VIII (contd) Page
(a) Tissue excision 'studies 189
(b) Whole body autoradiography 189
(c) The accumulation of drug-related products in 189
rat stomach wall and contents
(a) The elimination of drug-related products from 190
rat plasma and stomach wall over a 0-21 'day 
period
Results 191
(a) Tissue excision studies 191
(b) Whole body autoradiography 192
(c) The accumulation of drug-related products in 193
rat stomach wall and contents
(d) The elimination of drug-related products from 193
rat plasma and stomach wall over a 0-21 day
period
Discussion 195
CHAPTER IX: EXCRETION OF TIQUINAMIDE AND ITS METABOLITES 207 
IN RAT, PATAS MONKEY AND MAN_______
Summary of chapter 208
Introduction - 209
Experimental 210
(a) Excretion kineticsin rats 210
(b) Excretion kinetics in patas monkeys 210
(c) Excretion kinetics in man 211
Results 212
(a) Excretion kinetics in rats 212
(b) Excretion kinetics in patas monkeys 213
(c) Excretion kinetics in man 21^ +
Discussion 213
CHAPTER X: DISCUSSION 22A
References 237
ABSTRACT
Tiquinamide, 5 * 6,7,8-tetrahydro-3-methylquinoline-8-
thiocarboxamide, is a novel tetrahydroquinoline structure with 
gastric anti-secretory properties. This thesis describes its 
metabolism and disposition in rat, patas monkey and man.
Gastric absorption was found in anaesthetized, pylorus- 
ligated patas monkeys, but occurred inconsistently in conscious 
animals studied by a novel mixed isotope method. Tiquinamide 
did not significantly alter the rate of gastric emptying in the 
patas monkey.
Metabolic studies in the rat, patas monkey and man revealed 
that w-oxidation of the 3-methyl group to the corresponding 
-carboxylic acid was a common pathway in all three species, as was 
all.ylic hydroxylation resulting in a 5-kydroxylated product which 
was subsequently conjugated with glucuronic acid. Desulphuration 
of the thioamide group to the nitrile occurred by chemical/ 
metabolic means. Aromatization of the saturated ring occurred in 
the rat and man, but not in the patas monkey. Some quantitative 
species differences were also found.
Plasma kinetic studies revealed that tiquinamide was rapidly 
absorbed and eliminated. However, metabolites were more quickly 
excreted in patas monkey and man than in the rat. An unidentified 
metabolite constituted the outstanding component in rsft plasma 
during the slow elimination phase.
Tissue distribution studies revealed no major depots from 
which slow delivery could have occurred. However, tissue uptake 
and gastric re-cycling, resulting in high stomach -concentrations, 
may have been factors contributing to slow elimination in the rat.
Rapid urinary excretion occurred in patas monkey and man, 
whereas a slower phase predominated in the rat. The difference 
was attributed to the more extensive formation of water-soluble 
3-carboxylic acids and glucuronides in the former species. Faecal 
excretion was extensive only in the rat. No evidence of entero- 
hepatic circulation was observed.
Factors contributing to the species difference in elimination 
are reviewed. The significance of the metabolism and disposition 
of tiquinamide for its development as ananti-secretory agent is 
discussed.
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SECTION Is PEPTIC ULCER DISEASE AND ITS TREATMENT
TEE HISTORY AND GENERAL BACKGROUND TO PEPTIC ULCER DISEASE 
The existence of peptic ulcer disease has been known since the 
earliest period of medical history. It was known to Hippocrates 
as long, ago as 4-00 B.C. and engravings on the pillars of the temple 
of Aesculpus, dating back to the end of the 4th century B.C. describe 
some complications of gastric ulcer. The first comprehensive 
dissertation on gastric ulceration was by Aetius in the 6th century A.D. 
Duodenal ulcer, however, was not discovered until much later, being 
first suggested by Muralt in 1688. (Smith and Rivers, 1953)*
In more recent times, it has come to be one of the major 
afflictions of populations worldwide. For example, at least 1 in 10 
Americans is afflicted with the disease during a lifetime (Grossman, 
Isenberg and Walsh, 1975)* Each year in the United States 
yk million people develop the disease (Thompson, 1972)^ In the 
United Kingdom according to statistics of the DHSS, published in 
1970, the number of gastric ulcer. patients annually was 4-0,000, 
duodenal ulcer patients 175*000 and patients with peptic ulcers of 
indeterminate site 115,000.
Thus there is clearly a great need in clinical practice for 
drugs which make effective contributions to the treatment of peptic 
ulcer disease.
A BRIEF SUMMARY OF GASTRIC PHYSIOLOGY RELEVANT TO PEPTIC ULCER DISEASE 
The chemical function of the stomach is to perform the first
t
stage of proteolysis. To this end, the gastric mucosa, the 
epithelial layer lining the innermost surface of the stomach wall, 
contains specialized glands. These secrete the proteolytic enzyme 
precursor pepsinogen, the hydrochloric acid which releases active 
pepsin in situ in the stomach lumen, and the mucus which forms a 
layer over the inner surface of the gastric epithelium, protecting 
it against the proteolytic action of its own secretions. Cardiac 
glands in the regions near the oesophageal orifice and pyloric 
glands covering a transitional zone above the pyloric region 
contain chiefly cardiac mucous cells and argentaffin cells. They 
secrete mainly mucus as well as the hormone gastrin. Oxyntic 
glands which occur widely in the mucosa of the body of the stomach, 
excluding cardiac and pyloric regions, contain mucous cells,
mucous neck cells and some argentaffin cells, but are characterized 
by the specific secretory cells, the oxyntic or parietal cells and 
chief cells, which secrete respectively, hydrochloric acid and 
pepsinogen.
The secretion of acid and pepsinogen in the stomach is primarily 
under the control of the vagal nerve and the hormone gastrin. The 
vagal nerve, through release of the neurotransmitter acetylcholine, 
acts directly on oxyntic glands to stimulate secretion of both acid 
by parietal cells and pepsinogen by chief cells. ' It also acts on 
t'he pyloric glands to induce release of gastrin, which, on reaching 
oxyntic glands via the bloodstream, stimulates secretion of acid 
and pepsinogen. The vagal nerve not only stimulates the secretion 
of acid and pepsinogen directly, but also sensitizes the oxyntic 
glands to the action of gastrin (Emas, 1973). Thus the effect of 
gastrin is enhanced 2-8 fold in the presence of sub-threshold 
parasympathomimetic stimuli (Davenport, 1966). Histamine is also 
known to stimulate acid secretion. Although the original view of 
histamine as the mediator of the effects of acetylcholine and gastrin 
is no longer accepted (Johnson, 1972), it is believed that all 
three of these chemostimulants act directly on the parietal cell 
to stimulate acid secretion and that their receptors may be mutually 
interactive (Grossman, Isenberg and Walsh, 1975; Debas, 1977).
THE ETIOLOGY OF PEPTIC ULCER DISEASE
The precise mechanism of peptic ulceration is poorly understood. 
The disease has been conceived of as the result of a conflict 
between the aggressive and defensive factors vital to peptic 
digestion (Shay^ 1959; Wise, 1972). Optimal functioning of the 
stomach in peptic digestion involves the secretion of acid and 
pepsin into the gastric lumen in sufficient concentrations to bring 
about proteolysis of food without damage to the proteinaceous 
gastrointestinal epithelium. Factors which contribute to the 
secretion of acid and pepsin are termed aggressive factors whereas 
those which increase the protection of the mucosa against 
proteolysis are termed defensive factors. Aggressive factors 
which have been discussed as pertinent to ulcerogenesis include 
vagal overreactivity, excessive gastrin or histamine secretion, 
disturbed gastric emptying, bile.salt reflux and reduced mucosal
blood flow. Defensive factors include reduction in the amount 
or proteolytic resistence of secreted mucus or poor disposal of 
acid in the duodenum as a result of reduced bicarbonate secretion. 
However, one of the few sure facts to have emerged is that the 
presence of hydrochloric acid is essential for ulcer formation 
(Grossman et al., 1976). Pepsin secretion is apparently closely 
linked to that of gastric acid, and its role in promotion of ulcers 
is probably secondary to that of acid (Ivey, 1974; Grossman et al.,
1976). Other possible etiological factors in gastric and duodenal 
ulcer have been discussed in various reviews of the subject 
(Rovelstad, 1976; Grossman, Isenberg and Walsh, 1975; Skillman, 
1974; Blum, Peter and Krejs, 1975).
DRUG TREATMENT OF PEPTIC ULCER
Drug treatment of peptic ulcer disease relies principally 
on the neutralization of acid stomach contents by antacids and 
inhibition of acid secretion by anticholinergic drugs or 
histamine Hp-receptdr antagonists. Sedatives and tranquillizers 
are quite commonly prescribed as an additional part of drug therapy 
in order to reduce anxiety which may be a predisposing factor to 
the peptic ulcer.
Antacids
The use of antacids to neutralize gastric acid' both relieves 
pain and produces an environment conducive to ulcer-healing. In 
addition to reducing the stimulus of acid itself to ulcer formation 
this treatment reduces the conversion of the enzyme precursor 
pepsinogen to active pepsin, which occurs only at pH<4.5. The 
simplest antacid is sodium bicarbonate. However, because it is 
rapidly emptied from the stomach and readily absorbed, massive 
doses of the order of 60-140 g dissolved in 3 litres of milk are 
necessary to maintain pH 7*4 for 24 h (MUller-Wieland and 
Ossenberg, 1971). Furthermore, its absorption results in alkalosis 
and liberated <20^  may result in increased pain and even perforation 
(Thompson, 1972).
The most potent antacids are compounds of magnesium and 
calcium. The use of magnesium oxide, hydroxide or trisilicate 
is limited by excessive magnesium absorption (Thompson, 1972).
Calcium carbonate may form concretions in the bowels resulting in 
constipation and nausea (Mttller-Wieland and Ossenberg, 1971).
Aluminium hydroxide delays gastric emptying, resulting in 
constipation. Also, aluminium chloride formed as a result of 
acid neutralization may irritate the gastrointestinal tract 
(MUller-Wieland and Ossenberg, 1971)* It can also interfere with 
absorption of amino-acids, phosphates, glucose and ascorbic acid.
Some preparations combine a magnesium-based antacid with one based 
on aluminium or calcium so as to maintain an acceptable frequency 
of bowel movement.
Anti-secretory drugs
Anticholinergics: Anticholinergic drugs are natural or
synthetic derivatives of atropine, an alkaloid found as a constituent 
of deadly nightshade, (A'tropa belladonna). These compounds act 
on the parasympathetic nervous system by attachment to the post­
ganglionic receptor and subsequent prevention of access to this 
site by acetylcholine. Apart from inhibiting acid secretion and 
reducing gastric emptying rate in a manner analagous to that 
effected by vagotomy, they also block the effect of the vagus on 
the cardiovascular system, reduce the flow of saliva and of 
secretions of mucous membrane in the mouth, nose, pharynx and 
bronchi, paralyse accommodation of the eye, reduce sweating and 
relax smooth muscle in the bronchi and bronchicULes and in the 
ureters and bladder (Bowman, Rand and West, 1968). Because of 
their non-specific mode of action, side-effects of anticholinergic 
drugs often associated with doses sufficiently high to inhibit 
acid secretion include dryness of mouth and nose, dryness of skin 
and flushing, mydriasis, tachycardia and reduction of smooth- 
muscle tone leading to urinary retention and constipation 
(Sodeman, Augur and Pollard, 1969). Thus the usefulness of 
anticholinergic drugs in the treatment of peptic ulcer is 
controversial. At best, when combined with.a suitable antacid, 
they can help maintain neutralization of gastric acid in those 
patients able* to tolerate the side effects.
Histamine ^-Receptor Antagonists: Histamine H2~receptor
antagonists represent a new class of drugs which has made a major 
contribution to the control of peptic ulcer disease. Their 
invention followed the discovery of two stable conformations for
the histamine molecule, having inter-nitrogen distances 4.55 and 
3.6 A° (Kier, 1968) and the suggestion of two receptors, and 
H2- respectively, corresponding to each of the conformations 
(Ash and Schild, 1966). Conventional anti-histamine drugs, 
which did not inhibit acid secretion, had inter-nitrogen distances 
corresponding to a role as H^-receptor antagonists. Since histamine 
was known to stimulate gastric acid secretion, it seemed logical 
to suppose that the reason why known anti-histamines had no effect 
on this process was that the receptor .involved was the Eg-receptor. 
The first Hg-receptor antagonist was burimamide, (Black et al., 
1972). This was followed by the more potent metiamide 
(Black et al., 1973)» which was eventually rejected on the grounds 
that some patients developed a reversible granulocytopenia 
(Forrest et al., 1975)* Since the cause of the toxicity was 
believed to lie in the thioureido group, this was replaced by a 
cyanoguanidine moiety to give cimetidine (Brimblecombe et al.,
1975) which had no toxic effects on bone-marrow (Brimblecombe 
and Duncan, 1977)•
Cimetidine is a very effective inhibitor of both basal and 
meal-stimulated acid secretion (Spence, Celestin and McCormick,
1977; Barbezat. and Bank, 1977; Pounder et al., 1977; Richardson, 
Walsh and Hicks, 1976; Pounder et al., 1976). It has also been 
shown to be extremely effective in healing both gastric ulcers 
(Ciclitira et al., 1977; Bader et al., 1977) and duodenal ulcers 
(Bodemar, Norlander and Walan, 1977; Peter et al., 1977)*
Since the introduction of cimetidine into clinical practice 
in 1977, adverse effects reported have included induction of 
mental confusion in the elderly (Wood, Isaacson and Hibbs, 1978; 
Flind and Rowley-Jones, 1979)V  anti-androgenic activity 
(Winters, Banks and Loriaux, 1979) which may result in 
gynaecomastia (Sharpe and Hawkins, 1977)1 inhibition of vitamin 
B12 absorption (Steinberg, King and Toskes, 1978) and possible 
interference with immune response as a result of antagonism H^- 
receptors in T-lymphocytes (Avella et al., 1978). The clinical 
limitations of these and other adverse effects will only be 
appreciated as the drug continues to be evaluated in clinical 
practice.
The successful introduction of cimetidine has led to the 
search for other EL^-receptor antagonists and several similar 
compounds are now in the later stages of development e.g. 
ranitidine, a compound four times as potent as cimetidine against 
pentagastrin-stimulated acid secretion (Domschke, Lux and 
Domschke, 1979)*
Sedatives and tranquillizers: Sedatives (e.g. phenobarbitone,
secbutobarbitone) or tranquillizers (e.g. thioprazate, 
chlordiazepoxide) are prescribed to reduce insomnia and anxiety 
and so ameliorate predisposing factors. The argument that stress 
causes increased acid secretion which leads to ulcer development 
might imply that a tranquillizer alone could bring about ulcer- 
healing by reducing acid secretion. However, there is no evidence 
to support this case (Thompson, 1972)•
Ulcer-healing drugs: Very few drugs are known which actively
promote ulcer-healing rather than inhibiting acid secretion. 
Carbenoxolone sodium apparently improved the rate of gastric 
ulcer-healing in ambulatory patients to the same extent that 
hospitalization would, but did not improve the rate of healing 
in hospitalized patients (Davis, 1976). Its effectiveness in 
treatment of duodenal ulcer is sfcill somewhat controversial.
However, the enteric-coated formulation, Duogastrone, which 
releases the drug only in the small intestine, has been shown 
to be highly effective in healing duodenal ulcers by a recent 
double-blind controlled trial against placebo (Davies and Reed,
1977).
Carbenoxolone sodium has side-effects of an aldosterone-like 
nature on salt and water retention (Khan and Sullivan, 1968), 
resulting in muscle weakness, weight gain, oedema and hypertension 
due to hypokalaemia and sodium retention.
SECTION 2: AN INTRODUCTION TO TIQUINAMIDE
THE SEQUENCE OF EVENTS LEADING TO THE DEVELOPMENT
OF TIQUINAMIDE
Like the development of the ^-receptor antagonists, the 
discovery of tiquinamide resulted from fundamental advances in 
the understanding of the stereochemistry of the common chemical 
secretagogues. As discussed previously molecular-orbital calculations 
led Kier (1968) to put forward the idea of two stable histamine 
conformations in which the inter-nitrogen distances were ^.55 A0 
and 3*6 A0. Subsequently, Bustard and Martin (1972) found the 
same critical distance of 3«7 - 0.2 A0 between the nitrogen atoms 
of the C-terminal amino acid amide, phenylalanine amide, of the 
hormone gastrin, and between the hetero-atoms of a number of 
compounds found to inhibit gastric acid secretion. Hence an 
inter-nitrogen distance of 3*7 A° apparently had critical ,
significance for the control of gastric acid secretion at the 
parietal cell.
“An additional feature common to a number of inhibitors of 
gastric acid secretion was the presence of a sulphur atom in close 
proximity to the two nitrogen atoms. The discovery of antigastrin, 
2-phenyl-2-(2-pyridyl)-thioacetamide, (Cook and Bianchi, 19&7) was 
followed by reports that a number of the other heterocyclic 
derivatives of thioacetamide had similar antisecretory properties 
(Kanno et al., 1973)*
The 5»6,7,8-tetrahydroquinoline-8-thiocarboxamide series of 
antisecretory agents, of which tiquinamide is a member, resulted 
from attempts to make a thioacetamide derivative in which the 
distance between the heterocyclic and thiocarboxamide nitrogen 
atoms was fixed at-3*7 A° by removal of the capacity for free 
rotation within the molecule. This was to be achieved by 
substituting the thiocarboxamide function on a coplanar hetero­
cyclic ring system whilst maintaining a separation oT two carbon 
atoms between the heterocyclic nitrogen.atom and the point of 
attachment of the thiocarboxamide group. The first structure 
designed incorporated a methylene bridge between the phenyl and 
pyridyl rings of 2-phenyl,2-(2-pyridyl)-thioacetamide to yield 
a tricyclic structure. However, it proved impossible to synthesize 
this structure because of steric hindrance at the 8-position.
CSNHo
Antigastrin
(2 phenyl,2-(2-pyridyl)-thioacetamide)
CSNH
2-pyridyl 
fs| thioacetamide
c s n h2
Wy-23995
(5,6,7,8-tetrahydroquinoline-8 
thiocarboxamide)
c s n h2
c s n h 2
Tiquinamide
(5,6,7,8-tetrahydro-3-methylquinoline 
8-thiocarboxamide)
Fig.I.1.:The historical development of tiquinamide
Because 2-pyridyl thioacetamide had been shown to have potent anti­
secretory properties (Pascaud, Errard and Blouin, 197*0* it was 
concluded that the phenyl ring was not vital for antisecretory 
activity. Omission of this ring from the above structure resulted 
in 5 ,6,7*8-tetrahydroquinoline-8-thiocarboxamide (Wy 23995)* which 
could be readily synthesized and was found to be an active anti­
secretory agent. Synthesis of analogues of this fundamental 
structure resulted in the discovery of tiquinamide, 3-iaethyl- 
5,6,7»8-tetrahydroquinoline-8-thiocarboxamide as the most potent 
member of the series (Curran and Shepherd, 197&; Beattie et al.,
1977). (Fig. 1.1).
THE GASTRIC ANTI-SECRETORY AND ANTI-ULCER PHARMACOLOGY OF TIQUINAMIDE 
Animals
Tiquinamide has been shown to be a potent inhibitor of basal
acid secretion and of gastric secretion induced by a wide*? variety
of chemical secratogogues (Beattie et al., 1979a)* It was more
active than the ^-receptor antagonist cimetidine against basal
secretion or against secretion stimulated by histamine, penta-
gastrin or carbachol in pylorus-ligated rats. Thus against basal
secretion, tiquinamide had an ED^q value of 7.8 mg/kg. A 30 rag/kg
intraduodenal dose reduced the total volume of secretion of gastric
contents by 83%* compared with 57% for cimetidine. For antagonism
of histamine-stimulated acid secretion, tiquinamide had an ED__bO
value of 5*^ mg/kg. At 30 mg/kg intraduodenally, it inhibited 
total secretion volume by 85%, as against 39% for cimetidine.
Against pentagastrin-stimulated secretion t'he E D ^  for tiquinamide 
was 3*0 mg/kg and reduction of total volume of secretion 9^% at 
-30 mg/kg, compared with 6l% for cimetidine. Inhibition of carbachol- 
stimulated secretion was marked for tiquinamide (65% at 30 mg/kg 
intraduodenally) but cimetidine had no effect on this parameter.
The anti-secretory effect was observed in a wide variety of species. 
Thus, basal secretion in the pylorus-ligated guinea-pig was inhibited 
70% following a 30. mg/kg intraduodenal dose. Similarly, histamine- 
stimulated secretion was inhibited in anaesthetized cats and monkeys 
by respectively 80% and 75% after a 20 mg/kg intraduodenal dose 
and was virtually obliterated by this dose in the anaesthetized 
dog. Pentagastrin-stimulated secretion was inhibited 70% by a
Erosion-inducing
agent
Tiquinamide
dose
Percentage inhibition 
of erosions
Indomethacin 
(20 mg/kg i.p.) 30 mg/kg p•0 • 9^
2-deoxy-D-glucose 
(256 mg/kg s.c.) 30 mg/kg p.o. 9^
5-hydroxytryptamine 
(50 rag/kg i.p.) 30 mg/kg p.o. 91
Adrenaline 
(0.*f mg/kg i.p. 
e
10 mg/kg 
intradu od enally 75
Histamine acid
phosphate
(0.25 mg/kg i.m.)
30 mg/kg p.o. 92
Table I#Is Inhibition of chemically-induced erosions
in rats by tiquinamide
20 mg/kg intraduodenal dose in the anaesthetized cat and secretion 
stimulated by gastrin tetrapeptide in the conscious, gastric- 
fistula dog was inhibited kb% by this dose.
Tiquinamide produced more than 90% inhibition of gastric 
erosion formation induced in rats by a 3 h period of cold- 
restraint, when administered orally at doses of 10 mg/kg or more.
By comparison, metiamide had no significant effect against erosion 
formation at doses up to 100 mg/kg. Tiquinamide markedly inhibited 
the formation of gastric erosions induced in rats by a range of 
chemical agents. Table 1.1 shows percentage inhibition by 
tiquinamide of erosions induced by indomethacin, 2-deoxyglucose, 
5-hydroxytryptamine, adrenaline and histamine acid phosephate.
Man
Early investigations in man suggested that significant 
inhibition of gastric acid secretion could be obtained at quite 
low doses. In one study, k subjects received oral doses of 
tiquinamide HC1 ranging from 10-60 mg. Approximately 50% 
inhibition of pentagastrin-induced acid secretion was demonstrated 
at doses of 50 mg (personal communication from Dr. M. Lancaster- 
Smith, Queen Mary's Hospital, Sidcup to Mr. P. Southgate,
Department of Clinical Pharmacology, Wyeth Laboratories). In a 
second study, 4 subjects received 25» 50 and 75 mg oral doses of 
tiquinamide HC1J. At the 25 mg dose, 50% inhibition of pentagastrin 
induced acid secretion was observed and at 75 mg 60-70% (personal 
communication from Dr. Parkins, Charing Cross Hospital, London 
to Mr. P. Southgate, Department of Clinical Pharmacology, *?yeth 
Laboratories). Thus the potency of the compound apparently compared 
very favourably with that of cimetidine, which elicited a maximum 
inhibition of acid secretion of more than 75% after a single 
intraduodenal dose of 200 mg (Burland et al., 1975)*
MECHANISM OF ANTI-SECRETORY ACTIVITY OF TIQUINAMIDE
Attempts to elucidate the mechanism of action of tiquinamide 
have so far involved a thorough study of its effects on the 
autonomic nervous system and on gastric mucosal blood flow.
However, no plausible explanation for the potent gastric anti­
secretory activity of this compound has yet been discovered 
Beattie et al., 1979b).
Many conventional anti-secretory compounds used in clinical 
practice, such as atropine and ambutonium, are anti-cholinergic 
drugs. However, in studies using the guinea-pig isola&4ileum 
preparation, non-competitive antagonism of cholinergic receptors 
by tiquinamide was demonstrable only at concentrations as high as 
10~^M. Thus for all practical purposes tiquinamide was devoid of 
anti-cholinergic activity.
The newer class of anti-secretory compounds, typified by 
cimetidine and its precursor compounds burimamide and metiamide, 
are inhibitors of histamine H^-receptors. Whilst tiquinamide 
demonstrated some weak ^-receptor antagonism in the isolated 
guinea-pig atrial preparation, the pA 2 value for this effect was 
only 4.06 compared to and 5*85 for burimamide and metiamide
respectively. Since tiquinamide had been found to be a more 
potent inhibitor of acid secretion than these compounds, it is 
unlikely that its H2-receptor antagonism accounted for more than 
a small part of its anti-secretory activity.
Some drugs which inhibit gastric acid secretion do so by 
enhancing gastric mucosal blood flow. However, in studies to 
examine the effect of tiquinamide on gastric mucosal blood flow, 
aniline clearance was reduced in parallel with acid secretion. 
Therefore it is unlikely that tiquinamide exerted a primary effect 
on gastric mucosal blood flow.
Investigations into other possible autonomic effects of 
tiquinamide revealed an absence of ganglion-blocking or local 
anaesthetic activity and showed no evidence of antagonizing effects 
of either noradrenaline or 5-hydroxytryptamine. Thus it seemed 
unlikely that tiquinamide exerted its effect via the peripheral 
nervous system. Possibly elucidation of its mechanism of action 
will depend on further development of fundamental knowledge about 
the control of gastric acid secretion.
In view of the absence of central or autonomic effects for 
tiquinamide coupled with its ability to antagonize the stimulation 
of acid secretion by a wide range of chemical secretagogues 
(e.g. pentagastrin, histamine, carbachol) deemed to act close to 
the site of acid secretion in the parietal cell, it seems likely 
that tiquinamide too exerts its effect here.
OTHER PHARMACOLOGICAL PROPERTIES OF TIQUINAMIDE
It emerged from early volunteer studies that tiquinamide 
possessed some undesirable side-effects. Doses in excess of about 
*+0 mg apparently resulted in nasal congestion and sinusitis-type 
headaches. Furthermore, tachycardia was frequently observed, 
usually at doses of around 100 mg, but in some subjects at lower 
doses and in one subject at as low as 10 mg. The tachycardia 
normally occurred at about 2-4 h after dosing and was associated 
with postural hypotension (Coleman, A. J. personal communication 
to Mr. P. Southgate, Department of Clinical Pharmacology, Wyeth 
Laboratories).
Serious consideration was given to the nature and mechanism 
of the tachycardia, this being a potentially lethal side-effect.
A model for the tachycardia was established in conscious, 
normotensive rats. When blood pressure in the rat tail vein was 
monitored using pressure transducers linked to a polygraph and heart 
rates were derived from the blood pressure traces, it was possible 
to show that doses of 10-50 mg/kg tiquinamide HC1 administered 
orally promoted increases in heart rate of up to 40% of the pre- 
dose value and intravenously up to 30%. Marked falls in blood 
pressure were associated with the tachycardia in orally dosed 
animals. Onset of action occurred more rapidly after oral 
administration ( ^-10 min at 10 mg/kg) than after intravenous 
dosing (£=30 min). Once evident the tachycardia persisted until 
at least 2 h after dosing when the experiment was terminated 
(Waterfall, 1978)..
The more rapid onset of tachycardia in orally-dosed animals 
than in those administered the drug intravenously prompted the 
suggestion that the effect could be mediated by a metabolite.
SOME CHEMICAL PROPERTIES OF TIQUINAMIDE 
pKa
Tiquinamide (5*6»7»8-tetrahydro-3-methylquinoline-8- 
thiocarboxamide) is a weak base of pKa 5*2.
Solubility in water and organic solvents
The aqueous solubilities of tiquinamide and its hydrochloride 
salt are respectively 0.84 and 364 mg/ml.
Partitioning of C-tiquinamide between pH 7.4 0.1 M phosphate 
buffer and various organic solvents when mixed for 12 h at ambient
temperature was as shown in Table 1.2. The initial concentration
Ik
of C-tiquinamide HC1 in buffer was 200 jug/ml.
Solvent
Solven t/aqu eous
partition
coefficient
Heptane 0.17
Benzene 5.53
Chloroform 17.3
1-octanol 15.4
Table 1.2: Partition coefficients of ^C-tiquinamide between
various organic solvents and pH 7.4 0.1 M phosphate 
buffer
Because of the known tendency of the thioamide group to degrade 
to a nitrile function (see below), the determined values may not 
have been the true partition coefficients of the thioamide, but 
may have included a contribution from the corresponding nitrile.
Stability
Tiquinamide HC1 is unstable in aqueous solution. In the dark
at 25°C, a 1.6 mg/ml solution underwent oxidative degradation
(10% after 10 days). The main products of the degradation were
the amide derivative, Wy 24117 and elemental sulphur. Lesser
amounts of the nitrile derivative, Wy 24146, were also formed.
The compound was no less stable in acid solution (0. 1 N HC1) but
in alkali (0.1N NaOH) degradation was accelerated, such that only
58% of a 5 mg/ml solution remained unchanged after 1 week.
(Davidson, 1974). • More importantly, at lower concentrations
(i.e. 4.100 fig/ml) likely to occur in biological fluids after 
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administration of C-tiquinamide HC1, desulphuration to the 
nitrile derivative occurred. Such degradation made manipulation 
of drug in biological fluids difficult. Certain manipulations 
enhanced the extent of degradation. Thus extraction of tiquinamide 
into toluene from a 2 jig/ml solution in plasma basified to pH 9 
resulted in virtually complete degradation. -However, the
degradation could in this case be almost completely overcome for the 
purpose of analyzing samples containing radio-labelled drug, by 
adding unlabelled tiquinamide HC1 to a concentration ^ 100 jug/ml 
before extraction. Thus whenever unchanged tiquinamide was to be 
assayed, it was necessary to adopt this procedure and to make 
allowance for the extent of desulphuration by taking standards 
containing known concentrations of tiquinamide through the entire 
assay. Further complications were introduced by the possibility 
of thioamide-containing metabolites and these will be discussed 
more fully in the chapters concerned with the metabolism of the drug.
POTENTIAL CONSEQUENCES OF THE PHYSICAL CHEMISTRY OF TIQUINAMIDE 
FOR ITS ABSORPTION, TISSUE DISTRIBUTION AND EXCRETION
Absorption „
Since the work ofSchanker et al., (1957) and Hogben et al.,
O '
(1957)i it has become a well established principle that drugs are 
usually absorbed by passive diffusion and that their rates of 
absorption are dependent on the lipid-solubilities of their most 
lipophilic forms. For most drugs, the unionized forms have much 
greater lipid solubility than do their ionized counterparts, and 
therefore it is normally found that unionized drugs are absorbed 
rapidly, ionized ones more slowly.
It follows that weak bases which are extensively unionized 
at the pH of intestinal contents (5-8) are well absorbed from the 
small intestine but poorly absorbed from the stomach (pH 1-3)* 
where they are largely ionized. Weak acids are unionized in the 
stomach and therefore more likely to be absorbed from this site 
than are basic compounds.
Tiquinamide is a weak base (pKa 5*2), expected to be almost
completely unionized in the contents of the small intestine.
In addition it has a moderately high lipophilicity. Its octanol/
»
aqueous buffer partition coefficient of 12 was similar to the 
value of 10 found to be optimal for the intestinal absorption of 
carbamates (Houston, Upshall and Bridges, 1974 and 1975)* Further­
more, its partition coefficients between, respectively, heptane, 
benzene or chloroform and pH 7*4 aqueous buffer were 0.17» 5*5 and 
17*3, of a similar order to those of aniline (0.55i 0.90 and 17) 
and aminopyrine (0.15* 0.40 and 73) (Brodie, 1984), which are weak 
bases (pKa 5«0) known to traverse biological membranes rapidly
(Mayer, Maickel and Brodie, 1959)* It thus seemed very likely that 
this drug would be well absorbed from the small intestine. However, 
there existed the additional possibility that it would be significantly 
absorbed from the stomach. Although basic drugs such as tiquinamide 
would not normally be expected to be absorbed from the stomach 
because of their extensive ionization at this site, Sehanker et al., 
(1957) did show that bases could be absorbed from the stomach 
provided that the pH of gastric contents was maintained above the 
pKa of the drug, so promoting the presence of significant concentrations 
of unionized drug. Because tiquinamide was a potent inhibitor of 
gastric acid secretion believed to act directly on the parietal cell, 
it was envisaged that the pH of gastric contents would begin to rise 
as soon as sufficient drug had been absorbed to initiate the anti- 
secretory effect, following its uptake into parietal cells from the 
systemic circulation. Then^ , as a result of the low pKa of this 
drug, at pH’s greater than about pH 4, a significant proportion 
of the. drug would be unionized and hence available for absorption. 
Furthermore, there was an indication from experiments in rats that 
it inhibited gastric emptying (Beattie et al., 1979b). Thus 
subsequent absorption might occur directly from gastric contents 
as a consequence of the combination of the low pKa of tiquinamide 
with its inhibitory effect on acid secretion and gastric motility.
Tissue distribution
The factors governing the transfer of drugs from blood into 
tissues are similar to those governing their absorption. Thus it 
has been shown that the .permeability constants for drugs passing 
from plasma into cerebro-spinal fluid are related firstly to their 
pKa’s and secondly to their partition coefficients between various 
organic solvents and aqueous buffer (pH 7*4) (Mayer, Maickel and 
Brodie, 1959; Brodie, Kurz and Sehanker, 19&0). This model 
represented the case in which the pH on both sides of the membrane 
is identical i.e. pH 7*4, as is true at the interface between plasma 
and many tissues. In some cases, however, a lipid membrane 
separates plasma from a tissue or fluid in which the pH differs 
substantially from that of plasma. Then the pH may markedly affect 
drug distribution in a manner dependent on the pKa of the drug 
concerned. Thus weak bases are known to be rapidly transferred 
from plasma into gastric juice (pH 1-3) and hence secreted into
the gastric lumen (Shore, Brodie and gogben, 1957)* Similarly, 
the localization of basic drugs in the lung is believed to result 
from the intracellular trapping of these drugs in their ionized 
forms because the intracellular pH in lung is approximately 0.5 pH 
units below that in plasma (Waddell, 1973)*
Thus the moderately high lipophilicity of tiquinamide suggested 
that it would be rapidly taken up into tissues and maybe also into 
gastric contents. It was a possibility, however, that the elevation 
of the pH o® gastric contents, as a result of the anti-secretory 
activity of tiquinamide, would reduce the extent of gastric 
secretion of the drug.
A possible site of accumulation of tiquinamide was the thyroid 
in view of the presence of a thioamide group in its structure.
A number of thioureas and thiouracils are accumulated at this site 
and are in fact active as anti-thyroid agents e.g. thiourea (Maloof 
and Soodak, 19&5)♦ thiouracil (Maloof and Soodak, 1957)* propyl 
thiouracil (Marchant et al., 1971) and methimazole (Marchant and 
Alexander, 1972). Furthermore, the thioamide anti-turbercular 
compound ethionamide has been found to exert an anti-thyroid effect 
in some subjects (Moulding and Fraser, 1970).
Excretion
Drugs and their metabolites are normally excreted most extensively
in the urine and following biliary secretion, in the faeces, though
i
elimination may also take place through secretion intomother body 
fluids such as sweat and saliva and, in the case of volatile compounds, 
by exhalation from the lungs. The extent and rate of excretion of 
a given compound via each of the major routes is determined by 
physical and structural properties of the molecule. Drugs in 
solution in plasma pass freely into urine by glomerular filtration. 
Passage is through the pores of the membrane and thus the process is 
independent of the ionization state of the molecule or of its 
solubility in lipoidal membranes. However, the concentration of 
drug in the filtrate will often greatly exceed that in capillaries 
intimately associated with the renal tubule and thus reabsorption 
may take place in a manner dependent on pKa and lipid solubility.
Thus lipophilic drugs unionized in urine (i.e. at pH 4.5-8) will 
tend, to be reabsorbed, v/hereas ionized species will usually be
too poorly soluble in lipoprotein for this process to occur 
significantly (Brodie and Hogben, 1957)* Variations in urinary 
pH may substantially affect the extent of renal reabsorption of 
weak acids and bases, and in so doing profoundly affect the rate 
of their renal elimination. Thus, for example, it was found that 
the weakly basic drug amphetamine was excreted substantially 
unchanged in human urine but that the rate of excretion fluctuated 
as urinary pH varied in the range 4.9-8.3- Under controlled acid 
conditions (pH 5) &0% of the dose was excreted in urine in 16 h, 
whereas when urine was kept alkaline (pH 8) only 2-3% of the dose 
was excreted in urine in the same period (Beckett and Rowland,
1965 )• An additional mechanism by which some compounds may enter 
the urine involves active secretion into the proximal kidney tubule. 
Separate specific mechanisms exist for the active secretion of 
strong organic bases such as N-methylnicotinamide, tolazoline and 
hexamethonium (Peters, i960) and of organic acids such as salicylic 
acid, hippuric acid and glucuronide conjugates (Sperber, 1959)*
The largest single factor governing the extent of biliary 
secretion of a drug is its molecular weight. It is now well 
established that there is a molecular'weight threshold for biliary 
secretion which varies from species to species. Low molecular 
weight compounds are po'orly excreted in bile. For compounds of 
molecular weight above the threshold value the proportion of the 
dose excreted in bile increases dramatically with the increase in 
molecular weight until, for compounds of molecular weight 200 or 
so greater than the threshold value, elimination occurs almost 
entirely by biliary secretion (Millburn, Smith and Williams (1967; 
Aziz et al., 1971)*
It has already been established that tiquinamide is a weak 
base likely to readily traverse biological membranes in its 
unionized state. Furthermore, its pKa (5*2) falls within the normal 
range of urinary pH (4.5-8) and thus it was probable that the drug 
would exist in substantially unionized form in urine. Therefore 
it was predictable that if the drug was extensively excreted in 
urine unchanged, it would be prone to reabsorption by passive 
diffusion in the renal tubules. The absence of strongly basic or 
acidic groups in the molecule suggested that active renal tubular
secretion of tiquinamide was unlikely. Extensive biliary secretion 
of the unchanged drug was precluded on the grounds of its low 
molecular weight (206), which fell well below the lowest known 
threshold value of 325 - 50 in the rat (Millburn, Smith and 
Williams, 1967; Aziz et al., 1971)* The combination of its 
lipophilicity with low pKa, resulting in a high degree of unioni­
zation at physiological pH (7*4), would have predisposed it to 
passive entry into other body fluids e.g. sweat and saliva (Stowe 
and Plaa, 1968). However, these do not normally constitute pre­
dominant routes of excretion. It was thus possible that excretion 
of tiquinamide from the body in unchanged form would prove 
difficult. Thu6 elimination might be dependent on metabolism to 
more polar products.
POTENTIAL ROUTES OF METABOLISM OF TIQUINAMIDE
Reactions involved in the metabolism of drugs by the mammalian 
liver include, for example, hydroxylation, N- or S- oxidations,
0—, N- or S- dealkylations, hydrolyses and reductions as well as 
conjugation with a variety of polar endogenous compounds e.g. 
sulphate, glucuronic acid or glycine. These fundamental pathways 
have been extensively reviewed by Williams (1959a) and Parke 
(1968a). In addition a series of monographs covering the routes 
of biotransformation of a very large number of different foreign 
compounds has been published in recent years (Hathway, 1970, 1972, 
1975$ 1977 and 1979)- Whilst the liver is the major site of 
metabolism it has become obvious in recent years that microsomal 
oxidases of a similar nature to those in liver occur also in a 
number of different extra-hepatic tissues, including lung, 
intestinal tract, placenta, kidney, adrenals, skin, brain and 
testes (Murphy, 1972; Lake et al., 1973)* In addition, a wide 
range of metabolic reactions have now been attributed to gastrointes­
tinal microflora. These tend to be reductive and degradative rather 
than oxidative and synthetic. They include reductions, hydrolyses, 
decarboxylations, dealkylations, dehalogenations, deaminations, 
heterocyclic ring fissions, aromatizations, acetylations and 
esterifications. These reactions and their significance have been 
discussed by Scheline (1973)$ Williams (1972) and Goldman (1978).
It is not the intention to dwell on the basic routes of metabolism, 
since these have been well covered in the literature and thus further 
discussion will be confined to reactions which could have been 
directly concerned in the biotransformation of tiquinamide.
Since 5i6,7»8-tetrahydroquinolines were not previously known 
prior tothe synthesis of tiquinamide and related compounds (Curran 
and Shepherd, 197&), the metabolism of such compounds has not been 
described. Some work on 1 , 2 , 3 tetrahydroquinolines and 1,2,3*^— 
tetrahydroisoquinolines has been reported, but has not lead to any 
general conclusions as to how this type of ring structure is 
metabolized. For example, Bernhard (1939) reported that 1,2,3*^- 
tetrahydroquinoline. underwent in the dog aromatization and hydroxy- 
lation at the 2- position, resulting in 2-hydroxyquinoline. On 
the other hand, a derivative of this structure, the anti-schistosomal 
compound 2-isopropylaminomethyl-6-methyl-7-nitro-l, 2 , 3 tetra­
hydroquinoline , was in mouse, rat, rabbit and rhesus monkey, not 
metabolized in the tetrahydroquinoline ring, but purely by oxidation 
of methyl and isopropylaminomethyl substituents (Kaye and Woolhouse, 
1972). Still other metabolic routes predominated in the metabolism 
of the 1,2,3 ,*+-tetrahydroisoquinoline compound debrisoquine by rat, 
dog and man. This compound was metabolized principally by allylic 
hydroxylation yielding ^f-hydroxydebrisoquine. Another significant 
route involved opening of the saturated ring and subsequent 
oxidation to yield carboxylic acids (Allen et al., 1975? Allen,
Brown and Marten, 197&). Thus reports on the metabolism of compounds 
possessing partially saturated heterocyclic ring systems similar to 
that of tiquinamide were rare and yielded a diversity of possible 
metabolic routes. (Fig. 1.2). In order to assist speculation about 
possible biotransformation routes for tiquinamide, the ring structure 
was considered as fused cyclohexene and pyridine rings. Thus 
knowledge of the metabolism of aromatic heterocyclic amines, 
cycloalkenes, methyl-substituted aromatic compounds and thioamides 
was all pertinent to the possible metabolism of tiquinamide. 
Heterocyclic aromatic amines
Aromatic hydroxylation: Pyridine and quinoline and related 
compounds have been quite commonly found to undergo aromatic 
hydroxylation. Quinoline, for example, is hydroxylated by the
rabbit at a number of different positions, notably at the 2-, 3-»
5- and 6- positions (Williams, 1959b) (Fig. 1.3)*
N-methylation: The, vitamin nicotinic acid has been found to 
undergo extensive N-methylation in a wide range of species e.g. 
rat (Lin and Johnson, 1953)» dogv hamster, mouse (Leifer et al.,
1951) and man (Reddi and Kodicek, 1953) (Fig. 1.3)• However, 
this reaction has been found to be only a minor one for exogenous 
compounds such as pyridine (Williams, 1959c), nicotine (Hansson, 
Hoffmann and Schmiterlow, 196*0 and quinoline (Williams, 1959&).
H-oxidationt A number of aromatic,heterocyclic amines have 
been found to; undergo N-oxidation eg.nicotinamide,nikethamide,
3*-acetyl-pyridine and cotinine(Gorrod,1973)(Fig.1.3.).
For pyridine the reaction was found to occur quite extensively 
(e.g.*fO% of the dose in mice),but 3-methyl substitution markedly 
reduced its quantitative significance(Gorrod and Damani,1980).
Ring scission: Ring scission is an uncommon reaction of pyridine 
or quinoline derivatives. Apart from the cleavage of the 1,2,3*^- 
tetrahydroisoquinoline ring of debrisoquine mentioned above, there 
exists only one or two examples for instance, 8-methylquinoline was 
extensively degraded in dogs and rabbits such that quinoline- 
related structures could not be traced (Cohn, 1895* cited by 
Williams, 1959)*
C.ycloalkenes
Allylic hydrox.ylation: Cycloalkene rings, whether independent 
or fused to an aromatic ring system, are commonly found to undergo 
allylic hydroxylation i.e. at a position adjacent to the double bond 
This reaction has only recently been established for cyclohexene 
itself (Leibman and Ortiz, 1978) (Fig. 1.3) » but has long been, known 
for derivatives such as the cyclohexenyl barbiturates (Williams, 
1959e). It is sometimes accompanied by further oxidation to the 
corresponding keto-derivative. Thus, for example, hexobarbital 
was found to be metabolized in the rabbit and dog principally by 
3 ’-hydroxylation in the cyclohexene ring, yielding 3'-hydroxy- 
hexobarbital and by further oxidation to ketohexobarbital (Holcomb, 
Woodside and Bush, 1969; Gerber et al., 1970; Holcomb, Gerber and 
Bush, 197*0.
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Aromatization: Evidence for aromatization of cycloalkenes or 
of saturated rings fused to aromatic systems is scarce. As mentioned 
previously, Bernhard (1939) reported the aromatization of l,2,3»*t— 
tetrahydroquinoline in the dog, which, in combination with hydroxy­
lation, yielded 2-hydroxyquinoline (Fig. 1.2). Shikimic acid is 
known to undergo aromatization, but it has been established that 
this only occurs as a result of initial reduction by intestinal 
micro-organisms (Brewster, Jones and Parke, 1977a) followed by 
aromatization of the resulting cyclohexane carboxylic acid (Brewster,
Jones and Parke, 1977b) "____ The mechanism is specific for
saturated rings with carboxylic acid substituents, since it requires 
the formation of an acylcoenzyrae A intermediate (Babior and Bloch, 
19o6).
Methyl-substituted aromatic compounds
Oxidation: Methyl substituents to aromatic rings are oxidized 
to the corresponding carboxylic acid derivatives. This reaction 
has been known since the late 19th century, and numerous exaraoles 
of compounds oxidized in this manner are cited by Williams (1959f*) 
e.g. toluene, <*-methylpyridine, 2 ,5-dimethylfuran, 6-methylquinoline. 
It is now known that the complete metabolic pathway involves the 
formation first of the hydroxyraethyl derivative and subsequently 
the corresponding aldehyde, oxidation of which yields the carboxylic 
acid (Gillette, 19&3) (Fig. I.^).
Thioamides
Sulohoxidation: One established route of thioamide metabolism 
involves sulphoxidation. Thus, for examole the anti-tubercular 
compound ethionamide was metabolized in the man, rat, mouse and dog 
to ethionamide sulphoxide, which was in dynamic equilibrium with 
the unchanged drug. (Bieder and Mazeau, 196^; Bieder, Brunei and 
Mazeau, 1966; Johnston, Kane and Kibby, 1967). Other metabolites 
arising from further oxidation of ethionamide and its sulnhoxide 
were 2-ethylisonicotinamide and its hydrolysis product
2-ethylisonicotinic acid (Fig. I,k),
Desulnhuration: An alternative route of metabolism of 
thioamides has been found to involve desulphuration to the nitrile. 
For example, 2 ,6-dichlorothiobenzamide was desulphurized to 
2,6-dichlorobenzonitrile in the rat to the extent that the metabolic 
patterns following oral administration of the thioamide or nitrile
27
could not be distinguished. The major urinary metabolite, 
representing about 30% of the administered dose was 2,6-dichloro-
3-hydroxybenzonitrile and its conjugates (Griffiths et al., 19^6)
(Fig. 1.4).
Conclusions
In conclusion, the evidence from the literature suggested that 
tiquinamide might undergo hydroxylation in the saturated ring at 
one of the allylic positions adjacent to the points of fusion of 
the saturated and aromatic rings and/or in the aromatic ring.
Methyl group oxidation was another likely possibility. The thioamide 
group seemed certain to be metabolised, probably by one of two 
alternative routes: either by oxidation to the sulphoxide or by 
desulohuration to the corresponding nitrile. N-oxidation, N-methylation 
and aromatization represented other possibilities.
The nature of any subsequent conjugation reaction would obviously 
be dictated by the routes of Phavse I metabolism. Thus hydroxyl 
metabolites might be conjugated with glucuronic acid or sulphate 
or carboxylic acids with glucuronic acid or amino acids such as 
glycine, glutamine or taurine, for example (Parke, 1968b).
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Methyl group oxidation
NO, NO NO,
live
micr
soma
Si
liver
soluble
liver
. soluble |J
1 alcohol aldehydeV^^
CH OH CHO C O O H
2 dehydrogenase dehydrogenase
p-nitro- p-nitro- p-nitro- p-nitro-
toluene benzyl alcohol benzaldehyde benzoic acid
Thioamide group
1. Sulphoxidation 
:SNHL
N^ C2H5
Ethionamide
S NH
5
Ethionamide
sulphoxide
ONH.
^ n ^ c 2h5
2 -ethyl-'*w>- 
nicotinamide
OOH
N ^ C2H5
2-ethyl - - 
nicotinic acid
2. Desulphuration
2,6-dichloro- 
thiobenzamide
2,6-dichloro-benzonitrile
Fig.1.4..* Reactions potentially relevant to the metabolism 
of tiquinamide.*
2.Reactions of methyl and thioamide substituents
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SECTION 3: OBJECTIVES OF THE PRESENT STUDY:
SOME ASPECTS OF THE METABOLISM AND DISPOSITION OF 
TIQUINAMIDE POTENTIALLY RELEVANT TO ITS DEVELOPMENT 
AS A GASTRIC ANTI-SECRETORY AGENT___________________
Before speculating on ways in which study of the metabolism 
and disposition of tiquinamide might aid its development as an anti- 
secretory agent useful in the treatment of peptic ulcer disease, 
it is perhaps pertinent to give some thought to the properties 
which are desirable in such a compound. In general, these are not 
very different from what would be expected of any drug, whatever 
its intended use - namely that it should reach its site of action 
rapidly, that it should remain there at effective concentrations 
for a period likely to be significant with respect to the time- 
course of the condition to be treated and that it should be 
eliminated at a rate which makes possible the design of a dosage 
regime appropriate to this condition.
Thus the primary consideration for an anti-secretory drug deemed 
to act directly on the parietal cell is that, once administered, it 
should be taken up rapidly and efficiently into the gastric mucosa. 
The most appropriate route of administration would appear to be 
the oral route. Hospital confinement of peptic ulcer patients 
normally gives way to the ambulatory state during the course of 
treatment. Furthermore, daily administration of the drug over a 
period of months after the return of the patient to normal life 
'may be necessary if recurrence of theuulcer is to be prevented.
An oral dosage form constitutes a convenient means of administration 
of a drug to a non-hospitalized patient. In addition, the oral 
route may be particularly appropriate in diseases of the gastro­
intestinal tract because it offers the opportunity to introduce 
the drug close to the intended site of action. Thus it is 
particularly desirable for a gastrointestinal agent of this type 
that it should have good oral bioavailability. In this respect, 
cimetidine scored, having an oral bioavailability of 12%> in man 
(Griffiths, Lee and Taylor, 1977)* It was of interest to know 
whether tiquinamide would perform as well. On a dose-for-dose 
basis in animals this compound was more potent after oral 
administration than was cimetidine. Whilst it seemed probable 
that tiquinamide would be well absorbed, it was not known whether
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it would be more extensively metabolized than cimetidine on its 
first passage through the intestinal wall and the liver.
The site of gastrointestinal absorption also has particular 
significance ,for an agent acting directly on the gastric mucosa.
An ideal compound would be taken up directly and rapidly from the 
stomach contents. In this way, the possibility of a low active 
site availability resulting from high first-pass metabolism and 
dissipation of drug among other tissues would be circumvented.
Indeed, allied to extensive gastric absorption, a high first-pass 
effect could be positively advantageous for a drug acting on the 
gastric mucosa, since the resultant low systemic drug concentrations 
would mean a minimal risk- of side-effects, provided that metabolites 
were innocuous. Gastric absorption had not been suggested as a 
significant feature of cimetidine. It was less likely for this 
compound than for tiquinamide in view of its higher pKa (7 as 
compared with 5*2), but in any case was perhaps of little significance 
in this case because of the high bioavailability after intestinal 
absorption. For tiquinamide, extensive gastric absorption might 
prove useful if the reduction in bioavailability by first-pass 
metabolism should prove high.
The nature of the association of a direct-acting anti-secretory 
compound with the gastric mucosa may be significant. Particularly 
important is the question of whether this association is a readily 
reversible one in v/hich drug in the mucosa rapidly equilibrates 
with that in the systemic circulation. Under these circumstancfes, 
the time-course of drug in plasma is representative of that in the 
gastric mucosa and monitoring plasma concentrations may help the 
clinician to adhere to the most effective therapeutic regimen for 
a given subject. Otherwise the kinetics of release of the drug fr.om:. 
the receptor site may differ markedly from those of elimination
t
from plasma, and thus pharmacodynamics will not be related to 
plasma kinetics. Studies with cimetidine in normal volunteers 
had indicated a relationship between plasma concentration of drug 
and inhibition of acid secretion (Burland et al., 1975)* It was 
of interest to see whether such a relationship would also exist 
for tiquinamide.
In the event that plasma concentrations did mimic those at the 
receptor site, what would represent an optimal plasma elimination 
half-life? In defining the shortest acceptable half-life for an
anti-secretory drug, one must take account of the fact that a major
limiting factor in the use of antacids is the rapidity with which
they are emptied from the stomach. However, it is possible to
effectively control ulcer pain by maintaining pH of gastric
contents)*k with hourly doses of sodium bicarbonate (1 g), even
in quite severe cases (Card, (1966)). Thus there is little
advantage over conventional antacids of a drug which has to be
administered more than, say, four times a day. Another factor which
determines the ideal half-life for an anti-secretory compound is
related to nocturnal acid secretion. Ideally, 'the half-life of
the drug should be sufficiently high to maintain therapeutic plasma
concentrations throughout an average sleep period. Otherwise the
ulcer patient will be awakened by pain during the night. This is
the time when he is most vulnerable to gastric acid secretion
because natural buffering by food in the stomach is minimal.
»
A rapidly absorbed drug of half-life equal to the average sleep 
duration of 8 h, will result, in plasma concentrations which 
fluctuate between a maximu’m of 25% above the steady state level to 
a minimum of 25% below this value. Thus, if the dose magnitude is 
adjusted so that the minima exceed the concentration required to 
control the rate of acid secretion, the nocturnal ulcer pain can 
be avoided. Maxima of 25% above the steady-state concentrations 
should be tolerable provided that the drug in question has a 
satisfactory therapeutic index. A drug with a half-life of 8 h 
fits neatly »into a 3 times daily regimen of equal doses. By 
comparison, consider the case of a rapidly absorbed drug of half- 
life 2 h. A 8-hour sleep represents 4 half-lives, during which 
time the plasma concentration has dropped to only 6.25% of its 
maximum value. Therefore very high maximum plasma concentrations 
must be achieved if the minima are still be exceed the minimum 
therapeutic concentration. Such peaks could conceivably be 
associated with side effects for a drug which does not have a very 
high therapeutic index. Cimetidine has rather a short half-life 
for an anti-secretory compound, around 2 h in man (Griffiths,
Lee and Taylor, 1977; Burland et al., 1975)* In order to cope 
with nocturnal acid secretion, the bedtime dose administered 
is ^00 mg, which is twice the dose given three times during the 
dy.y.. In this case, no acute side-effects are known to result.
Indeed single oral doses as high as 800 rag have been administered 
without ensuing difficulty (Blackwood and Northfield, 1977)*
However, risk of side-effects would obviously be minimized if wide 
fluctuations in plasma concentration could be avoided, and therefore 
it was felt that an ideal half-life for an anti-secretory compound 
such as tiquinamide would be of the order of 8 h.
Metabolism of a drug can lead to the formation of active 
metabolites. Thus, for example, 4-hydroxypropranolol is a metabolite 
of the /* -receptor antagonist propranolol formed after oral dosing 
and contributing quite substantially to the anti-hypertensive activity 
of this compound (Paterson et al., 1970). It is important that 
such metabolites should be defined so that their contributions 
to the overall pharmacological activity of the drug can be assessed. 
Attempts to correlate drug plasma concentrations with pharmacological 
effect may need to take into account the plasma concentrations 
and relative potencies of active metabolites in order to arrive at 
a meaningful relationship. Thus it was of interest to know whether 
active metabolites of tiquinamide existed. The most likely 
candidates to show anti-secretory activity would be compounds 
containing the thioamide group since the nitrile compound 
corresponding to tiquinamide showed substantially diminished activity 
and the analogous amide was inactive (Beattie et al., 1977)*
Safety evaluation forms a critical part of the development
of a potential drug. Animal species chosen for the study of a
compound’s toxicity should be appropriate models for man. Thus 
it is necessary to compare the rates and extents of absorption
and elimination in candidate species with those in man so as to
know how the dosage regime applied in animal toxicity studies 
relates to the anticipated therapeutic regime and to establish 
either that they metabolize the drug in the same manner as man 
or that the differences are not significant. Candidate species 
for the study of the toxicity of tiquinamide were the rat and patae 
monkey, these being chosen from among a relatively few species 
of animal for which an adequate data bank of normal values for 
haematological, biochemical and histological parameters was 
available. It remained to be seen whether these species would 
resemble man in the manner of metabolism and disposition of 
tiquinamide.
One aspect of a drug’s disposition which may be particularly 
important with respect to its potential safety is the extent and 
nature of the localization in tissues of the drug or its metabolites 
Compounds may accumulate to high concentrations in certain tissues 
as a result, for example, of covalent binding to. tissue components 
such as proteins, nucleic acids, or pigments. Such localization 
may lead to toxic lesions. Thus, for example, high concentrations 
of the anti-malarial compound chloroquine in the uveal tract which 
result from binding of the compound to melanin have been associated 
with the retinopathies produced by this drug (Bernstein et al., 
1963).
The possibility of active metabolites has been discussed in 
connection with their potential contribution to the pharmacological 
activity of the drug. However, it may also be the case that 
metabolites have acute or chronic toxic effects. Thus, for example 
the severe hepatic necrosis which results from paracetomol over­
dosage has been attributed to a reactive N-hydroxy-metabolite 
which, at low doses, is conjugated with glutathione and safely 
eliminated, but which at higher doses exceeds the supply of 
glutathione, binds covalently to liver macromolecules and induces 
centrilobular necrosis (Healey et al., 1978). Thus evaluation of 
the toxicities of identified metabolites may contribute greatly 
to confidence in the safety of a drug or may identify potentially 
limiting side-effects or adverse reactions. The most obvious 
threat of toxicity from tiquinamide was the risk of generation of 
hydrogen sulphide during the desulphuration of the compound. As 
discussed previously (p.26), desulphuration to the nitrile was a 
likely route of metabolism for such a thioamide and it was possible 
that free hydrogen sulphide would be released by this reaction. 
Hydrogen sulphide is an extremely toxic compound, having LD50 values 
in the rat of 0.27-0.55 mg/kg intravenously and 2.3-2.8 mg/kg intra- 
peritoneally (Smith and Williams, 19&1). It was implicated as the 
primary agent responsible for the high acute toxicity of monosub­
stituted arylthioureas e.g. phenylthiourea, which underwent 
desulphuration to the nitrile in a manner at least superficially 
analagous to that proposed for tiquinamide (Smith and Williams, 
19ol). Thus evaluation of the rate and extent of this reaction as 
related to the acute toxicity of the drug formed one of the
objectives of the study. It was possible also that evaluation 
of the toxicological properties of the major metabolites of 
tiquinamide would prove desirable. Thus to conclude, at the 
outset of the present study, there was nothing known about the 
extent or nature of the metabolism of tiquinamide in animals or 
man, on rates of disposition, processes such as absorption or 
elimination, or on tissue accumulation or localisation of drug- 
related products. Furthermore, tiquinamide represented an example 
of a novel class of compounds, the 5 »6,7,8-tetrahydroquinolines.
The metabolism and disposition of this type of compound had not 
previously been studied. Information on the metabolic behaviour 
of other partially saturated quinoline or isoquinoline compounds 
was very scarce. The objective, therefore, was to furnish 
fundamental information about the metabolism and disposition of 
this compound and, wherever possible, to make use of this information 
to aid the development of the drug.
£
CHAPTER II: MATERIALS AND METHODS
MATERIALS
CHEMICALS
l2f
The preparation of C-tiquinamide base was performed by 
The Radiochemical Centre, Amersham. The synthetic routes involved 
are shown in Fig. II.1.
Conversion to the hydrochloride salt was carried out by 
Dr. R.' Crossley, Department of Medicinal Chemistry, Wyeth 
Laboratories (U.K.). The final product was shown by thin-layer 
chromatography to be 97% radiochemically pure. Further 
purification was deemed inadvisable in view of the tendency of the 
thioamide to undergo spontaneous dissociation to the nitrile 
8-cyano-5»6,7*8-tetrahydro-3-Kiethylquinoline, such that it always 
existed in the presence of a small proportion of the latter compound 
Specific activities of various batches of the hydrochloride 
ranged from 7«7~8.8 juCi/mg. Dilution with unlabelled drug was 
carried out as dictated by the needs of individual experiments.
Unless otherwise stated, solvents were of reagent grade, 
obtained from May and Baker Limited, Dagenham, Essex.
THIN-LAYER CHROMATOGRAPHY: PLATES AND SOLVENTS
For thin-layer chromatography, plates were of silica gel,
0.25 mm with fluorescent marker (E. Merck & Co. Ltd., Darmstadt,
West Germany, supplied by Anderman & Co., East Moseley, Surrey). 
Plates with a pre-adsorbent zone made by Quantum Industries Ltd., 
Fairfield, New Jersey, U.S.A. were supplied by Microbio Laboratories 
London. Similarly, preparative layer plates were either 2 mm 
silica gel (E. Merck & Co. Ltd.) or 1 mm silica gel with pre- 
adsorbent zone (Quantum Industries Ltd).
The following solvents were used for thin-layer chromatography 
of end-products of tiquinamide in plasma, urine and bile.
Acidic solvents
Solvent 1: Chloroform/methanol/acetic acid (18:2:1)
Solvent 2: Chloroform/acetic acid (19:1)
Solvent 3: Toluene/ethyl formate/formic acid (60:35:5)
Solvent A-: Toluene/ethyl f or mate/formic acid (5:^:1)
Solvent 15: Ethyl acetate/acetic acid/methanol/water (70:10:20:5)
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Neutral solvents
Solvent 5: Dichloromethane/acetone (5:4)
Solvent 6: Toluene/ethanol (4:1)
Solvent ?: Ethyl acetate/methanol (95:5)
Solvent 8: Chloroform/acetone (1:1)
Solvent l6: Ethyl acetate
Solvent 19: Chloroform/methanol (95:5)
Basic solvents
Solvent 9: Chloroform/raethanol/ammonia (5:4:1)
Solvent 10: Chloroform/isopropanol/ammonia (90;10:1)
Solvent 11: Dichloromethane/methanol/ammonia (65:35:5)
Solvent 12: Ether/ethanol/ammonia (6:4:1)
Solvent 13: Ether/ethanol/ammonia (8:2:1)
Solvent 14: Ethyl acetate/methanol/diethylamine (70:20:15)
t
Solvent 17: Cyclohexane/chloroforra/diethylamine (5:4:1)
Solvent 18: Chloroform/methanol/ammonia (90:10:1)
ANAESTHETIC
Halothane anaesthetic was supplied by ICI Ltd.,
Pharmaceuticals Division, Alderley Park, Macclesfield, Cheshire. 
ANIMALS
R^ts: Male and female COBS* rats, CD strain, descended from 
Sprague.-^Dawley were supplied by Charles River (U.K.) Ltd.,
Marston, Kent. They were maintained on a diet of Oxoid 4lB pellets 
and weighed between 200-300 g at the time of use unless otherwise 
stated. The same 4 male and 4 female animals were used throughout 
plasma kinetic, excretion balance and tissue excision studies.
Rats for biliary excretion studies were larger, circa 400 g.
Monkeys: Male and female red patas monkeys (Erythrocebus 
patas), weighing 2-5 kg were supplied by Shamrock Farms Ltd., 
Brighton, Sussex or Animal Suppliers (London) Ltd., Welwyn, Herts. 
They were kept on a diet of Oxoid 413 pellets, supplemented daily 
by fresh fruit. The same 4 monkeys were used to investigate plasma 
kinetics and excretion. Two of these animals were subsequently 
used for study of tissue distribution by tissue excision. Plasma 
kinetic data was subsequently supplemented by results in two 
further animals.
* Caesarian-originated, barrier sustained
Human subjects: Human subjects were two healthy male volunteers, 
ML and DM, weighing respectively 80 and 95 kg. They were fasted 
overnight but allowed to drink at will, though asked to refrain 
from stro'ng tea or coffee on the day of the study.
METHODS
DRUG ADMINISTRATION
All animals were starved overnight and for approximately 4 h
after drug administration, but were allowed water ad libitum.
14For oral administration to rats, C-tiquinamide HCl was given
by gastric intubation as a solution in saline (10 ml/kg). The
usual dose given was 10 mg/kg unless otherwise stated. This was
chosen as a dose which had a median anti-secretory effect.
For oral administration to monkeys, the drug was given by
gastric intubation as a solution in saline (5 ml/kg). The dose
was 10 mg/kg unless otherwise stated.
For administration to man, the drug was given in No 4 soft
gelatin capsules filled out with lactose. Each volunteer received
14
initially a 20 mg dose containing 5 ji2i C-tiquinamide HCl.
After a period of 7 Jays, the same volunteers were subsequently
14administered a 50 mg dose containing 50 juCi C-tiquinamide HCl.
The 5 jtiCi dose was of sufficiently high radioactivity to allow 
approximate determination of the rate of elimination such that the 
potential radiation exposure to a subject receiving a 50 ;uCi dose 
could be assessed. The 50 /iCi dose was adequate for more precise ‘ 
delineation of the pharmacokinetic profile over a period of several 
days and also allowed determination of the chromatographic pattern 
of radioactive end-products in 0-24 h urine.
SAMPLE 'COLLECTION
Blood: Blood (0.1-0.5 ml portions) was collected from the tail 
vein of conscious rats. When larger volumes (6-8 ml per animal) 
were required, animals were exsanguinated from the inferior venae 
cavae while under ether anaesthesia.
Monkeys were bled from the femoral vein (2-3 ml) and human 
volunteers from the cephalic, vein (10-20 ml).* In all cases, blood 
was collected in pre-heparinized tubes. Plasma and red cells 
were separated by centrifugation using either a Mistral 4l centrifuge 
(MSE Ltd., Crawley, Surrey) or for small volumes, a Beckman 
Microfuge, , Beckman Instruments Ltd., Croydon, Surrey.
Tissues: Small portions (100-200 mg in triplicate) of a wide 
range of tissues of rats and monkeys were removed by excision.
Urine, faeces and expired air; For collection of urine and
faeces, rats were housed in all-glass metabolism cages (Jencons Ltd.
14
Hemel Hempstead, Herts). Expired CO^ was trapped by drawing air 
into the cages and through Nilox columns containing 33% 
ethanolamine in ethanol.
Monkeys were housed either in specifically constructed primate 
metabolism cages (National Iron and Wire Co. Ltd., Manchester) 
or in conventional primate cages (E. K. Bowman Ltd., London) 
modified by the addition of sloping urine collection trays 
draining into suitable collecting vessels.
Human subjects voided urine samples directly into plastic 
collection bottles and faecal samples into small round polythene 
tubs (2.5 litre capacity, supplied by Solmedia Ltd., Walthamstow).
Bile; Bile was collected from the cannulated bile-ducts of 
female rats anaesthetized with halothane. Anaesthesia was induced 
with a 5% mixture of halothane in oxygen at 2 1/min and maintained 
for periods of up to 6 h on 1.5-2% mixture at 500 ml/h. In each 
animal, an abdominal incision was made’ and the bile duct located 
and freed from surrounding connective tissue. An incision was 
made in the duct wall with scissors and a cannula (Green Luer,
2 FG, Portex Ltd. Hythe, Kent) was inserted. The cannula was 
pushed into the duct in the direction of the liver until bile 
flowed freely along it and was then secured in position by two 
ligatures. The cannula was cut to a suitable length and the 
secreted bile allowed to drain into a 2 dram glass vial.
In monkeys, bile was collected from the gall bladders of the 
animals killed for tissue excision studies.
SAMPLE PREPARATION
Blood and tissues: V/hole blood and tissues were prepared for 
scintillation counting by an in-vial wet oxidation method similar 
to that described by Mahin and Lofberg (1966). Up to 250jul blood 
or 250 mg tissue was placed in a suitable scintillation vial 
(Packard, low potassium glass vials, type ,6001050) 0.5 nil 70% V/v 
perchloric acid and 1.0 ml 100 vol hydrogen peroxide were added 
and the vial sealed with a cap containing a polythene scive.
The vial was heated in an oven at 70°C for 1 h and subsequently 
cooled at -20°C for 20 min.
Bile: Bile was prepared, for liquid scintillation counting 
by direct incorporation of aliquots (20 pi) into NE260 scintillant. 
For thin-layer chromatography, bile was diluted with ethanol, 
evaporated to dryness under reduced pressure and residues dissolved 
in small volumes of methanol.
Faeces: Rat faeces were homogenized in methanol and the 
supernatant after centrifugation decanted. The pellet was dried 
overnight in an oven at 70°C. Portions of the dried pellet were 
treated by the in vial wet oxidation method of Mahin and Lofberg 
(19o6), as described previously. Monkey and human faeces were 
homogenized to a stiff sludge in a 0.1% aqueous solution of the 
bacteriostat chlorhexidine ("Hibitane", ICI Pharmaceuticals Ltd., 
Macclesfield, Cheshire), using a Colworth Stomacher paddle homo- 
genizer (A. J. Seward & Co. Ltd., London), as described by 
Morrison ai^ d Franklin (1978). Aliquots of the homogenate were 
treated by the modified Mahin and Lofberg acid digestion procedure 
described above. ,
Carcasses: Carcasses were dissolved by overnight incubation 
at 60°C in SHT solubilizer (1 litre/rat containing 80 g NaOH,
100 ml Triton X-*f05, 300 ml methanol a,nd 600 ml water), according 
to the method of Dent and Johnson (197*0*
Extraction from plasma or urine of a toluene-soluble fraction 
containing unchanged tiquinamide: The search for a specific assay 
for tiquinamide was made difficult by its readiness to degrade 
to the corresponding nitrile derivative during simple extraction 
procedures from biological fluids at initial concentrations below 
100 pg/ml approx. This meant that the unchanged drug could only 
be specifically assayed in plasma of animals dosed with radio­
labelled drug by a procedure involving loading of plasma to the 
appropriate concentration with unlabelled drug, solvent extraction 
of basified plasma with toluene and subsequent thin-layer 
chromatography of the extract, followed by quantitation of the 
band corresponding to unchanged drug by liquid scintillation 
counting. Such a procedure was adopted in order to determine 
unambiguously the kinetics of unchanged tiquinamide in animals. 
However, the method was relatively insensitive, requiring large 
volumes of plasma which necessitated, at least in rats, working
with pooled samples from several animals. Thus it imposed 
limitations on experimental design. Therefore, in some 
experiments in which it was more important to monitor the general 
kinetics of tiquinamide and related metabolites rather than the 
absolute concentrations of unchanged drug, a simplified procedure 
was utilized in which toluene-soluble radioactivity was used 
without subsequent t.l.c. as a measure of the maximum concentration 
of unchanged drug present.
•In a glass scintillation vial, plasma (0.1-2.0 ml) was made 
alkaline by addition of 1M bicarbonate buffer (pH9). Toluene-based 
scintillant (10 ml; 8.5 g butyl PBD* in 1 litre BDH "Analar" 
toluene) was added and after agitation for 15 sec on a vortex 
mixer and phase separation effected by gravity, 8 ml of the toluene 
scintillant was transferred to a clean glass vial. The aqueous 
phase and residual toluene were dissolved in 15 ml NE260 
scintillant and total radioactivity determined as the sum of toluen 
soluble- and residual radioactivity. The method was based on the
9
in vial extraction procedure described by Hess et al., 1972.
Tiquinamide was extracted quantitatively by this procedure, 
but extracts contained in addition the nitrile derivative and 
two other metabolites. The specificity of this assay will be 
discussed in more detail in Chapter VII.
DETERMINATION OF RADIOACTIVITY
Liquid scintillation counting: The universal scintillant for 
incorporation of all samples except toluene extracts was NE260
(Nuclear Enterprises Ltd., Edinburgh). Up to 2.0 ml of plasma
or urine, 1 ml of SHT digests, 20 ul of bile, or the total product 
of acid digestion of blood, tissues or faeces (up to 250 mg)
were dissolved in 15 ml NE260 prior to liquid scintillation
counting.
Determination of radioactivity was in a Packard "Tri-CarV1 
3380 liquid scintillation spectrometer, equipped with automatic 
external standardization. Counting efficiency correction curves 
(external standard ratio vs efficiency) were determined following 
chemical quenching by chloroform of scintillant to which had been 
added known amounts of a labelled standard ■ (^C-hexadecane).
* 2-(4-tert-Butyl phenyl)-5-(*+,t-biphenylyl)-l,3i^— oxadiazole
Comparison of the efficiency correction curves prepared by chemical
or colour quenching (using Su^an Yellow in toluene) showed them to
l*fbe very similar except at C efficiencies less than 30%.
1^In counting mixed isotope samples containing -carbon and
tritium, a restricted "window" setting was used which virtually
eliminated inclusion of tritium counts in the carbon channel.
For determination of tritium, however, a correction for spillover
of carbon into the tritium channel had to be made, based on a
calculation using the isotope ratio •
Isotope ratio =
efficiency of counting tritium in tritium channel 
efficiency of counting carbon in tritium channel
The isotope ratio was determined at different levels of quench and
its application allowed the calculation of the actual dpm in the
tritium channel due to tritium. The calculation was made by a
dedicated computational facility. (Packard Automatic Activity
Analyzer). The use of the isotope ratio method makes use of the
assumption of negligible spillover of tritium into the carbon
channel. This assumption was valid except in the gastric absorption
studies in conscious monkeys, when the specific activity of
3 14H-inulin greatly exceeded that of C-salicylic acid at the later
time-points. Therefore, in these experiments, the actual dpm due
to carbon and tritium had to be calculated manually fr©m simultaneous
equations using the carbon and tritium cpm values and the known
efficiencies for counting carbon and tritium in each channel.
Detection and quantitation of radioactivity on thin-layer
olates: Radioactivity on thin-layer plates was detected by use of
a thin-layer scanner (Panax Equipment Ltd., Redhill, Surrey) or
by apposition autoradiography.. Autoradiography was performed by
placing thin-layer plates in contact with X-ray film (X-O-Mat RP,
Kodak Ltd., London) in suitable light-proof X-ray cassettes
(Kodak Ltd., London) for periods of 7 days or more.. At the end
of the exposure period, films were removed and developed in an X-ray
developer (Ilford DX-80, diluted with A parts-water). After 3 min
in the developer, each film was transferred to a stop-bath
containing acetic acid and finally to a third bath containing
fixative (Ilford FX-*fO, diluted with 4 parts water). Films were
washed in cold, running water for 15 min each and hung u p to dry.
Quantitation of radioactivity on thin-layer plates was by 
scraping and subsequent liquid scintillation counting. The area 
of the plate between 1 cm below the origin and the solvent front 
was segmented as described in the relevant Experimental section.
Each segment was scraped off with a straight-edged scalpel blade, 
powdered and transferred to a polypropylene scintillation vial. 
Desorption of radioactivity was effected by addition of 2 ml 
methanol/water (1:1), and assay of radioactivity was by liquid 
scintillation counting, following the addition of 15 nil scintillant.
WHOLE BODY AUTORADIOGRAPHY
Whole body autoradiography was performed by Dr. P. Nicholls and 
Dr. D.K. Luscombe (Department of Pharmacology, University of Wales 
Institute of Science and technology, Cardiff). The animal carcass was 
pinned to a board and rapidly frozen in a mixture of hexane and CO^.
The frozen rats were then embedded in frozen 1% carboxvmethylcellulose 
and saggital sections at 20 u thickness were cut from the left side of 
the animal. The frozen sections were transferred to 3M’s tape and 
dehydrated at -20°C for 4 days. The sections were then exposed to 
Kodak X-ray film for either 4 weeks (Kodirex, Kodak Ltd., London) or 
3 months (Industrex, Ilford Ltd., London). After this time the sections 
were removed from the photographic emulsion in air in the darkroom.
The X-ray film was developed in Ilford X-ray developer for 4 min at
20°C to yield the autoradiograms.
*
PHARMACOKINETIC ANALYSIS
Analysis of plasma kinetics assumed first order, linear kinetics 
and was performed according to methods described, for example, by 
Wagner (1971)* Plasma concentrations of unchanged drug, toluene-soluble 
radioactivity or total radioactivity were logarithmically transformed 
(log^) and plotted against time. If the resulting plot was linear, 
representing a monoexponential relationship, the best-fit straight line 
was determined by regression analysis, when the elimination half-life 
could be determined from the slop&of the line, thus:
Elimination rate constant, kel = 2.303 x slope
Elimination half-life, tVz = 0.693
kel
In those cases when the plot was not linear throughout the entire 
time-course, the process of curve-stripoing was performed, in order 
to distinguish two exponential components, a fast (*) chase and 
a slow (/3 ) phase. It was not found necessary in these experiments
to resort to more than two exponential components to define the 
time-course of any elimination process. The half-life of each phase 
was determined after regression analysis as in the monoexponential 
case.
Areas under plasma concentration - time curves were calculated 
by means of the trapezoidal rule and were expressed as dose/area 
ratios for the purposes of comparison at different doses.
Analysis of urinary excretion kinetics was by the sigma-minus 
method described by Martin (1967). The total proportion of the 
radioactive dose excreted by the urinary route was summed and the 
amount excreted by a given time after dosing expressed as a 
percentage of this total. The percentage of the total activity 
remaining to be excreted in urine was then determined by subtraction. 
Plots of logjQ (percentage total remaining to be excreted in urine) 
against time resulted in curves which could be represented as the 
sum of two exponential components, separable by curve-stripping 
as described above. Regression analysis performed to define the 
best-fit straight lines representing the individual component 
chases (**and^ ) made possible the calculation of the half-life 
for each phase from the slope of the line, as described above.
The proportions of total excretion occurring in each phase were 
represented by the respective y-intercepts.
For analysis of urinary excretion kinetics in the rat, a 
modification of the sigma-minus method was required in order to 
allow for the fact that excretion was incomplete at 7 days when 
the last collections of urine and faeces were made. Since carcass 
residue studies revealed the proportion of the dose remaining to 
be excreted at this time, the proportion of this amount which 
would be ultimately eliminated in urine could be determined from 
the ratio of urinary/faecal excretion occurring during the slow 
phase in the previous 7 days, found to be fairly constant. Thus 
a value for the true total percentage of the dose eliminated in 
urine in infinite time could be determined so as to provide the 
basis for sigma-minus analysis.
CHAPTER III; ABSORPTION OF TIQUINAMIDE IN THE PATAS MONKEY
SUMMARY
The extent of gastric absorption of tiquinamide in the patas 
monkey was investigated in view of the possibility that the 
combination of the low pKa with the relatively high lipophilicity 
of this compound promoted absorption by this route. Studies in 
conscious animals employed a novel mixed-isotope method which 
allowed determination of gastric absorption rates in the presence 
of normal gastric emptying. The gastric absorption rate was
determined as the rate of decline of the ratio of concentration of
lh 3
C-labelled drug to that of an inert marker, H-inulin.
Results showed that whilst tiquinamide was apparently well
absorbed from the stomachs of anaesthetized, pylorus-ligated
monkeys, it was inconsistently gastrically absorbed in conscious
animals with uncontrolled starting pH of gastric contents. Reasons
t
for this difference were discussed.
Tiquinamide was found not to significantly alter the rate of 
gastric emptying in the patas monkey.
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INTRODUCTION
Gastric absorption of the weakly basic tiquinamide was a 
finite possibility because of the combination of its anti-secretory 
properties with its low pKa and moderately high lipophilicity, 
as discussed in Chapter I, It was of interest to establish the 
extent of gastric absorption of tiquinamide because it could be 
advantageous for an inhibitor of acid secretion to be absorbed 
through the gastric mucosa, especially if the compound were subject 
to a high degree of first-pass metabolism. Because delayed gastric 
emptying would enhance the extent of any gastric absorption which 
occurred, it was important also to determine the effect of tiquinamide 
on the rate of gastric emptying. There had been a previous indication 
that the compound inhibited gastric emptying in rats (Beattie et al. , 
1979b), but it was more relevant to establish its effect in a 
primate because the normal rate of gastric emptying in primates,^ 
and particularly in man', was considerably slower than in rats.
Thus gastric emptying half-lives in patas monkey and man arz j 
respectively approximately 30 min (Franklin, 1977) and ^7-70 min 
(Van Dam, 197^; Griffith et al., 1968; Harvey et al., 1970) 
compared with around 10 min only in the rat (Feldman, Wynn &
Gibaldi, 1968; Franklin, 1977).
The method most frequently used for investigating the gastric 
absorption of drugs is that employed by Schanker et al., (1957) <. 
which involves measurement of the decline in concentration of drug 
in the pylorus-ligated stomach. In the absence of adsorption to 
the stomach wall, this provides a means of studying the potential 
for gastric absorption of a drug in relation to its lipophilicity 
and pKa and for comparing this potential with those of other drugs. 
However, the method is subject to the limitation that it doesi.not 
permit evaluation of the significance of gastric absorption in the 
presence of normal gastric emptying. Furthermore, the presence 
of an anaesthetic as an accessory tothe pylorus-ligation may itself 
influence the course of gastric absorption by altering gastric 
motility and blood flow to the stomach. Hence, if the significance 
of gastric absorption of a given drug under normal physiological 
conditions is to be properly evaluated, this process should be 
examined in conscious animals with a functioning pylorus.
Several workers have described the use of non-absorbable 
markers in absorption studies to make an allowance for loss of 
drug by gastric emptying and also for dilution of stomach contents 
by gastric secretion. For example, Cooke and Hunt (1970) used the 
marker phenol red when studying the gastric absorption of 
acetylsalicylic acid in man. The method relies on the principle that 
changes in drug concentration resulting from gastric emptying and 
dilution of stomach contents are paralleled by similar changes in 
the concentration of the marker. Any additional decline in drug 
concentration must then result from gastric absorption. In all 
previous studies, the non-absorbable marker was unlabelled and was 
determined spectrophotometrically by an assay separate from that 
used to measure concentrations of the drug in-stomach contents.
The low sensitivity of the assay methods necessitated the use of
£
relatively high concentrations of non-absorbable markers. Under
these conditions, the method is subject to the criticism that the
marker itself may influence the absorption of the drug (Beerman,
Groschinsky-Grind and Rosen, 1976). Because of these limitations,
a novel mixed isotope procedure was developed during the present
work to investigate absorption under normal physiological conditions.
l*fThe ratio of concentration of a C-labelled drug to that of an 
3
H-labelled marker was used to make automatic compensation for
effects of volume changes and gastric emptying. The high specific
activity of the marker made possible the use of a much lower
concentration than that of drug, so minimizing the possibility of
interference with absorption. The rate of gastric absorption
1 3
was indicated simply by the rate of decline of the C/ H ratio 
in gastric contents.
MATERIALS AND METHODS
Materials 
 J5—
C-salicylic acid (specific activity 87*2 ;uCi/mg), 
^C-polyethylene glycol kOOO (PEG kOOO; 3^»7 jiCi/rag) and 
^H-inulin (500 pCi/mg) were obtained from The Radiochemical Centre, 
Amersham and diluted as dictated by the needs of individual 
experiments
EXPERIMENTAL
(a) Absorption of tiquinamide in anaesthetized, pylorus-ligated
and sham-operated patas monkeys
Surgery was performed under halothane anaesthesia (0.5-^*0%). 
Animals were kept warm by means of a thermal blanket. Rectal 
temperature and respiration rates were monitored throughout. Depth 
of anaesthesia was adjusted as necessary by varying the halothane/ 
oxygen ratio.
Tracheotomy was performed to assist breathing under anaesthesia 
and abdominal incisions were made. In three animals, the pylorus 
was subsequently ligated. In the other two animals sham-operation 
was performed by passing a ligature underneath the pylorus but
leaving it untied and the pylorus- unrestricted. A solution of
Ik oC-tiquinamide HC1 in isotonic saline was warmed to 37 C to reduce
the probability of regurgitation, and was then administered by
gavage at a dose of 10 mg/ kg (5 ral/kg).
Blood samples (circa 2 ml.) were collected from the femoral
vein at various times up to 5 h after dosing as detailed in
Fig. III.l. Concentrations in plasma of total radioactivity and
toluene-soluble radioactivity containing unchanged drug were
determined by liquid scintillation counting, as described previously.
(Chapter II p.45 ).
(b) Gastric absorption of tiquinamide in conscious*patas monkeys
Salicylic acid was chosen for the validation of the mixed
isotope method because it was readily available in radiolabelled
form and, like many other weak acids, it had been shown to be
rapidly absorbed from the stomach (Schanker et al., 1957?
Hogben et al., 1957)•
^C-salicylic acid (1.60 juCi/rag) was administered at 0.5 mg/kg
by gastric intubation using a solution (5 ml/kg) of the drug in
saline containing 1 jug/ml ^H-inulin (500 juCi/mg). Alternatively, 
l^ fC-tiquinamide HC1 (0.21 MCi/mg) was administered in the same 
manner at 10 mg/kg. The dose solution in this case was in isotonic 
saline containing 6 ug/ml ^H-inulin (500 ^ iCi/mg).
For a period of 1 h after drug administration, small aliquots 
(0.5-1*0 ml) of gastric contents were withdrawn at 10 min intervals. 
At the end of this time, stomach contents were aspirated so that
the amount of remaining ^H-inulin could be assayed. Because of
the possibility of incomplete recovery of stomach contents in the
final gastric v/ash, the efficiency of this recovery was checked
14by introduction of an additional non-absorbable marker, C-PEG
4000. It was administered by gastric intubation of 20 ml of a
12 jng/ml solution (8.15 hCi) in isotonic saline and was recovered
within 3 min of dosing by washing out with 3 x 50 ml isotonic
14saline. Radioactivity administered as C-PEG 4000 was in large
14excess over that of any remaining C-salicylic acid, which thus
14did not interfere with the determination of the C-labelled marker.
All samples of gastric contents were centrifuged to precipitate
any solid matter. An estimate of the pH of each sample was made
using pH papers (Whatman BDH narrow range, graduated in 0.5 pH 
14
units). Carbon and tritium activities of 0.1-0.5 ml aliquots.
were assayed by liquid scintillation counting as described.
(Chapter II p.45).
The half-life of gastric absorption of salicylic acid was
calculated from the slope of the regression lines relating log.
14 3
C/^H ratio to time after dosing. The gastric emptying half-life
3
was determined from the amount of H-inulin not emptied from the 
stomach, assuming exponential emptying, as established by Hunt 
and MacDonald (1954) from studies in man. The method of calculation 
used the formula:
Gastric emptying VM r- Q— —  \
losi o / M
3where/XQ\was the fraction of the dose of H-inulin remaining
—\X,/ in the stomach at time t.
The total percentage of the administered dose absorbed from 
the stomach was calculated from the rate constants for gastric 
absorption and gastric emptying, k and k respectively, as 
follows:
kPercentage dose absorbed * ga x 100%,
■ k + k ga ge
where rate constant, k = 0.693
t#
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(c) E.ffect of tiquinamide on gastric emptying in conscious patas 
monkeys
The half-life of normal gastric emptying was determined using
l*fC-PEG *f000 (21.A- jiCi/rag) as an 11 jag/cal solution in isotonic
saline. Each animal received by oral intubation 20 ml containing
5 hCi (0.06 mg/kg). Unlabelled tiquinamide HC1 was administered
at 10 mg/kg as a solution in the above vehicle (5 ml/kg). The
experiment was performed twice in each monkey. In each experiment
1^
every monkey received a control dose containing C-PEG *f000 alone 
in the morning followed by a dose containing also tiquinamide HC1 
in the afternoon.
At 30 min after dosing, H-inulin (89*7 MCi/mg) at 6 jag/m 1 
in saline (20 ml) was introduced into the stomach and gastric 
contents were washed out with 3 x 50 ml isotonic saline. AVI
gastric washes from each animal were pooled and replicate 1 ml
14 •
aliquots were assayed for -carbon and tritium content by the
liquid scintillation counting procedure, described in Chapter II 
p. ^5 •
Gastric emptying half-lives were determined by the method 
described above.
RESULTS
(a) Absorption of tiquinamide in anaesthetized, pylorus-ligated 
and sham-onerated monkeys
In Fig. III.l are expressed plasma concentrations of toluene-
soluble radioactivity and total radioactivity in anaesthetized,
pylorus-ligated or sham-operated patas monkeys.
It was evident from the detection of the significant
concentrations of toluene-soluble and total radioactivity in the
plasma of pylorus-ligated monkeys that gastric absorption had
occurred in these animals.
Toluene-soluble radioactivity concentrations in plasma increased
at similar rates in pylorus-ligated and sham-operated animals for
a period of at least 2 h. Thus concentrations in pylorus-ligat-ed
•* l^ fanimals were 0.7-1.2 ;ug equivalents C-tiquinamide HCl/ml at 
1 h after dosing and in sham-operated animals were 0.7-0.8 jig equi­
valents/ml at this time. Similarly at 2 h plasma concentrations 
in pylorus-ligated animals were 1.1-2.2 pg equivalents/ml and in 
sham-operated animals 1.1-1.4 jug equivalents/ml. Thus absorption 
rates were similar in the two groups of animals over this period. 
Concentrations of total radioactivity in plasma confirmed these 
observations, despite somewhat greater inter-animal variations in 
this parameter among the pylorus-ligated animals. Thus at 1 h 
after dosing total radioactivity concentrations in plasma of 
pylorus-ligated animals were 1.2-^.^ /ig equivalents/ml and in 
sham-operated animals were 1.7-1*9 P-g equivalents/ml. At 2 h 
after dosing, the concentrations were 2.1-5*3 y^ g equivalents/ml 
in pylorus-ligated animals and 2.9-3*0 p g  equivalents/ml in sham- 
operated animals.
Absorption occurred more slowly after about 2 h, as it 
approached completeness. Thus in pylorus-ligated animals, 
the maximum value (2.2 jug equivalents/ml) of toluene-soluble 
radioactivity was achieved in one animal (+ 309) at 2 h after 
dosing and in the other two animals, a plateau value of 1.3-1*6 pg 
equivalents/ml was approached from 3 h after dosing onwards.
The maximum proportion of unabsorbed drug at the termination of 
the experiment was 12-35%>i as represented by total radioactivity 
in the gastric contents, which, however, might have included some 
absorbed drug secreted back intothe stomach. In sham-operated
* The unit jig equivalent l^C-tiquinamide.HC1 is derived by division of 
the determined radioactivity (dpm) by the specific activity (dpm/jig 
tiquinamide.HC1) .
animals, less than 3% of the dose remained in the gastric contents 
at the termination of the experiment, but there may, of course, 
have been unabsorbed drug in the small intestine of these animals.
Areas under the plasma-concentration time curves indicated that 
there was not a substantial difference in the total extent of 
absorption over the 0-4 h period between pylorus-ligated and sham- 
operated animals. Thus the areas under the plasma concentration 
time curve from 0-4 h for toluene-soluble radioactivity were 
3*9-5*4 and 4.4-6.2 jug h.ml respectively. Similarly, for total 
radioactivity, areas calculated over the same time period were
7.4-20.1 and 13*9-14.4 jug h.ml ^ respectively (Table III.l).
The pH of gastric contents at the time of death was relatively 
high in all animals, ranging from 4.1-6.4 in pylorus-ligated 
monkeys and from 6.7-7*7 in sham-operated animals.
(b) Gastric absorption of tiquinamide in conscious patas monkeys
far
Validation of the method for salicylic acid: In Fig. III.2
14 3are expressed the ratios of C-salicylic acid/ H-inulin in samples
of gastric' contents withdrawn at various times up to 60 min after
14a 0.3 mg/kg oral dose of C-salicylic acid administered simultaneously
3
with an 0.05 mg/kg dose of H-inulin to 3 patas monkeys. Ratios 
declined monoexponentially with time (mean correlation coefficient =
0.996),*indicating that gastric absorption of salicylic acid had 
occurred. In Table III.2 are presented the half-lives of gastric 
absorption and gastric emptying and the percentages of dose absorbed 
from the stomach. The half-life of gastric absorption was approxi­
mately 13 min and of gastric emptying 37 min.
The percentage of the administered dose absorbed from the 
stomach would therefore have been of the order of 70%.
Tiquinamide: In Fig. III.3 are expressed the ratios of
14 3
C-tiquinamide/ H-inulin and the approximate pH values in samples
of gastric contents withdrawn at various times up to 60 min after
14
a 10 mg/kg oral dose of C-tiquinamide HC1 administered
simultaneously with a 0.05-mg/kg dose of ^H-inulin to five
conscious patas monkeys.
14 3
The change in the C/ H ratio was more complex and showed 
greater inter-animal variation for tiquinamide than for salicylic 
acid. The major factor in the inter-animal variation appeared to 
be the pH of gastric contents. In two animals (cT351 snd <^354),
14 3the C/ H ratio declined within 1 min to 80-90% of the.initial 
value, but subsequently remained approximately constant in this 
range for the following 60 min. The pH was found to decline from 
the initial starting value of *f.7 in the dose solution in saline 
to pH 2.5 (d*351) and pH 3-5-^ (0*35*0 at 1 min after dosing and 
subsequently did not rise above pH 2.5 in either monkey over the 
50 min period of monitoring.
In two other monkeys (+312 and +322), the ^C/^H ratio 
declined respectively to 31%’ at 10 min and 23% at 20 min after 
dosing and subsequently rose to settle around the range k0r50% and 
50-60% respectively of the starting value. In these animals, the 
pH changes were less marked, remaining in the range *+.5-5»5» close
to the pH of the dose solution, throughout the 60 min after dosing.
- 14 3
In the fifth monkey, ct355» the C/ H ratio declined rapidly
over the firs't 30 min to a value of less than 2% of the starting
value and remained below 10% of this value for the remainder of the
experiment. There was evidence of gastric bleeding in this animal,
and hence gastric mucosal damage may have contributed to the more
rapid absorption of tiquinamide. However, it was also observed
that the pH in gastric contents of this animal rose to pH 7 at
10 min after dosing and to pH 8-5-9*0 subsequently.
In view of the wide inter-animal variation and the absence
14 3
of a simple linear relationship between log ( C/ H ratio) and 
time, no sensible attempt could be made to determine half-lives 
of gastric absorption of tiquinamide in these animals. Consequently, 
the percentage of drug absorbed from the stomach could not be 
determined.
(c) Effect of tiquinamide HC1 on the rate of gastric emptying 
in conscious patas monkeys
In Tsi)le III.3 are expressed percentage recoveries of
Ik 3C-polyethylene glycol, percentage recoveries of H-inulin and
gastric emptying half-lives in patas monkeys in the presence and
absence of a 10 rag/kg oral dose of tiquinamide HC1.
Whilst the majority of values of gastric emptying half-life
were below 50 min, there were some very high values indicative
of gastric stasis. It has been suggested that depressed
psychological states can result in delayed gastric emptying
(Mayersohn, 1971)• Possibly the trauma associated with removal
of animals from cages and restraint during dosing induced a delay 
in the onset of gastric emptying on some occasions. 'In view of the 
short experimental period of 30 min, quite a brief delay in the 
onset of emptying would have resulted in an apparent gastric 
emptying half-life substantially longer than normal. The 
distinction between normal gastric emptying and gastric stasis was 
made on the basis of a frequency distribution (Table Ill.^f) which 
clearly demonstrated an approximately normal Gaussian distribution 
for 19 values in the range 0-50 min with an additional 9 observations 
distributed randomly over an interval from 70 to CO . Gastric 
stasis did not occur any more frequently in tiquinamide-dosed 
monkeys (5 observations) than under control conditions 
(k observations). When these values were excluded from the 
statistical analysis, the mean gastric emptying half-life in control 
animals, averaged over two experiments, was 1 7 - *+*0 min. in the 
presence of a 10 mg/kg oral dose of tiquinamide EC1, the mean half- 
life in the same 7 animals was 26.6 - k.J> rain. Hence there was an 
indication that a 10 mg/kg oral dose of tiquinamide HC1 delayed 
gastric emptying in the patas monkey to a minor extent. However, 
the difference was not significant at the 5% level (p= 0.1-0.2, 
as determined by Student’s t-test).
DISCUSSION >
A novel mixed isotope method for studying the gastric
absorption of drugs
The effectiveness of this novel mixed isotope method for
demonstrating the occurrence of gastric absorption was quite clearly
established with reference to the well-known example of salicylic
acid absorption. The only other circumstance which could have
14 3accounted for the monoexponential decline of the * C/ H ratio 
in this experiment was concentration-dependent adsorption of the 
drug to the stomach wall. However, the absence of significant 
adsorption of salicylic acid to stomach wall had already been 
demonstrated by Schanker et al., (1957)* who first observed the 
gastric absorption of this compound. The half-life of 13 min 
observed for the gastric absorption of salicylic acid in the present 
studies was very similar to the value of Ik min in man calculated 
from the data of Hogben et al., (1957) as presented by Levy and 
Leonards (19&6)*
In the rhesus monkey, Nayak and Benet (197*0 demonstrated 
quite rapid gastric absorption of salicylic acid. Though it was 
not possible to determine an accurate half-life from their data, 
the appearance of maximum plasma concentrations within 1.5 h of 
drug administration suggested a half-life of a similar order to
A
that determined in the present experiments. Thus the new mixed 
isotope method developed during the current work proved to be a 
useful simplification of previously described procedures for 
demonstrating the phenomenon of gastric absorption in conscious 
animals.
For acidic compounds such as salicylic acid not subject to 
secretion from plasma back into gastric contents, the method 
allowed simultaneous determination of rates of gastric absorption 
and gastric emptying and thus permitted a simple assessment of the 
total extent to which gastric absorption occurred under conditions 
of unimpaired gastric emptying.
The gastric absorption of tiquinamide
iln conscious animals, the extent of gastric absorption was 
equivocal. Differences between animals in the degree of gastric 
absorption were apparently related tothe wide variation of gastric 
pH. Gastric absorption was insignificant in those animals (d?*351 
and c? 35*0 with low gastric pH (2-2.5), moderate in those animals
(5+ 312 and ° 322) with pH at 4.5-8 in the range of the pKa of
tiquinamide (5*2), and very extensive in one animal (0*355) in
which the pH rose as high as 8.5-9* The reasons for the pH variation
are not known. Theoretically, the pH of the gastric contents
immediately after dosing would have been that of the dose solution
i.e. pH 4.6. However, it may be speculated that the low values
in two animals resulted from acidification by residual acid in the
stomach. The high value in one animal may, conversely, have
resulted from reflux of the duodenal secretions, particularly bile,
into the stomach.' Whatever the reasons for the pH variation, it
was a necessary consequence predicted by Schanker's pH-partition
hypothesis that tiquinamide would be more extensively gastrically
absorbed at higher than at lower gastric pH'§ with-a pKa of 5*2,
it would have been only 0.5%*unionized at pH 2, but 67% unionized
at pH 6 and 98% at pH 9* It is a generally valid assumption of the
above hypothesis that drugs are much more readily absorbed in their
14 3
unionized than in their ionized states. The tendency of the C/ H 
ratio in the two animals with median gastric pH to increase again, 
after significant initial gastric absorption, possibly reflected 
back-secretion of absorbed drug into the gastric contents as a 
result of the greater degree of ionization in gastric contents at 
pH 5-8 than in plasma at pH 7*4. It is common for basic compounds 
to be secreted into the normally very acidic (pH 1-3) gastric contents 
because the extensive and instantaneous ionization which occurs at 
such pH's ensures that there is always a concentration gradient in 
favour of the passage of unionized drug from plasma into gastric 
contents (Shore, Brodie and Hogben, 1957)* This would occur, 
though at a lower rate, even at higher pH's unless the gastric 
contents achieved pH 7.4.
The enhancement of gastric absorption in halothane-anaesthetized, 
pylorus-ligated animals was evidently a consequence of the artificiality 
of the conditions. Pylorus-ligation would have retained in the 
stomach drug which might otherwise have been emptied into the small 
intestine, making it no longer available for gastric absorption.’ 
Furthermore, it was possible that halothane anaesthetic had 
facilitated gastric absorption by enhancing gastric mucosal blood 
flow, since it is known to be a vaso-dilator (Johnstone, 1958).
062
Ethanol has been shown to promote drug absorption by such a 
mechanism (Magnussen, 1968)• In addition, halothane inhibits 
gastric emptying, and therefore could have promoted gastric 
absorption in the sham-operated animals by increasing the residence 
time in the stomach. (Marshall, Pittinger and Long, 1961)*
Finally, there is evidence to suggest that halothane elevates 
the pH of gastric contents by itself inhibiting acid secretion. 
MacKrell and Schwartz (1969) reported a dose-dependent decrease in 
hydrogen ion secretion in the isolated gastric mucosa of frogs 
anaesthetized with halothane. Furthermore, Christensen and Skovsted 
(1975) observed elevated pH of gastric contents in halothane- 
anaesthetized patients undergoing non-abdominal surgery. Thus, 
it seems possible that in halothane-anaesthetized monkeys in the 
present experiment, the pH of gastric contents may have been 
already significantly raised before absorption of tiquinamide took 
place. In view of the pH-dependence of gastric absorption of 
tiquinamide in conscious animals, it seems likely that it was
-r':Vi the elevating effect of Halothane on the pH of gastric 
contents which was primarily responsible for the enhancement of 
gastric absorption in anaesthetized, pylorus-ligated monkeys.
In conclusion, it seems evident, in view of the variable and 
pH-dependent gastric absorption of a single 10 mg/kg dose that 
gastric absorption of tiquinamide in a normally secreting stomach 
would be of low significance. However, the possibility still 
remains that once inhibition of acid secretion was established, 
subsequent doses would be more extensively gastrically absorbed. 
Results of investigations into the effect of tiquinamide on the 
rate of gastric emptying have suggested that any contribution to 
the overall extent of gastric absorption made by inhibition of 
gastric emptying would be minimal.
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Fig. m .1 :
Toluene-soluble and total radioactivity in plasma of anaesthetized, 
pylorus-ligated and sham-operated patas monkeys following 
oral administration of 14C-tiquinamide HCl. at 10mg/kg.
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Monkey
no
Gastric 
absorption 
tA (min)
Gastric 
emptying 
tA (min)
% dose
absorbed from 
stoma cbj
Z 1 35^ 13.1 22.7 63.4
° 356 9.6 53.8 80.9
? 358 15.7 35.^ Sk.3
Mean 12.8 37*3 69.0
- SEM i 1.5 - 9.0 ± 6.1
Table III.2: Half-lives of gastric absorption and gastric
emptying and percentages of dose absorbed from 
the stomach following 0.5 mg/kg administration
- j .
of C-salicylic acid to conscious •patas monkeys
CONTROL TIQUINAMIDE HC1
Monkey
No
%
recovery
14c-peg
%
recovery
3H-inulin
t'fc
(min)
%
recovery
^C-PEG
%
recovery
^H-inulin
Vk-
(min)
0*30.6 12*1,24.2
82.4, 
26.6
11.4,
19.3
14.8,
22.6
78.4,
73.5
12.4,
20.8
0*307 14.9,33.5
81.8, 
77.1
12.4,
26.6
84.4 , 
57.3
74.4,
50.8
CO .
,
00
% 313 83.5 ’, 
10.1
85.2,
59.6
1014 , 
12.8
76.9- , 
11.7
84.9,
57.6
237 ,
14.7
S- 314 6.42,
1.22
68.8,
73.6
8.7,
6.2
48.6,
38.0
79.7,
76.8
48.8,
32.9
? 291 91.2 , 
58.6
90.4,
61.4 49.0*
80.5~ 
30.1
93.3,
100.0
151. , 
14.1
? 312 59.3,
59.3,
92.7,
10.8
49.7,
13.9
68.9, 
49.9
92.8,
90.3
86.1 , 
32.7
+ 322 17.6,
15.6
85.6,
81.1
15.6,
13.4
40.7,
26.9
60.4 ,
75.7
41.3,
20.8
Mean 
i SEM 22.0
- 9.5,
24.0
- 8.4
83.8
- 2.9,
73.0
- 3.4*
19.6 
± 7.6 
+!5.7 
- 3.4
4 3.3 
-11.2, 
29.9 
- 5.4
81.6 
t 5.0, 
79.0 
i 3.8
34.2 
±11.0, 
22.8 
± 4.3
Overall 
Mean - 23*1 
SEM -6.0 
(2 exots)
78.4
-2.6
17.6 
- 4.0
35.2 
- 5.6
77.8 
i 3.8
26.6 
- 4.3
Table 111*3! Effect of 10 mg/kg C-tiquinamide HC1 on the
half-life of gastric emptying in conscious oatas 
monkeys
Each animal received, a control dose of 20 ml C-polyethylene 
glycol 4000 ((PEG) in isotonic saline in the morning. After 
30 min, a solution of H-inulin in saline was introduced to 
aid quantitation of the completeness of recovery of gastric 
contents. Gastric contents were washed out with 3 x 50 ml 
saline. Results expressed are the percentage recoveries of each 
radiolabelled marker and the half-life of gastric emptying of 
14C-PEG in saline.
In the afternoon each animal received a 10 mg/kg dose of tiquinamide 
HC1 dissolved in the 20 ml -^C-PEG saline solution. The experiment 
was performed tv/ice in each animal on different days.
Gastric emptying 
half-life (min)
No. of observations 
in range Comments
1-10 2 )
10-20 7 ) Normal
20-30 3 ) gastric
30-40 2 ) emptying
40-50 3 )
50-60 0
60-70 0
70-80 1 )
80-90 1 ) Gastric
90-100 0 ) stasis
100-1000 3 )
> 1000 4 ) ■
Table 111*4: Frequency distribution of gastric-emotying
half-lives in conscious natas monkeys
CHAPTER IV: METABOLISM OF TIQUINAMIDE IN THE RAT
SUMMARY
A study of the nature of end-products in 0-24 h urine of rats
revealed the presence of at least three major pathways of bio-
transformation. w-Oxidation of the 3-methyl group resulted in the
formation of 8-cyano-5*6*7,8-tetrahydro-3-hydroxymethylquinoline
and, after further Oxidation, 8-cyano-5»6,7,8-tetrahydroquinoline-3
carboxylic acid. Allylic hydroxylation at the 5-position and
subsequent glucuronide conjugation gave rise to 5,hydroxy,8-cyano-
5,6,7,8-tetrahydro-3-methylquinoline and its glucuronide conjugat
Aromatiz.ation of the tetrahydroquinoline ring resulted in 8-cyano-
quinoline-3-carboxylic acid. Desulphuration was probably a fourth
metabolic pathway, but some uncertainty remained about the extent
*
to which this reaction occurred enzymically because the thioamides 
would have degraded chemically to the corresponding nitriles.
Preliminary chromatographic characterisation of products 
in 0-6 h bile suggested that 8-cyano-5,6,7,8-tetrahydro-3-methyl- 
quinoline,8-cyano-5i6,7,8-tetrahy{iroquinoline-3-carboxylic acid 
and the glucuronide conjugate of 5-hydroxy,8-cyano-5,6,7,8-tetra- 
hydro-3-methylquinoline, as well as a polar product absent from 
urine, were all excreted in small amounts.
Possible mechanisms of formation of the major metabolites 
are discussed.
INTRODUCTION
As previously discussed (Chapter I p.31 ), the extent and 
nature of the metabolism of tiquinamide had potential significance 
for its pharmacology and toxicology. Furthermore, it was of 
interest for its own sake because the metabolism of 5*6,7,8-tetra- 
hydroquinolines had not previously been studied.
Possible routes of biotransforraation of tiquinamide, reviewed 
previously in Chapter I (p. 23) included desulphuration of the 
thioamide and/or sulphoxidation,w-oxidation of the 3-methyl group, 
aliphatic or aromatic hydroxylation in the tetrahydroquinoline 
ring system, aromatization and N-oxidation or N-methylation.
It remained to be seen which of these would prove most significant 
in vivo in the species of interest, or indeed whether previously 
unsuspected routes of metabolism would be revealed.
Methods used to study the nature of the major metabolites 
in 0-24 h urine were based on the establishment of a chromatographic 
pattern in a single suitable solvent system, combined with the 
testing of the homogeneity of individual components by further 
t.I.e. in different solvent systems. Some of the components 
present in the highest proportions were then isolated by preparative 
layer chromatography and characterised by physico-chemical means. 
Because of the inherent instability of the thioamide group of 
tiquinamide, combined with the knowledge that thioamide-containing 
metabolites were potentially pharmacologically active, attempts 
were made to establish; the extent of urinary excretion of such 
compounds.
V f
EXPERIMENTAL
(at) The chromatographic pattern of drug-related products in urine
Three female rats, weighing 180-200 g, each received 10 mg/kg
lA
C-tiquinamide HC1 as a solution in saline. Rats were housed in 
all-glass maetabolism cages (Jencons Ltd., Hemel Hempstead, Herts) 
and urine collected over the following intervals: 0-3* 3-6.5»
6.5-24, and 24-48 h. Collection vessels were surrounded by solid 
CO^ for the period up to 6.5 h, representing the remainder of a 
working day, but returned to room temperature on standing overnight.
A pooled 0-24 h urine sample was prepared for each animal. The 
chromatographic pattern was determined by t.l.c. on silica plates 
(Quantum Industries) in solvent 1 (p.38). Preliminary investigations 
of different solvents had revealed that this solvent system-separated 
the largest number of individual components. After location of 
radioactivity on t.l.c. plates by thin-layer scanning and auto­
radiography, the clearly definable bands were designated RT1-RT6 in 
order of increasing mobility, which was determined relative to 
5,6,7i8-tetrahydroquinoline-3-carboxylic acid (THQ-COOH). This 
was chosen as the reference compound after preliminary studies 
because it was a readily available compound which in solvent 
system 1 ran to a median position on the plate-near to several 
major radioactive components and was thus preferable t«o unchanged 
drug which ran to a position near ‘the solvent front. The 
distribution of radioactivity among the major and minor bands 
on the plate was quantitated by scraping 0.5 cm strips into 
scintillation vials followed by elution and assay by liquid 
scintillation counting.
As a check on the stability of the observed products, the 
determination of the chromatographic pattern was repeated on a 
portion of the 0-24 h urine allowed to remain at anfoient temperature 
for 7 days prior to analysis.
In an examination of homogeneity, components separated by 
chromatography in solvent 1 were scraped off, eluted with methanol 
and certain of the most prominent ones subjected to further thin- 
layer chromatography.
Bands RT3 and RT4 were chromatographed on silica plates 
(Merck) in solvents 2, 3* H  and 12.
Band RT5 was separated into two components, RT5A and RT5B 
by t.l.c. in dichloromethane/acetone (5:4). RT5A was subjected 
to further t.l.c. in solvents 4, 6, 10 and 15 and RT5B in solvents 
6, 10 and 13*
(b) The stability of the thioamide group under the conditions of
urine collection and determination of the chromatographic pattern
As has been previously stated (Chapter I), tiquinamide was
predisposed to chemical desulphuration at concentrations below 
approximately 100 jug/m1 in aqueous solution, resulting in formation 
of the corresponding nitrile derivative. Because of the possibility 
that thioamide-containing metabolites had been excreted in urine 
but had degraded during work-up to nitrile-containing end-product, 
it was neceissary to establish what proportion of any thioamides 
present would have degraded to nitriles under the conditions of 
determination of the chromatographic pattern.
14
Solutions of C-tiquinaraide HC1 (50 ;ug/ml) in control rat 
urine (5 oil) were prepared in triplicate and stored- in flasks 
surrounded by solid CO^ for 0-6.5h, but were subsequently allowed 
to return to room temperature over the 6.5-24 h period. These 
represented conditions similar to those pertaining during the 
collection of urine used to determine the chromatographic pattern 
of'urinary end-products. £
At the end of the 24 h period, unchanged tiquinamide was 
separated from any products of degradation by thin-layer chromato­
graphy in dichlorone thane/acetone (5:4). Tiquinamide and its 
nitrile derivative were run for comparative purposes. Major radio­
active areas were located by scanning, scraped into scintillation 
vials and eluted with methanol/l^O (1:1; 2 ml). Radioactivity was 
assayed by liquid scintillation counting.
(c) Hydrolysis of conjugated material
A portion of 0-24 h rat urine was incubated at 37°C for 
18 h with raolluscanP -glucuronidase/sulphatase (Sigma Chemical Co., 
Poole, Dorset; Helix pomatia Type H-l) at 20,000 units/ml in pH
4.5 0.1M acetate buffer.
Additionally, a non-mobile component, RT1, eluted from t.l.c. 
plates after chromatography in chloroform/methanol/acetic acid 
(18:2:1) was treated at 37°C for 18 h with both the molluscan
-glucuronidase/sulphatase and with bacterial P -glucuronidase 
(E. Coli. Type I, Sigma Chemical Co.) at 20,000 units/ml urine 
in pH 7*4 0.1M phosphate buffer saturated with chloroform.
In each case, incubation mixtures were centrifuged to remove 
proteins and the products of hydrolysis recovered from the super­
natants by reduction to dryness and dissolution in methanol. 
Characterization of aglycones was by comparative t.l.c. in 
solvent 1 against components RT4, RT.5B and authentic 5»6,7»8- 
tetrahydroquinoline-3-carboxylic acid.
(d) Isolation of drug-related products from urine
Eight rats (300-400 g), housed in all-glass metabolism cages,
were fasted overnight before dosing. Each animal received daily
14for 5 days a 100 mg/kg dose of C-tiquinamide HC1 as a solution 
in saline. Urine was collected daily and pooled from all animals 
over the whole collection period before extraction. Isolation of 
the major unconjugated drug-related products was as shown in 
Scheme V.l.
The fractionation procedure involved extraction with diethyl 
ether under basic and acidic conditions. Urine was adjusted to 
pH 9 and extracted with diethyl ether ( 3 x 2  vol). The aqueous 
phase was adjusted to pH 2 and extracted again with diethyl ether 
( 2 x 2  vol). The aqueous residue after this extractioh was 
S neutralized, taken to dryness and subsequently incubated with 
-glucuronidase/sulphatase (Helix pomatia, Type HI, Sigma 
Chemical Co., 20,000 units/ml urine) at 37°C for 24 h. The 
hydrolysate was adjusted to pH 9 and extracted with diethyl ether 
( 2 x 2  vol and 2 x 4 vol). The extracts were pooled with those 
obtained from the first pH 9 ether extraction.
The basic ether extract contained principally band RT5 which 
was separated from RT6 by preparative layer chromatography in 
solvent 1. Band RT5 was separated into two components, RT5A and 
RT5B, by subsequent thin-layer chromatography in solvent 5* Each 
of these components was further purified, free of endogenous 
contaminants, by thin-layer chromatogranhy in solvent 13 and 
subsequent chloroform extraction. RT5A was extracted at pH 9 into 
2 x 4 vol chloroform and RT5A at pH 2 into 2 x 5  vol chloroform.
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The acidic ether. extract contained components RT3 and RT4, 
which were separated by thin-layer chromatography in solvent 1.
Each of these components was further purified by extraction into 
chloroform ( 2 x 5  vol).
(e) Characterization of urinary end-products
u.v. Spectrophotometry: All u.v. spectra were obtained on a
Perkin-Elmer double-beam spectrophotometer from solutions in 
ethanol (10 pg/ml approx).
I.r. spectrometry: I.r. spectra were determined using a
Perkin-Elmer 521 spectrometer. RT3 was prepared as a KBr disc 
and RT5A as a solution in chloroform.
N.m.r. spectrometry: K.m.r. spectra were obtained in
deuterated chloroform, using a Varian XL-100 nuclear magnetic 
resonance spectrometer.
Mass spectrometry: The electron impact mass spectra of RT3,
ET*f and RT5A were determined using an AEI M330 mass spectrometer 
and that of RTpB using an AEI MS50 mass spectrometer.
Thin-layer chromatography: Chromatographic characterization
of RT6 was carried out on 0.25 mm silica plates (Merck) in 
solvents 1, 2, 5, 6, 10, 12 and 16. Authentic Wy-2^l46 (8-cyano-
5,6,7,8-tetrahydro-3-methylquinoline)was run for comparative purpos
(f) The chromatographic pattern of drug-related products in bile
Bile was collected over hourly intervals for periods of 6 h
from three bile-duct cannulated rats maintained under halothane 
anaesthesia and administered ^ +C-tiquinamide HC1 (2-^ juCi/mg) at 
10 mg/kg orally. Radioactivity in bile was assayed by liquid 
scintillation counting. A portion of the pooled 0-6 h sample of 
bile from each rat was subjected to thin-layer chromatography 
in solvent 1. Radioactive areas were subsequently located by 
thin-layer scanning.
RESULTS
(a) The chromatographic pattern of drug-related products in urine
The' 0-24 h urine of three female rats administered tiquinamide
HC1 orally at 10 mg/kg contained 40% of the administered dose 
(Table IV.1). Chromatography of this fraction in chloroform/ 
methanol/acetic acid (18:2:1) revealed the presence of 6 radioactive 
bands (RT1-RT6) which were readily distinguishable (Fig. IV.l).
The fifth of these bands, in order of increasing distance from the 
origin contained two components. A clear shoulder on the peak was 
evident, and 2 bands were distinguished by autoradiography 
(Fig. IV.2).
Percentages of the administered dose found to be present in 
each of components RT1-RT6 are expressed in Table IV.l. The most 
prominent bands were RT3 (8.5%) and RT4 (7.4%). Band RT1, 
remaining on the origin, constituted a significant proportion,
6.8% of the dose. Bands RT2 and RT5B (3*8 and 4.5% respectively) 
were lesser but still significant components. The other bands,
RT5A and RT6 (0.9% and 1.3% respectively) represented only minor 
components. TTo change was observed in the proportions of individual 
components when urine was allowed to remain at ambient temperature 
for 7 days prior to analysis.
On subjection to t.l.c. in several further solvent systems 
bands RT3» RT4 and RT6 were found to be essentially homogeneous*
Band RT5 was more readily separated into two components, RT5A and 
RT5B by t.l.c. in dichloromethane/acetone (5:4). Each of these 
components was found subsequently to be essentially homogeneous by 
further thin-layer chromatography in several additional solvent 
systems.
(b) The stability of the thioamide group under the conditions
of urine collection and determination of the chromatographic
pattern 
‘ 14C-Tiquinamide HC1 present in urine at 50 jug/ml degraded 
to its nitrile derivative under conditions which would have 
occurred during the collection, storage and subsequent work-up 
of urine from rats dosed with 10 mg/kg tiquinamide HOI for the 
purpose of determination of the chromatographic pattern of
metabolites. . Following an overnight thaw after a period of 6.5 h 
surrounded by dry ice the degree of degradation of tiquinamide to 
the nitrile was as much as 67%. No other significant degradation 
products were observed in either case.
(c) Hydrolysis of conjugated material
The polar fraction not extractable into diethyl ether consisted 
of conjugates. Treatment of the 0-24 h urine of tiquinamide-dosed 
rats with molluscan -glucuronidase/sulphatase followed by t.l.c. in 
chloroform/methanol/acetic acid (18:2:1) revealed the absence of 
the immobile component RT1 seen in untreated urine accompanied by 
a greatly enhanced presence of a component corresponding to RT5B 
(Figs. IV.l and IV.2).
When RT1 was isolated from untreated 0-24 h urine, and 
subsequently subjected to treatment with sulphatase-free bacterial 
-glucuronidase, further t.l.c. of the hydrolysate revealed^ 
virtually complete hydrolysis. The product was a single radioactive 
component which chromatographed identically with authentic RT5B 
in the solvent system. 'It could be reasonably concluded from these 
results that RT1 represented predominantly the glucuronide conjugate 
of RT5B.
(d) Characterization of urinary end-products
Basic, ether-soluble fraction
RT5A: Characterization of RT5A was by means of a combination
of analyses by ultra-violet, infra-red, nuclear magnetic resonance 
and mass spectrometry.
The u.v. absDrption peak at 270 nm with a shoulder at 277 nra ^ 
was characteristic of the pyridine ring of the 5»6,7,8-tetrahydro- 
auinoline system (Fig. IV.3). It also suggested that the 
cyclohexene ring remained saturated, if intact. The abfence of any 
influence of pH changes on the u.v. spectrum suggested the absence 
of aromatic hydroxyl groups.
The presence of bands in the region 3000-3500 cm ^ of the i.r. • 
spectrum suggested the presence of one or more hydroxyl groups.
A weak band at 2240 cm ^ could only be attributed to a nitrile group 
(Fig. IV.6).
In the n.m.r. spectrum of RT5A (Fig. IV.7), complex multiplets 
at cT 1.5-2.5 ppni and f 2.75~2.95 ppm were indicative of the cyclo- 
hexane ring protons of a tetrahydroquinoline system and thereby
suggested absence of substitution in the 5»& or 7 positions. The 
approximate triplet at (f 4.0-4.2 ppm indicated the presence of a 
single proton in the 8-position, The appearance of a strong singlet 
at <f 4.75 ppm instead of about 2,2 ppm was indicative of a 
3-hydroxymethyl substituent instead of the 3-methyl group. Doublets 
at cf 7*5 ppm and <f 8.45 ppm were indicative respectively of the 
aromatic protons at the 4- and 2-positions of the pyridine ring, 
confirming an absence of substitution at these positions.
Hence the combination of u,v., i.r. and n.m,r. spectra suggested 
that RT5A was 3-hydroxymethyl-5,6,7»8-tetrahydroquinoline-8-nitrile.
The mass spectrum of RT5A (Fig. IV,9) was entirely consistent 
with the proposed structure. The most abundant ion at m/e 188 
corresponded to the parent ion and another fragment at m/e 187 
(M-l) to the loss of a single proton. Fragments at m/e 160 (M-28) 
and 159 (f$-29) possibly arose as a result of the loss of -CO from 
the parent ion and the corresponding ion lacking in a single proton.
A fragment at m/e 148 (M-4o) corresponded to loss of -CH^ CN from 
the parent ion. This was an unusual fragmentation, but one found 
to occur also in the mass spectrum of the authentic reference 
compound 8-cyano-5i6,7»8-tetrahydro-3-fnethylquinoline (personal 
communication, C. B. Thomas to K. Heatherington). A fragment at 
m/e 132 (M-56) could be attributed to the loss of -HCN in addition
ft<vcL •prp'tbn
to -CO^from the parent ion.
RT5B: The characterization of RT5B is based on u.v., n.m.r. 
and mass spectra.
The presence of a u.v. absorption maximum at 269 nm with a 
shoulder at 276 nm (Fig. IV.3) was characteristic of the pyridine 
ring of the 5 »6,7i8—tetrahydroquinoline system. It also suggested 
that the cyclohexane ring remained saturated, if intact. The lack 
of any effect of change of pH on the u.v. spectrum was indicative 
of an absence of hydroxyl substitution of the pyridine ring.
In the n.m.r. spectrum of RT5B (Fig. IV.7), the complex 
multiplet at cf 1.-7-2.5 PP^ was indicative of the cyclohexane ring 
protons at the 6 and 7-positions of a tetrahydroquinoline system.
The presence of a strong singlet at c/” 2.35 *>pm was indicative of 
the 3-roethyl substituent. The multiplet at (f 3•9-4.2 ppm suggested 
the presence of a single proton in the 8-position. The presence 
of another multiplet at 4.7-5*0 ppm together with the absence of 
a multiplet at about £ 2.8 ppm was indicative of a single proton
in the 5-position* Doublets at <f 7*65 PPm anc* PPm i n°t quite
resolved, were characteristic, respectively, of the aromatic 
protons at the k and 2-positions.
On the basis of these spectra, RT5B could tentatively be 
identified as 5-hydroxy-5,6»7»8-tetrahydro-3-methyl-quinoline-8- 
nitrile9a structural isomer of RT5A.
The mass spectrum of RT5B (Fig. IV.9) was consistent with the 
assigned structure. The presence of a parent ion at m/e 188 and a 
fragment at m/e 187 corresponding to the loss of one proton were 
indicative of a structure of molecular weight identical with that
of RT5A. There were, however, differences in the details of the
fragmentation pattern. The presence of a fragment at m/e 173 
(M-15) was possibly attributable to the loss of -CH.,, suggesting 
that the 3-methyl group was intact. The presence of the nitrile 
group was indicated by observation of fragments at m/e l6l (M-27) 
and m/e l6o (M-28) which could be attributed to loss of HCN respectively 
from the parent ion and that resulting from the loss of a single 
proton. Prominent fragments at m/e 170 (M-l8 and M-.19) could have 
resulted from the loss of H^O from each of the latter two ions.
This fragmentation was indicative of an alcoholic hydroxyl group. 
Fragments at m/e 133 (M-55)*&nd m/e 132 (M-56) possibly arose from* 
the loss of both -HCN and -CO from the parent ion and that resulting
from the loss of a single proton.
Hence the overall conclusion, on the basis of its u.v., n.m.r. 
and mass spectra was that RT5B could be fairly certainly identified 
as 5-Bydroxy-5* 6,7,8-tetrahydro-3-methylquinoline-8-nitrile.
RTo: The characterization of RT6 was performed by comparative 
t.l.c. with Wy-24l46 (8-cyano-5i6,7i8-tetrahydro-3-methylquinoline) 
following the finding of correspondence between the compounds 
in solvent 1 (Fig. IV.l).
Comparactive t.l.c. in 7 different solvent systems tentatively 
identified this component as the nitrile derivative (Table IV.2).
Acidic, ether-soluble fraction
RT3: The characterization of RT3 rests principally on the 
evidence obtained from its u.v., i.r. and mass soectra.
Evidence of the acidic character of this product was obtained 
initially from the fact that it could be readily extracted from 
urine into diethyl ether under acidic, but not under basic conditions.
Furthermore, it showed chromatographic properties similar, though 
not identical, to those of the acidic reference compound THQ-COOH 
(Table IV.3)• Treatment of RT3 with ethereal diazomethane resulted 
in a product which behaved on t.l.c. in chloroform/methanol (*f:l) 
very similarly to 5*6,7»8-tetrahydroquinoline-3-methyl carboxylate 
(relative Rf 0.95) but very differently from unesterified TRQ COOH 
(relative Rf 5*75)*
The u.v. spectrum of RT3 (Fig. IV.5 ) showed obvious signs 
of increased aromaticity. Whereas unchanged tiquinamide and the 
closely related nitrile derivative, Wy-24l46, showed the characteristic 
u.v. spectrum of 5i6»7»8-tetrahydroquinoline with a m£j.or absorption 
maximum at 268 nm and a secondary peak at 276 nm, the spectrum of 
RT3 had a major absorption peak at 283 nm with a shoulder at 290 nm.
In addition, the u.v. spectrum of RT3 contained minor bands at 
312 nm and 326 nm. These minor bands were reminiscent of those 
observed in the spectrum of quinoline, but not 5 »7»8-tetrahydro- 
quinoline. The appearance of these bands at longer wavelengths in 
the spectrum of RT3 than in the spectrum of quinoline (300 and 313 nm 
respectively) presumably reflected bathochromic shifts resulting from 
aromatic substitution. Comparison of the u.v. spectra of quinoline, 
quinoline-8-nitrile and quinoline-3-carboxylic acid made possible 
the prediction of the absorption maxima for the anticipated three 
bands in thespectrum of 8-cyano-quinoline-3-carboxylic acid, according 
to the principle of additive bathochromic shifts e.g. Scott, 196 .^
The predicted values of 283 nm, 312 nm and 327 nm were in very close 
agreement with those observed for RT3 (Fig. IV.5).
In the i.r. spectrum of RT3 (Fig. IV.6), a sharp band at 
2220 cm”^ could be unambiguously attributed to anitrile group.
A broad band at 1600-1800 cm ^ was probably indicative of a carboxylic 
acid. The nitrile group almost certainly existed at position 8 as a 
result of desulphuration of the 8-thiocarboxamide group of tiquinamide. 
Therefore the carboxylic acid moiety was likely to be at position 3« 
Thus the combination of u.v. and i.r. spectra suggested that RT3 
was 8-cyano-quinoline-3-carboxylic acid.
In the mass spectrum of RT3 (Fig. IV.10) the most abundant ion 
at m/e 198 was consistent with the parent ion of the proposed 
structure. Another fragment, at m/e 153 (M-^5) corresponded to the 
loss of the.carboxyl group.
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RT4: The evidence for the proposed structure of RT4 comprises 
principally u.v., n.m.r. and mass spectra.
Initial evidence of the acidic nature of this compound came 
from the finding that it could be extracted into diethyl ether under 
acidic, but not basic conditions. Furthermore, it showed chroma'to- 
graphic properties similar, though not identical, to those of the 
acidic reference compound THQ-COOH (Table IV.3)*
The presence of a u.v. absorption maximum at 272 nra with a 
shoulder at 279 nm was indicative of the pyridine portion of the 
5,6,7,84-tetrahydroquinoline ring (Fig. IV.4), though the small 
(3-4 nm) shift to longer wavelength suggested aromatic substitution 
by an electron ?/ithdrawing group and the total spectrum was more 
closely identical v/ith that of THQ COOH than with that of the parent 
compound. The absorption maximum was, however, close enough to that 
of 5»6,7»8-tetrahydroquinoline to suggest that the second ring 
remained saturated, if intact. The absence of any significant 
influence by alkalinization on the u.v. spectrum of RT4 suggested 
the absence of aromatic hydroxyl substitution.
In the n.m.r. spectrum (Fig. IV.8), a complex multiplet at 
£ 1.5-2.5 ppni and an approximate triplet at Cf 2.75-3*1 Ppm were 
characteristic of the cyclohexane ring protons in the tetrahydro­
quinoline system. The multiplet at <f 4.1-4.3 ppm suggested the 
presence of a single proton at position 8 of this system. The lack 
of a strong singlet signal at about <f 2.2'ppm showed the absence of 
the 3-methyl substituent. Nevertheless, the pair of doublets with 
coupling constants 2Hz in the low field region was characteristic 
of a pyridine ring substituted at the 3-position. However, the 
shift of these signals to <f 8.15 and (T 9.15 ppm from the position
7.5 ppm and J  8.2 ppm seen with tiquinamide was indicative of 
the presence of an electron-withdrawing group at position 3* On 
the basis of the u.v. and n.m.r. spectra, the structure tentatively 
assigned to RT4 was 8-cyano-5i6,7,8-tetrahydroauinoline-3-carboxylic 
acid.
The mass spectrum (Fig. IV.10) confirmed this structure.
The most abundant ion at m/e 202 corresponded to the parent ion 
of the postulated acid. A fragment at m/e 201 (M-l) corresponded 
to the loss of a single proton. Fragments at m/e 175 (M-27) and 
m/e 174 (M-28) corresponded to the loss of -HCN from these two ions
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respectively. A fragment at m/e 157 (M-*f5) was attributed to the 
loss of -COOH from the parent ion and one at m/e 150 (M-72) to the 
loss of both -COOH and -HCN. A prominent fragment at m/e 162 
(M-**0) was attributed to the loss of -CH^CN, an unusual fragmentation, 
but one already found to be characteristic of 8-cyand-5 ,7,8- 
tetrahydroquinoline (p. 80).
(e) The chromatographic pattern of drug-related products in bile 
The 0-6 h bile of three female bile-duct cannulated rats 
administered tiquinamide HC1 orally at 10 mg/kg contained 5-13%
(mean 8%) of the administered dose. Chromatography revealed the 
presence of four significant components (Fig. IV.11). Three of 
these had Rf values similar to products seen in urine: RT1, RT*f 
and RT6 (respectively 0.00, 1.01, and l.*fO relative to THQ COOH).
The fourth was a polar band (Rf 0.07 relative to THQ COOH^ not seen 
to be a significant component in urine. Each of the four components 
represented a similar proportion of the total, excreted products.
Thus no individual band accounted for more than approximately 3% 
of the administered dose.
DISCUSSION
The major end-products of tiquinamide metabolism isolated from 
rat urine resulted from four separate Phase I processes: desulphuration 
of the thiocarboxamide group to the corresponding nitrile analogue,
A) -oxidation of the 3-methyl group, hydroxylation at the 5-position 
i.e. at the position adjacent to the point of fusion of the saturated 
and unsaturated rings, and aromatization of the 5v6»7»8-tetrahydro- 
quinoline ring system (Fig. IV.12).
In view of the known instability of the thioamide group of
tiquinamide, there remains an element of doubt as to whether the
nitriles detected were formed by metabolic or chemical desulphuration
or by a mixture of the two processes. Studies on the stability of
tiquinamide under the conditions of urine collection showed that
although extensive degradation of the thioamide group \7ould have
taken place, at least 33/^  of the thioamide-containing compounds
voided would have been detected in the metabolic pattern. Hence
for each nitrile compound, there would have been a thioamide analogue.
Whilst some of the nitriles and thioamide analogues might have
behaved similarly in this t.l.c. system, it is probable that some
additional components which subsequently degraded would have? been
observed. The fact that the major components in the t.l,.c. pattern
were each homogeneous and did not change their chromatographic
behaviour in this system at any stage between their initial
observation and their eventual identification constitutes some
*
evidence in favour of the identified nitrile compounds being true 
metabolites and against the view that substantial proportions of 
thioamides were voided in urine and were subsequently chemically 
degraded. It must be added that desulphuration of the thioamide 
group of tiquinamide was an expected route of metabolism of the 
compound predictable from the literature concernihg the metabolism 
of other thioamides. For example, antigastrin (Gibson and Hunter,
1969) and 2 ,6-dichlorothiobenzamide (Griffiths et al. , i960) v/ere 
both found to undergo extensive metabolic desulphurization and in 
both cases the workers involved specifically excluded the possibility 
of chemical desulphuration.
These considerations taken together lead to the conclusion 
that the nitrile compounds isolated probably represent metabolites 
of tiquinamide and that although thioamide analogues may have been
excreted and subsequently degraded, they did not form a major 
proportion of the drug-related products voided by the rat.
In all other respects the metabolites of tiquinamide were apparently 
stable, as indicated by their constant proportions after 7 days 
at ambient temperature. Thus there was no evidence that any 
reaction other than the desulphuration could have occurred either 
by chemical or by microbial action.
Of a total of 40.2% of the dose excreted in rat urine in the 
first 24 h, almost half i.e. 16.8% represented metabolites formed 
by methyl group oxidation, the majority of these 0.5*9%) being 
3-carboxylic acids. Hence this total slightly exceeded the sura of 
the amounts of the 5-hydroxylated metabolite RT5B (8-cyano-5-hydroxy-
5,6,7,8-te*trahydro-3-niethylquinoline) and its glucuronide conjugate, 
RT1, which together amounted to 11.3% of the dose in the 0-24 h 
period. However, the relative amounts of products irt urine may 
not have totally reflected the comparative importance of each of 
these routes for the metabolism of tiquinamide in the rat. Although 
the biliary excreted material did not obviously contain a preponderance 
of products of one route or the other, it was passible that the 
material unexcreted at 2k h did so.
The products of 3-mcthyl oxidation were almost entirely 
3-carboxylic acids, which by analogy with nicotinic acid would have 
had carboxyl groups of pKa around 2.0 (Wade, 1977)* They would 
therefore have been extensively ionized in urine and thus probably 
rapidly excreted by the urinary route. Although the excretion 
kinetics of the 3-carboxylic acid products of tiquinamide have not 
been studied directly, those of a related compound 5*6,7,8-tetra- 
hydro-3-methylquinoline-8-carboxylic acid, have been investigated.
The majority (76%) of an oral dose was excreted in the urine, mostly 
during the first 24 h (D. M. Pierce, unpublished observation).
It is reasonable to presume that the 3-carboxylic acids would have 
been equally rapidly excreted.
The basic metabolite, 5-hydroxy, 5 »6,7,8-tetrahydro-3-methyl- 
quinoline on the other hand would have had a pKa similar to that of 
the unchanged drug ( 5*2) and therefore could have been unionized 
to a relatively high extent in urine and thus susceptible to renal 
reabsorption. Thus there was a greater chance that the unexcreted 
material contained a significant proportion of 5-hydroxylated
•basic compound than that substantial amounts of 3-carboxlic acids 
remained to be excreted. The implications of such considerations 
will be discussed more fully in subsequent chapters.
The fourth significant Phase I reaction in the metabolism of 
tiquinamide in the rat was an aroraatization of the tetrahydro­
quinoline ring, resulting in about 8.5% of the dose being eliminated 
as 8-cyano-quinoline-3-carboxylic acid.
Conjugation of the 5-hydroxylated metabolite with glucuronic 
acid was a major route of further metabolism. The proportion of 
conjugated material excreted in the 0-24 h urine represented 60% 
of total 5-hydroxylated products.
Consideration on the mechanisms of reactions involved in tiquinamide 
metabolism in the rat
Desulphuration: The mechanism of metabolic desulphuration of 
thioamides has not been investigated in detail. The formation of 
nitrile products of the desulphuration of both antigastrin 
(Gibson and Hunter, 1969) and 2 ,6-dichlorothiobenzamide (Griffiths 
et al., 1966) implied an oxidative removal of H^S rather than the 
chemically more obvious hydrolysis which would have resulted in the 
corresponding amides viz the hydrolysis of thioacetamide (Rees,
Rowland and Varcoe, i960). Hence the nature of the reaction seemed 
to be similar to that found by Scheline, Smith and Williams (1961) 
to be involved in the desulphuration of l-phenyl:42-thiourea. It is 
possible that the metabolic desulphuration of tiquinamide occurred 
by a similar mechanism. Although the presence of amides could not 
be totally excluded, the overriding predominance of nitriles ruled 
out the hydrolytic route as the major desulphuration pathway.
However, the possibility also exists that desulohuration of 
tiquinamide involved an initial sulphoxidation in a manner analogous 
to that observed for ethionamide (Johnston, Kane and Kibfcy, 1967), 
followed by degradation of the sulphoxide product to the nitrile. 
Attempts to synthesize tiquinamide sulphoxide have resulted in the 
formation of its nitrile derivative, suggesting'this possible 
degradation (Curran, A. C. W., personal communication). (Fig. IV.13).
3-methyl oxidation: The oxidation of the 3-methyl group of 
tiquinamide was analogous to other examples of the oxidation of 
methyl substituents to aromatic rings. . The reaction is the simplest 
form of to-oxidation of an alkyl side phain. The mechanism of such
reactions has been discussed by Gillette (1963). Earlier work 
had established that the alkyl side chains of barbiturates, for 
example, were oxidized to alcohols and subsequently to carboxylic 
acids and that the microsomal mono-oxygenase was implicated (Cooper 
and Brodie, 1955 and 1957)* Subsequently, Gillette (1959) studied 
the mechanism of the reaction more closely, using p-nitro-toluene 
as a substrate. He established that the oxidation of this compound 
to p-nitrobenz.yl alcohol was carried out by liver microsomal mono­
oxygenase. However, in order for further metabolism of the alcohol 
to ensue, it was necessary to add the soluble fraction of liver 
homogenate to the incubation mixture. The alcohol was found to be 
oxidized to p-nitrobenzaldehyde initially in a reaction catalysed 
by a soluble liver alcohol dehydrogenase and to p-nitrobenzoic acid 
finally, catalysed by soluble liver aldehyde dehydrogenase. The 
oxidation of xylene to toluic acid by rabbit lung and liver was. 
observed to proceed via similar stages (Carlone and Fouts, 197*0 •
It is believed that the 3-methyl oxidation of tiquinamide occurred 
by this same mechanism (Fig. IV,If-.).
5-hydroxylation: The 5-hydroxylation of tiquinamide represented 
ally lie hydroxylation occurring in a fused saturcL-^  and aromatic ring 
system at a saturated carbon atom<* - to the double bond. Hydroxy- 
lation in the saturated ring rather than in the aromatic ring was 
consistent with the general rule that in fused alicyclic and aromatic 
ring systems, the preferred site of hydroxylation is in the alicyclic 
ring (Parke, 1968c)..- The reaction was very similar to the 4-hydroxy- 
lation which constitutes a major pathway in the metabolism of the 
1,2,3,4-tetrahydroisoquinoline compound debrisoquire (Allen et al., 
1975? Allen, Brown and Marten, 1976). Other compounds known to 
undergo this reaction include fluorene (Grantham, 1963; Chen and 
Lin, 1969)» fi -ionone (Ide and Toki, 1970), hexobarbital (Gerber 
et al., 1971)» tetralin (Elliott and Hanam, 1968) and indane 
(Billings, Sullivan and McMahon, 1970). The mechanism of the 
reaction has been found usually to be catalysed by a microsomal 
mono-oxygenase requiring HAD PH and 0^ e.g.. fluorene (Chen and Lin,. 
1969), hexobarbital (Cooper and Brodie, 1955) and indane (Billings, 
Sullivan and McMahon, 1970). The precise details of the mechanism 
have been investigated more closely, for example, for fluorene. 
Spectral investigation of the interaction of fluorene with cytochrome 
?450 from the livers of phenobarbital-treated rats revealed that
the first stage of fluorene oxidation involved the formation of a 
carbanion which complexed with reduced cytochrome P450. This 
carbanion was subsequently found to further react with molecular 
oxygen to form a hydroperoxide, which it is believed then gave rise 
to fluorenol. (Ullrich and Schnabel, 1973) (Fig. IV.15).
In hydroxylation reactions of this type involving replacement 
of a single hydrogen atom at a methylene group, the hydroxylated 
product frequently possesses an asymmetric carbon atom, and the 
potential for optical activity therefore exists if the enzyme 
catalysing the oxidation forms one diastereoisomer in favour of the 
other. Thus, for example, the hydroxylation of indane resulted in 
predominantly (S)(+)-indanol (Billings, Sullivan amd McMahon, 1970). 
Tiquinamide metabolite RT5B (5-hydroxy,8-cyano-5,6,7,8-tetrahydro- 
3-methylquinoline) possesses an optically active centre, but no 
attempt has been made to separate diastereoisomers.
Aromatization of the 5.6,7,8-tctrahydroquinoIine ring system: 
Aromatization of the tetrahydroquinoline ring, resulting in 8-cyano- 
quinoline-3-carboxylic acid represents a fairly uncommon reaction in 
foreign compound metabolism. There are a few compounds in the 
literature for which aromatization of alicyclic rings has been 
reported and at least two different mechanisms have been described.
(Fig. IV.14). Thus cyclohexane carboxylic acid was found to be 
aromatized in a reaction catalyzed by a mitochondrial enzyme of 
mammalian liver and kidney. The reaction involved the formation of 
an acyl CoA intermediate which was subsequently aromatized and 
conjugated with glycine to form hippuric acid (Babior and Bloch,
1966). Another aromatization reaction, that of quinic acid, is 
apparently carried out not by mammalian liver enzymes, but by 
gastrointestinal micro-organisms (Adamson et al., 1970a; Cotran,
Kendrick and Kass, I960; Asatoor, 1965). The aromatization of 
shikimic acid observed first by Asatoor (1965) was found to involve 
both metabolism by gut bacteria and subsequently by mammalian liver. 
Contrary to earlier beliefs, the compound was not aromatized directly 
by the gut bacteria,, but rather was reduced by these micro-organisms 
to cyclohexane carboxylic acid (Brewster, Jones and Parke, 1977a).
The subsequent aromatization of this acid was found to take place 
in isolated perfused rat liver, presumably by the mechanism discussed 
above (Brewster, Jones and Parke, 1977b). In addition to aromatization
of these alicyclic carboxylic acids, aromatization of tetrahydro- 
quinolines has also been described. The metabolism of 5,6,7,8- 
tetrahydroquinolines has not previously been studied, but 1,2,3,4- 
tetrahydroquinoline is known to undergo extensive aromatization 
(25%) in the dog, resulting in 2-quinolinol. It has been speculated 
that this reaction might proceed in two stages, since the aromatization 
of 8-hydroxy,l-methyl-l,2,3,4-tetrahydsoquinoline-7-carboxylic acid 
involved an initial partial dehydrogenation, an isolated intermediate 
being 1 ,4-dihydro-4,8-dihydroxy-l-methylquinoline-7-carboxylic 
acid (Williams; 1959g)* Other aromatization reactions which are 
known to occur are those concerned with the biosynthesis of certain 
steroid hormones. Thus,’ for example, 19-hydroxytestosterone undergoes 
aromatization during the formation of oestriol (Samuels, i960).
The aromatization of tiquinamide metabolites is unlikely to 
proceed via a mechanism analogous to that of cyclohexane carboxylic 
acid because the stereochemistry in 8-cyano-5,6,7,8-tetrahydro- 
quinoline-3-carboxylic acid (RT4) does not fulfil the requirements 
for this reaction. Reactions of this type require the presence of 
a carboxylic acid moiety substituted in the saturated ring, such 
that the first dehydrogenation of an acyl CoA derivative of this 
acid occurs * * , -  to the position of the carboxyl group (Babior and 
Bloch, 1966). Aromatization of metabolite RT4 of tiquinamide by 
gut micro-organisms is possible, but it would necessitate that the 
acid and/or its conjugates wei*e excreted in bile in order to expose 
the unsaturated acid to micro-organisms in the gastrointestinal 
trail. The low extent of biliary excretion made it unlikely that 
such a mechanism could have accounted for the excretion in urine 
of as much as 8.5% of the dose as the aromatized acid. Of the 
possible mechanisms for the aromatization of 8-cyano-5,6,7,8-tetra- 
hydroquinoline-3-carboxylic acid, the most attractive one resembles 
that proposed for the 1,2,3,4-tetrahydroquinolines. An interesting 
feature of this mechanism is that it apparently invokes hydroxylation 
in the alicyclic ring at a position ex.-to the point of fusion with 
the aromatic ring. Although no metabolite containing both 5-hydroxyl 
and 3-carboxylic groups has been identified for tiquinamide, it is 
not irapossible that such a compound could exist as a minor metabolite, 
representing an intermediate in the formation of the fully aromatized
carboxylic acid. Alternatively the aromatization involved in the 
formation of tiquinamide metabolite RT3 might occur by a mechanism 
related to one by which aromatization of steroids is effected.
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Metabolite Rat (1) Rat (2) Rat (3) Mean+
SEM
RT1 7.1. 6.3 ’ 7.0
6.8 +
073
RT2 3.9 3 A if.O
3,8
072
RT3 8*3 7.6 9.6
8.5
o76
RT^ f 7.5 6.2 8.if 7.4
o76
RT5A 0.9 0.9 0.9 0.9
0
RT.5B 5.9 3.^ ^.1 V
o77
RT6 1.5 1.1 1.2 H 3
o7 i
Total % dose 
in these bands 35.1 28.9 35.2
33.1
2'7i.
Total % dose 
in urine 43.0 35.8 if 1.9
4o .2 + .
1272
Table IV*1: Percentages of the administered dose present in each
of the major radioactive components separated by t*l.c. 
0-2 if h urine of female rats administered 10 mg/kg 
C-tiauinamide orally
Solvent
RT6
Rf
\Vy-2iflif6
Rf
1 0.76 0.75
2. o.5if 0.52
5 • 0.60 0.59
6 0.55 0.55
10 0.72 0.73
12 0.38 O.if 7
16 o.if9 0 A 7
Table IV.2: Comparative chromatography of RT6 with authentic
W,y-2iflif6 (fc-cyano-5*£*7« 8-tetrahydro-3-methylquinoline )
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Solvent
No.
RT3 RT4
Rf fcf THQ COOH Rf Rf THQ. COOH
1 0.63 0.95 0.60 1.09
2 0.26 1.85 0.14 2.80
3 0.45 4.30 0.22 4.40
11 0.80 1.03 ND ND
12 0.46 1.12 0.24 1.14
14 0.23 0.79 ND ND
Rf values are expressed in absolute terms and relative
to THQ COOH
ND = Wot Determined
Table IV.3: Comparative chromatogranhv of tiouinamide urinary
end-products RT3 and RT4 with 5<6.7.8-tetrahydroquinoline 
3-car boxy lie acid (THQ. COOH)
CHAPTER V: METABOLISM OF TIQUINAMIDE IN THE PATAS MONKEY
SUMMARY
A study of the nature of end-products in 0-24 h urine of patas 
monkeys revealed the presence of at least two of the biotransformation 
pathways seen previously in the rat. U> -Oxidation was the major 
route of. metabolism, occurring more extensively than in the latter 
species and more completely, giving rise to 8-cyano-5,6,7,8-tetra- 
hydroquinoline-3-carboxylic-acid but not apparently to the intermediate 
8-cyano-5«6,7,8-tetrahydro-3-hydroxymethyl quinoline. Allylic 
hydroxylation at the 5-position gave rise to 5-hydroxy,8-cyano-
5.6.7.8-tetrahydro-3-methylquinoline. The subsequent extent of 
conjugation of this compound, mainly with glucuronic acid, was 
greater than in the rat. There was no evidence of aromatization of 
the tetrahydroquinoline ring in this species. Desulphuration
probably occurred to some extent enzyraically, but there was evidence
0
of unstable sulphur- containing metabolites. The most predominant 
of these was a compound which apparently degraded to 8-cyano-
5.6.7.8-tetrahydroquinoline-3-carboxylic acid, and may, therefore, 
have been the corresponding thioamide. Possible reasons for the 
species difference in metabolism between the patas monkey and the 
rat are*, discussed.
INTRODUCTION
Once the major pathways of tiquinamide metabolism had been 
established in the rat, it became of interest to establish whether 
the same pathways applied to other species. The patas monkey was 
particularly relevant because it was a candidate species for 
toxicity studies. Thus the methods developed for the study of the 
metabolism of tiquinamide in the rat were subsequently anplied to 
an investigation of metabolism in the patas monkey.
EXPERIMENTAL
(a) The chromatographic pattern of drug-related products in urine
Two patas monkeys (? 288, weighing 5*0 kg and <T 3&0, weighing
14
5.6 kg) each received 10 mg/kg C-tiquinamide HC1 as a solution 
in saline. Urine was collected at the following times after 
dosing: 0-2, 2-5 * 5-12 and 12-2A- h. In order to minimise chemical 
degradation, collections over the first 12 h were made in vessels 
surrounded by solid CC^* Subsequently, samples collected over the 
0-24 h period were pooled for each animal. The chromatographic 
pattern of radioactivity in each 0-2 h and 0-24 h pooled urine 
sample was determined by t.l.c. in Solvent 1. After location of 
radioactivity on thin-layer plates by scanning and autoradiography, 
the clearly definable bands were designated MT1-MT4 in order of 
increasing mobility, which was calculated relative to THQ COOH as 
for the rat metabolites (Chapter IV. p.73 ).
The distribution of radioactivity among the bands on the plate 
was quantitated by scraping 0.5 cm strips into scintillation vials, 
followed by elution and assay by liquid scintillation counting as 
described previously (Chapter II).
Two of the mobile components, MT3 and MT4, separated by chroma­
tography in Solvent 1 were scraped off, eluted with methanol, and 
subjected to further thin-layer chromatography. MT3 v,:as run in 
Solvents 2, 3 and 11 and MT4 in Solvents 6, 8, 10 and 11.
(b) The stability of the thioamide group under the conditions of 
urine collection and determination of the chromatographic pattern 
As discussed previously in connection with the rat (Chapter IV.
p. 74 ) it was necessary to establish what proportion of any thioamides 
initially present would have degraded to nitriles under the conditions 
of determination of the chromatographic pattern.
14
Solutions of C-tiquinamide HC1 in control monkey urine (5. ml) 
at 100 jug/ml were prepared so as to mimic the concentration in urine 
if all metabolites were thioamides. Triplicate portions were stored 
in flasks surrounded by dry ice for 0-12 h but allowed to return to 
room temperature over the period 12-24 h. These represented 
conditions similar to those pertaining during the collection of 
urine used to determine the chromatographic pattern of.urinary 
end-products. At the end of 24 h period, unchanged tiquinamide was
separated from any products of degradation by thin-layer chroma­
tography, as previously described for the rat.
(c) Hydrolysis of conjugated material ,
Portions (5 nil) of the 0-24 h urine of a single patas monkey
14 0
administered C-tiquinamide HC1 were incubated at 37 C for 18 h
with molluscan-glucuronidase/sulphatase (Helix pomatia, Type HI
obtained from Sigma Chemical Co., Poole, Dorset) at 20,000 units/ml
in pH 4.5 0.114 acetate buffer. Control samples containing acetate
buffer but no enzyme were incubated concurrently under identical
conditions.
Additionally, a component, MTl, which remained on the origin 
after chromatography in chloroform/methanol/acetic acid (l8i2:l) 
was eluted from the t.l.c. plate and portions were treated at 37°C 
for 18 h with either molluscan /3 -glucuronidase/sulphatase or with 
bacterial ^-glucuronidase (E.Coli Type I, obtained from Sigma 
Chemical Co. ) at 20,000 units/ral urine in pH 7*4 0.114 phosphate 
buffer saturated with chloroform.
In each case, incubation mixtures were centrifuged to remove 
proteins and the products of hydrolysis recovered from the superb 
natants by reduction to dryness and dissolution in methanol. 
Characterization of aglycones was-carried out by comparative t.l.c. 
in chloroform/methanol/acetic acid (18:2:1) against the unconjugated 
MT4.
(d) Isolation of drug-related products from urine
A single patas monkey, weighing 5»1 kg, received a 250 mg/kg
14
oral dose of C-tiquinamide HC1 as a suspension in 0.5/ carboxy- 
methylcellulose/Tween 80 at 5 ml/kg. Urine was collected over a 
0-24 h period. Isolation of unconjugated drug-related products 
was carried out as described in Scheme V.l.
The procedure was a simplified version of that described for 
the isolation of urinary end-products in the rat (Chapter IV p. 7*o )• 
The acidic compound MT3 was isolated from a diethyl ether extract 
prepared under acidic conditions (pH 2). The amount of MT4 present 
was enhanced initially by treatment with molluscan -glucuronidase/ 
sulphatase to hydrolyse conjugated material. The ether extraction 
step under basic conditions employed for isolation of the comparable 
fraction of products in the rat was omitted and separation effected 
entirely by t.l.c.
Scheme V.l: The isolation of some end-products of tiquinamide
metabolism in the patas monkey
Urine (1) Adjusted to pH 2
(2) Extracted with diethyl ether ( 2 x 3  vol)
Aqueous
(1) Incubated with
-glucuronidase/sulphatase 
at 37°C for 18 h (20,000 
units/ml urine in pH 4.5
0.1M acetate buffer).
(2) Protein removed by 
centrifugation, pellet washe 
with HgO,. supernatant and 
washings pooled.
(3) Prep, t.l.c. in solvent 1 on 
1 ram silica plates.
(4) Eluted with MeoE/E^O (1:1).
(5) T.l.c. in solvent 5»
(6) Eluted with MeoH.
(7) T.l.c. in solvent 13*
(8) Eluted with MeoH.
1
Organic phase
(1) Reduced to dryness and 
dissolved in 20 ml /10 
NsOE'
(2) Treated with 
decolourizing charcoal 
and centrifuged.
(3) Supernatant reacidified 
(pH 2) and extracted 
with diethyl ether
(2 x 5 vol).
(4) Prep, t.l.c. in solvent 
on 1 mm silica plates.
(5) Eluted with methanol.
■*
MT3
(e) Characterization of urinary end-products
Preparation of MT3 methyl ester: MT3 methyl ester was made by 
treatment of the free acid with diazomethane in ethereal solution 
at ambient temperature for 30 min. Excess reagent was removed by 
rotary evaporation.
U.v. spectrophotometry: The u.v. spectrum of MT4 was determined
on a Perkin-Elmer double-beam spectrophotometer. That of MT3 was
determined using a Pye-Unicara SP 700 double-beam spectrophotometer. 
Compounds were prepared as solutions in 95/ ethanol (circa 10 ug/ml).
I.r. spectrophotometry: I.r. spectra were determined using a 
Perkin-Elmer 521 spectrophotometer. MT3 methyl ester was prepared 
as a solution in chloroform. KT4 was incorporated in a KBr disc.
N.m.r. spectrophotometry: The n.m.r. spectrum of MT3 methyl 
ester was determined using a Varian EM3oO spectrometer. The compound 
was prepared as a solution in deuterated chloroform. Te^ramethyl- 
silane was present as an internal standard.
Gas chromatography: Gas chromatography of MT3 methyl ester,
as a solution in chloroform, was performed on a Pye 104 gas chroma­
tograph. The column was of glass, 2 ra x 3 ram i.d. and containing 
10/ SE30 on AW Chromasorb W. The column temperature was 200°C.
The carrier gas was nitrogen with a flow rate of 40 ml/min.
Mass spectrometry: The electron impact mass spectrum of MT3 
methyl? ester was determined on an AEI MS12 mass spectrometer inter­
faced to the Pye 104 gas chromatograph. The electron impact mass 
spectrum of MT4 was prepared on an AEI MS50 mass spectrometer.
RESULTS
(a) The chromatographic pattern of drug-related products in urine
The 0-24 h 'urine collection from two patas monkeys, + 288 and 
360, contained respectively 86.9% and 90.1% of the administered 
dose. Chromatography of this fraction in chloroform/methanol/ 
acetic acid (18:2:1) revealed the presence of 4 radioactive bands 
(MT1-MT4) (Fig. v.r).
Percentages of the administered dose found to be present in 
each of components MT1-MT4 are expressed in Table V.l. By far the 
largest single component was MT3» which represented 46.6% and 37*8% 
of the administered dose in monkeys £ 288 and <P 360 respectively.
MT1 constituted a lesser component (15.8% and 18.6% respectively). 
MT2 and MT4 were minor^components. The 0-2 h collection contained 
55.6% (+ 288) and 43.5% ( &  360) of the administered dose. Chroma­
tography of this fraction in solvent 1 revealed the presence of five 
radioactive bands (Fig. V.l). These had the same Rf values as those 
observed in the pooled 0-24 h urine pattern, with the exception„that 
a major additional band, designated MTU, contained a similar 
proportion of the total radioactivity to component MT3* This 
component was unstable during storage at -20°C and subsequent 
thawing, apparently degrading in favour of component MT3*
Following isolation of MT3» the major radioactive component
separated from monkey urine by t.l.c. in chloroform/methanol/
*
acetic acid (18:2:1), this component was shown to be essentially
homogeneous by further t.l.c. in three different solvent systems.
Similarly, band MT4 was shown by further t.l.c. in four
solvent systems to comprise predominantly one component.
(b) The stability of the thioamide grout) under the conditions of
iirine collection and determination of the chromatographic
pattern
14C-tiquinamide HC1 degraded to its nitrile derivative at
100 ug/ml under the conditions .of collection and storage of urine
14
from patas monkeys dosed v/ith C-tiquinamide HC1 for the
purpose of determination of the chromatographic pattern of drug- 
related products. In urine stored in flasks surrounded by dry ice 
for 12 h and then allowed to return toroom temperature over the 
following 12 h, the extent of degradation to the nitrile was 
56.3 - 1.3%. No other significant degradation product was observed.
(c) Hydrolysis of conjugated material
Following treatment of the 0-2** h urine sample with raolluscan 
P -glucuronidase/sulphatase and t.l.c.. in chloroform/methanol/ 
acetic acid (18:2:1), the only significant radioactive components 
.present were MT3 and MT*f (Fig. V. 2) , (relative mobilities 1.06 and 
1.30 respectively, relative to THQ COOH), MT1 was virtually absent.
MTA- was apparently significantly enhanced by comparison with its 
presence in urine treated with pH k,5 0.1M acetate buffer alone.
Hence this observation suggested that MT1 comprised glucuronidase 
and/or sulphate conjugates of MT4.
Treatment of the polar component MT1 in isolation with 
bacterial -glucuronidase followed by t.l.c. showed that hydrolysis 
was incomplete, but that a band found at the expected location of 
MT*f (Rf 1.31 relative to THQ COOH) was a significant product 
(Fig. V.3)* Since the bacterial -glucuronidase preparation was 
essentially free of aryl sulphatase, it follows that MT1 contained 
the glucuroni'de conjugate of MTA- (5-hydroxy-8-cyano-5,6,7,8- 
tetrahydro-3-methylquinoline). The unhydrolysed fraction may have 
contained a different conjugate e.g. sulphate or may simply have 
represented incomplete hydrolysis of the glucuronide.
(d) Characterization of urinary end-products
MT3: The evidence for the structure of MT3 comprises principally 
the u.v., i.r., n.m.r. and mass spectra of this compound and/or its 
methyl ester.
Initial evidence of the acidic nature of this compound came 
from the fact that it could be extracted into diethyl ether under 
acidic but not basic conditions. Furthermore, it showed chromatographic 
properties similar, though not identical, to those of the acidic 
reference compound THQ COOH (Table V.2). The formation of the 
methyl ester derivative confirmed its acidic character.
The presence of a u.v. absorption maximum at 272 nm was 
indicative of the pyridine portion of the 5*6,7,8-tetrahydroquinoline 
ring (Fig. V.4), though the small (3-^ nm) shift to longer wavelength 
suggested aromatic substitution by an electron withdrawing group and 
the total spectrum was more closely identical with that of THQ COOH 
and with the acidic rat metabolite RT*+ than with that of unchanged 
tiquinamide. The absorption maximum was, however, close enough to 
that of 3 ,6,7*8-tetrahydroquinoline to suggest that the second ring
remained, saturated, if intact. The absence of any significant 
effect of alkalinization on the u.v. spectrum of MT3 suggested the 
absence of aromatic hydroxyl substitution. The i.r. spectrum of 
the methyl ester of MT3 (Fig. V.5) contained a band at 1720 cm"'*'
oconsistent with the presence of an ester carboxyl group. A strong 
band at 22*f0 cm ^ could only be attributed to a nitrile group.
In the n.m.r. spectrum of MT3 methyl ester, (Fig. V.6) broad, 
ill-defined signals at <f 1.5-2.5 ppm and at (f 2.8-3.1 ppm were 
characteristic of the cyclohexane ring protons in a tetrahydro- 
quinoline system. The multiplet at d *f.2-4.5 ppm indicated the 
presence of only one proton at position 8 of this system. The 
absence of a strong singlet at about <f 2.2 ppm showed the lack of 
a 3-raethyl substituent. However, the pair of doublets with coupling 
constant 2Hz in the low field region was characteristic of a 
pyridine ring substituted^at the 3-position as in tiquinamide. 
Moreover the shift of these signals to <f 8.2 and 9*15 ppm from the 
position of { 7*5 and 8.2 ppm found with tiquinamide was indicative 
of the presence of an electron withdrawing group at position 3»
A three-proton singlet at <f 3.95 ppm was characteristic of a siingle 
0-methyl grqup.
On the basis of the u.v., i.r. and' n.m.r. spectra, the 
structure assigned t-o MT3 was that of 8-cyano-5,6,7»8-tetrahydro- 
quinoline-3-carboxylic acid i.e. a structure identical to that of the 
rat metabolite RT4.
The mass spectrum of MT3 methyl ester (Fig. V.8), obtained 
after g.l.c. (Fig. V.7)» was consistent with this structure, having 
a parent.ion at m/e 2l6. The next most abundant ions at m/e 185 
(M-31) and m/e 157 (>M-59) corresponded respectively to loss of
-OCH, and -8-0CH, from the molecular ion. A fragment at m/e 130
3 3
(M-86) resulted from the loss of both ester and nitrile groups.
A fragment at m/e 17& (M-^0) was attributed to the loss of -CH^CN 
which had. proved to be an unusual characteristic feature of the 
mass spectra of nitrile metabolites of tiquinamide (Chapter IV.
p. 80 ) .
MT4: The characterization of MT^ t is based on its u.v., i.r. 
and mass spectra. The presence of a u.v. absorption maximum at 
269 nm with a shoulder at 277 nra (Fig. V.^ f) was characteristic of 
the pyridine ring of the 5 ,o»7,8-tetrahydroquinoline system. It 
also suggested that the cyclohexane ring remained saturated, if
intact. The lack of any effect of change of pH on the u.v. spectrum 
was indicative of an absence of hydroxyl substitution of the 
pyridine ring.
The i.r. spectrum of MT^ (Fig. V.5) contained a weak band at 
2230 cm"'1' which was assigned to a nitrile group. Broad signals 
at 3000~3600 cm ^ were indicative of the presence of a hydroxyl 
group.
On the basis of the u.v. and i.r.<spectra, the structure 
tentatively assigned toMT^f was that of a hydroxylated derivative of 
3-methyl, 8-cyano-5»6»7t8-tetrahydroquinoline. Since aromatic 
hydroxylation had been ruled out on the basis of the u.v. spectra, 
alternative structures were 8-cyano-5»6,7,8-tetrahydro-3-hydroxy- 
methylquinoline (cf RT5A in rat) or an isomer hydroxylated in the 
saturated ring.
The mass spectrum of MT4 (Fig. V.8) was consistent with such? 
a hydroxylated structure, having a parent ion at m/e 188. Furthermore, 
it was found to be very similar to the mass spectrum of component 
RT5B (Fig. IV.9) isolated from rat urine and identified as 5-hydroxy, 
8-cyano--5i6,7*8-tetrahydro-3-methylquinoline. Moreover, it was 
quite different from that of RT5A, the 3-hydroxy-methyl isomer 
Fig. IV.9). Whereas the most ororainent ion in the mass spectrum 
of RT5A was the parent ion at m/e 188,in.that both MT*f and RT5B was 
a fragment at m/e 132. Other fragments shared by MTA and RT5B but 
not RT5A were those at m/e 173 ♦ 170, 169 and 168. Furthermore, 
fragments at m/e 159 and m/e 1^8 in the mass spectrum of RT5A 
were absent from those of both MT*f and RT5B. Hence the mass 
spectral evidence definitely eliminated the possibility that MTA- 
could be. the 3“hydroxymethyl compound. The extreme similarity of 
the mass spectrum of MTA to that of the rat metabolite RT5B made 
it most likely that these compounds were identical i.e. that MT^ f 
was 5-hydroxy,8-cyano-5»6,7,8-1etrahydr o-3-me thylquinoline•
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DISCUSSION
The metabolism of tiquinamide in the patas monkey showed some 
similarities and some differences from that in the rat. The major 
end-products isolated from monkey urine resulted from three Phase I 
processes: desulphuration of the thiocarboxamide group to the 
corresponding nitrile analogue, oxidation of the 3-methyl group 
and hydroxylation at the 5-position. All these processes had also 
been observed to occur in the rat. Unlike the rat, however, the 
monkey did not aromatize the 5 ,6,7,8-tetrahydroquinoline ring 
system (Fig. V.9)*
Whereas no evidence could be found to support the existence
of a substantial proportion of thioamide-containing metabolites in
rat urine (Chapter IV. p.83 ), there seems every likelihood that
such compounds were excreted in the urine of the patas monkey, but
were chemically desulphurized before they could be identified.
14Studies on the stability of C-tiquinamide HC1 added to control
monkey urine and stored under the conditions of collection and
storage of urine from tiquinamide-dosed animals revealed that,
although substantial degradation would have taken place, at least
k5% of thioamide compounds voided in the 0-24- h urine v/ould have
been detected. Hence major thioamide metabolites would have been
detected in the chromatographic pattern though it would have been
anticipated that they would degrade during subsequent work-up.
Hence the observation in the 0-2 h urine of monkeys of a mjaor
radioactive component, which subsequently degraded to MT3
(8-cyano-5,6*7,8-tetrahydroquinoline-3-carboxylic acid) suggested
that this unstable metabolite was such a thioamide i.e. 5*6*7,8-
tetrahydroquinoline-8-thiocarboxamide-3-carboxylic acid. That this
comnonent was not apparent in the chromatographic pattern of the
0-24 h urine was in all probability due to its degradation during
the processes of thawing, pooling of samples collected over shorter
periods, and re-freezing and re-thawing which took place before the
0-24 h pattern was determined. It must be concluded therefore that
although some metabolic.desulphuration may have taken place, some
of the desulphuration of tiquinamide-related products in the patas
monkey occurred by chemical degradation. Hence the nitrile
14
compounds isolated from urine of monkeys dosed with C-tiquinamide HC1 
arose, at least partially, as degradation products of thioamide-
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containing metabolites. Less extensive metabolic desulphuration 
in the monkey than in the rat was consistent with the more rapid 
elimination of metabolites in the monkey. Metabolism at other sites 
in the molecule apparently occurred more rapidly than did 
desulphuration, resulting in products containing highly polar 
groups which were readily excreted in urine before metabolic 
desulphuration could take place.
The predominant biotransformation step in the monkey was the 
U) -oxidation of the 3-methyl group of tiquinamide to the 
corresponding 3-carboxylic acid. This resulted in the recovery 
from 0-24 h urine of 33-475® of the dose in the form of MT3 (8-cyano- 
5,6,7»8-tetrahydroquinoline-3-carboxylic acid). As discussed above, 
this compound may have been formed partially as a true metabolite 
and partially as a degradation product of its thioamide analogue.
The rate of the oxidation of the 3-methyl group was extremely 
rapid in this species, as judged by the fact that such a high 
proportion of the dose was excreted as carboxylic acid metabolites 
and that there was no evidence for excretion of the intermediate 
3-hydroxymethyl derivative seen in the rat,! Furthermore, the 
3-carboxylic acid metabolites constituted the major portion of the 
50% of the dose which was eliminated within the first 2 h after 
drug administration. Thus the formation of 3-carboxylic acids was 
both faster and more extensive than in the rat, which excreted 
only 1o% of the dose in urine in this form1 and less than 3% in 
bile. An alternative explanation for the lo?/er amounts of these 
acids in rat urine was that they were extensively further 
metabolized. Possible routes of further metabolism included 
conjugation with glucuronic acid, as for nicotinic acid (Reddi 
and Kodicek, 1953) or with amino-acids such as glycine, as for 
6-chloropicolinic acid (Ramsey et al., 1974).
However, these products would themselves have been rapidly 
excreted by virtue of their high polarity. Although such compounds 
may have been present in 0-24 h urine they could not have been 
present in high enough amounts to account for the difference between 
the amounts of 3-carboxylic acids excreted in rat and monkey. 
De-carboxylation was another possible route of further metabolism, 
but this has only been seen as a minor reaction e.g. 1% for nicotinic 
acid (Leifer et al., 1951)* Thus it was apparent that the
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W  -oxidation pathway to the 3-carboxylic acid in the monkey 
proceeded to an extent at least double that in the rat.
The other identified route of metabolism of tiquinamide in 
the monkey was hydroxylation at the 5-position i.e. ben-r.ylic hydroxy- 
lation at a position ^ - to the point of fusion of the saturated 
and unsaturated rings in the tetrahydroquinoline system. This 
route could have been responsible for up to 20% of the dose excreted 
in the 0-2k h urine, assuming that all the conjugated material in 
band MT1 was comprised of glucuronides or sulphates of 5-hydroxylated 
metabolites. Thus, at the most, the extent of this process 
represented one-quarter to a half that of the^-oxidation step.
There could be more certainty about the relative importance of 
these two routes in the monkey than in the rat because virtually 
all of the dose (circa 90%) was excreted in theformer species in 
the 0-2*f h urine and therefore no speculation about the nature of 
subsequently excreted products was necessary to evaluate the 
maximum proportions of the dose which could have been excreted 
by each route.
The extent of conjugation of the 5-hydroxylated product was 
greater than in the rat. Thus free 5-hydroxylated metabolites 
represented only 11-13% of the total 5-hydroxylated compounds, 
compared to k-0% in the rat (Chapter IV. p. 87).
Some possible reasons for the species difference in metabolism 
between the rat and patas monkey
Two major competing pathways of oxidative metabolism of 
tiquinamide in the rat and patas monkey are <P-oxidation and allylic- 
hydroxylation at the 5-position. As discussed in Chapter IV, the 
ensymes probably involved in these biotransforraation pathways are 
those outlined below:
- Oxidation:
R CH., microsomal y R C^O H  soluble ^ R CHO soluble. R COOH 
^ mono-oxygenase ~ alcohol aldehyde
dehydrogenase dehydrogenase
Allylic-hydroxylation:
,CH CHOHmicrosomal
mono-oxygenase
HC CH HC CH
Whilst examples ofu)-oxidation of aromatic methyl substituents 
by the rat are known and several compounds have been found to be 
oxidized completely to the corresponding carboxylic acids e.g. 
banol (Strother, 1972), 5-hiethyl-4-(2-hydroxy-3-t-butyl-aminopropoxy) 
coumarin (Hayashi et al. , 1975) and 3-chloro-*f-methyl-aniline 
(Peoples and Westberg, 1975)* there is evidence that the rat 
performs this oxidation less well than primates so* that an 
alternative route of metabolism may often be favoured. Thus, 
for example, diazoxide was metabolized to the extent of up to 70% 
in the monkey and 5**— 60% in man by oxidation of an aromatic methyl 
substituent to hydroxymethyl and carboxylic acid derivatives, but 
was excreted without extensive metabolism in the rat (Pruitt,
Faraj and Dayton, 197*0* Similarly, mepirazole was extensively 
metabolized by methyl group oxidation to the carboxylic acid 0 
derivative in man, but the only significant route of metabolism 
in the rat involved aromatic hydroxylation of the pyrazole ring 
(Kodama and Takabatake, 1972). For a number of compounds, this 
U) -oxidation proceeds only as far as the hydroxymethyl compound 
in the rat, whereas primates oxidize completely to the corresponding 
carboxylic acid. Thus for tolbutamide, the hydroxymethyl oxidation 
product was t'he major metabolite in the rat (80%) and the carboxylic 
acid only relatively minor (*f%), whereas in man as much as 33% 
of the dose was excreted as the acid (Thomas and Ikeda, 19&6). 
Similarly, for 2-isopropylaminoraethyl-6-methyl-7-nitro-l,2 ,3,*+— 
tetrahydroquinoline, the 6-carboxylic acid metabolite was a major 
product in man, but the rat formed only the 6-hydroxymethyl 
derivative (Kaye and Woolhouse, 1972). For the sulphonamide 
compound, tosifen, no comparable data in primates is available, 
but it is known that the rat performsW-oxidation as far as the 
hydroxymethyl derivative (5**—57%)* but further oxidation to the 
carboxylic acid is less extensive (7-19%) (Lin et al., 1978).
Part of the reason for the poorer oxidation of aromatic 
methyl substituents to the corresponding carboxylic acids by the 
rat may be that the activity of liver alcohol dehydrogenase in the 
rat is substantially lower than in primates. It has long been 
known that the oxidation of the hydroxymethyl compound' to the 
aldehyde which occurs as an intermediate step in the W-oxidation 
of methyl groups to carboxylic acids is catalysed by a soluble
dehydrogenase in the liver (Gillette, 1959). More recently it has 
been demonstrated that this reaction is carried out, in fact, by 
the liver' alcohol dehydrogenase which catalyses ethanol oxidation 
(Von Wartburg and SchUrch, 1971)* Furthermore, these authors showed 
that, for the oxidation of ft -pyridyl carbinol, human liver possesses 
2.8 times the alcohol dehydrogenase activity of rat liver and monkey 
liver 2.3 times that of rat liver. With ethanol as substrate, they 
found activities in man and monkey of 1.6 and 1.7 times that in the 
rat, slightly lower than the ratio of *)/ 2.3 between man and rat 
observed by Krebs and Perkins, 1970. Alcohol dehydrogenase, 
rather than aldehyde dehydrogenase, was the rate-limiting step 
in the oxidation of ft-pyridyl carbinol to nicotinic acid.
In addition to the retarding effect of the lower alcohol * 
dehydrogenase activity in the rat on the side-chain oxidation, 
there may well be an additional factor, namely the specificity of 
the microsomal mono-oxygenases in this species, tending to promote 
5-hydroxylation rather thank*-oxidation. There is some evidence . 
from work on the kinetics of hexobarbital metabolism to support 
the view that this reaction occurs more rapidly in rats than in 
primates. Hydroxylation in the cyclohexane ring at a position ^  " 
to the double band constitutes the rate-limiting step in the 
elimination of this compound and is an analogous reaction to the 
5-hydroxylation of tiquinamide. The most recent estimate of the 
half-life of hexobarbital in the rat suggest that it may be as 
short as 12 min (Holcomb, Gerber and Bush, 197*4-)*» whereas in the 
rhesus monkey it has been found to be much longer i.e. nearly 
2 h (Davis-, Brown and Strike, 1971). Hence the mono-oxygenase 
catalysing this reaction may possess a greater activity in the rat 
than in the monkey. It is envisaged, in contrast, that the mono­
oxygenase catalysing the k)-oxidation has a greater activity in the
(
monkey than in the rat. This explanation assumes the more recent 
view, for which there is increasing evidence, that there are several 
different microsomal mono-oxygenases with diverse activities. This 
view is supported, for example, by evidence that enzymes catalysing 
the hydroxylation of pentobarbital, the N-demethylation of ethyl- 
morphine and the l6-c*--hydr oxylation of testosterone have been 
differentiated from testosterone-7-tf- and 6-/4-hydroxylase by their 
differing stabilities to storage at -15°C (Levin et al., 19&9)*
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Similarly, the 7-o(» - and l6-©t-hydroxylations of testosterone
have been distinguished from one another (Kuntzmaii et al. , 1968). 
Substantive evidence has come also from the finding of multiple 
forms of cytochrome P-450 in liver microsomes (e.g. Coon et al., 
1977; Johnson and Muller-Eberhard, 1977) which have varying 
substrate specificities. It is not difficult to envisage that 
such polymorphism among microsomal mono-oxygenase could account 
for many of the known species differences among routes and rates 
of drug oxidation, including possibly the observed species 
difference in the oxidative metabolism of tiquinamide in rats 
and monkeys.
Why the monkeys did not form the fully aromatized metabolite, 
8-cyano-quinoline-3-carboxylic acid, as did the rat, was unclear. 
Species differences in the extent of aromatization have been 
reported for cyclohexane carboxylic*acid (Babior and Bloch, 1966) 
and for quinic acid (Adamson et al., 1970&)* However, as has 
previously been discussed, (Chapter IV. p. 89 ) these reactions 
occur by different mechanisms and it is quite possible that the • 
aromatization which apparently occurs during the metabolism of 
tiquinamide in the rat does so by yet another mechanism. Hence 
the reason for the absence of the aromatization reaction in the 
patas monkey necessarily remained obscure in the absence of a known 
mechanism for this reaction.
1 2 ?
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MT1 18.6 15.8
MT2 8.0 7.0
MT3 37.8 A-6.6
MT4 2.7 1.9
Total
these
% in 
bands 67.1 71.3
Total % dose 
in urine 90.1 86.9
Table V.l: Percentages of the administered dose present in each of 
the manor radioactive components in 0-2^ h urine ofu - ■ ■   - ■ -- - - --- T ll ~ ~ ~ 1 " " 1 "
patas monkeys administered 10 mg/kg x^C-tiquinamide orally
Solvent system Rf
MT3
Rf
THQ COOH
1 O.65 O.63
2 0.18 0.18
3 0.15 0.0*f
11 0.82 0.7^
12 0.38 * 0.29
Table V.2: Comparative t.l.c. of MT3 with 5«6«7.8-tetrahydro
quinoline-3-carboyylic acid
CHAPTER VI: METABOLISM OF TIQUINAMIDE IN MAN
SUMMARY
A study of the nature of end-products in 0-2^ h urine of male 
volunteers suggested that there were pathways identical to those 
in the rat. D -Oxidation resulted in the formation of 8-cyano- 
5,6,7,8-tetrahydroquinoline-3-carboxylic acid and, after aromatization, 
in 8-cyano-quinoline-3-carboxylic acid. Allylic hydroxylation at the 
5-position gave rise to 5-hydroxy,8-cyano-5»7,8-tetrahydro-3- 
methylquinoline, which was extensively conjugated at least partially 
with glucuronic acid. Characterization of products isolated from 
urine suggested that they were nitriles, but no distinction could 
be made between chemical and enzymic degradation of the thioamide 
group. Therefore the extent of metabolic desulphuration in man 
was not known. With respect to the degree of conjugation of the 
5-hydroxylated compound and the extent of w -oxidation to carboxylic 
acids, man resembled the patas monkey more closely than the rat.
Thus there were similarities with both animal species studied.
The comparative metabolism of tiquinamide in rat, patas monkey and 
man is discussed.
INTRODUCTION
Studies of the metabolism of tiquinamide in rat and monkey 
had defined the major route of biotransforraation in these species 
and had indicated some similarities and some differences between 
them. It was essential to define the metabolic pattern in man in 
order to relate biological activities and disposition in man to 
those in the rat and monkey.
Concentrations of drug-related products in urine after a singl 
50 mg dose were too low to make isolation of sufficiently large 
quantities for physico-chemical characterization a practical 
proposition. However, it seemed likely that the establishment of 
the chromatographic pattern of urinary end-products in man v/ould 
indicate how closely the metabolism in this species resembled that 
in the rat or monkey. Thus it seemed a useful approach to define 
the qualitative and quantitative 0-2*f h urinary pattern of radio­
active products following t.l.c. in solvent 1 and to supplement 
this, where possible, by additional comparative t.l.c. in other 
solvent systems to confirm the identities of products with compound 
isolated from rat urine.
EXPERIMENTAL
(a) Chromatographic pattern of drug-related products in urine
Two male volunteers, DM and ML, were each administered a 
1450 mg dose of C-tiquinamide (50 uCi) orally by capsule as previously 
described (Chapter II. p. 42). Urine was collected at 3-hourly 
intervals for the first 12 h, and subsequently at 24 h. Portions 
of a pooled 0-24 h urine sample (20 ml) were reduced to dryness 
and residues dissolved in methanol (2 ml). Aliquots were subjected 
to t.l.c. in solvent 1 on 0.25 mm silica plates with pre-adsorbent 
zone. Radioactivity was located by scanning.
The clearly definable components were designated HT1-ET4 in 
order of increasing mobility, which was determined relative to 
THQ-COOH.
The distribution of radioactivity on the plate was quantitated 
by scraping 0.5 cm strips into scintillation vials followed by 
elution .with methanol/water (1:1, 2 ml) and liquid scintillation 
counting.
(b) Comparative t.l.c. of ether-soluble acidic compounds with those
in rat urine
•The acidic, ether soluble components HT3 and HT4 were isolated 
fro.m human urine by extraction into diethyl ether at pH2 followed by 
thin-layer chromatography in solvent 1 on 0.25 mm silica plates 
with pre-adsorbent zone. Radioactive bands were located by scanning, 
scraped off and eluted with methanol. RT3 and RT4 were isolated 
in a similar manner from rat urine.
The chromatographic properties of HT3 and RT3 and of HT4 and RT4 
were compared in solvents 1, 2, 3* 11* 12 and 14, (Chapter II. p. 38)
(c) Hydrolysis of conjugated material
The residue of a 20 ml portion of 0-24 h human urine after 
diethyl ether extraction under basic (pH 9) and acidic (pH 2) 
conditions was incubated for 18 h at 37°C with bacterial 
/8 -glucuronidase (E. Coli Type I Sigma Chemical Co., Poole, Dorset) 
at 18,000 units/ml in pH 7.4 0.1M phosphate buffer satur«&Awith 
chloroform. Protein precipitation was performed by addition of 
methanol, followed by centrifugation. Supernatants were reduced 
by dryness, dissolved in water (5 ml) and subjected to extraction 
with diethyl ether ( 2 x 4  vol) under basic (pH 9) or acidic 
(pH 2) conditions.
Chromatography of the basic, ether-soluble material was 
performed in solvents 4, 5» 7 and 10, (Chapter II* p. 38).
Location of radioactivity was by scanning and comparison was made 
with previous traces of RT5B isolated from rat urine and subjected 
to t*l*c. in these same solvent systems.
RESULTS
(a) Chromatographic pattern of drug-related products in urine 
The 0-2*1- h urine of two male volunteers administered a single
50 mg dose of "^C-tiquinamide HCI orally contained 6l% and 88% 
of the dose. Chromatography of this fraction in solvent 1 revealed 
the presence of four principal radioactive bands, designated 
HTl-HT*f, which corresponded to bands RT1-RT*+ in the rat (Fig. IV.l). 
HT1, HT3 and HT*f were clearly" evident as individual components, 
whereas HT2 was a more diffuse band, possibly containing several 
components (Fig# VI.1).
In Table VI.1 are expressed the percentages of the administered 
dose found in each of these radioactive components. The most 
prominent bands were HT1 (17-27%) and HT*f (17-25%)* The component
ET3 was present in somewhat lower amounts (7-10%). Band HT2 contained
a
11-20%, but was a diffuse, ill-defined area.
(b) Comparative t.l.c. of ether-soluble acidic compounds with 
those in rat urine
A diethyl ether extract of untreated human urine made under 
acidic conditions (pH 2) contained only components HT3 and HT*f.
HT3 was' •found to have very similar chromatographic properties 
in six solvent systems (Table VI.2) to rat metabolite RT3« identified 
as 8-cyano-quinoline-3-carboxylic acid (Chapter IV. p.82 )•
Similarly, HT*f had similar chromatographic properties in six 
solvent systems (Table VI.2) to those of rat metabolite RT*f, 
identified as 8-cyano-5*6»7,8-tetrahydroquinoline-3-carboxylic 
acid (Chapter IV. p.83 )• '
(c) Hydrolysis of conjugated material
Treatment of.the polar component HT1 with bacterial 
P> -glucuronidase resulted in partial hydrolysis of this material. 
Extraction of the incubation mixture with diethyl ether following 
basification (pH 9) resulted in 2*f% extraction of radioactivity 
into the ether phase. Chromatography of the extracted radioactivity 
in three solvent systems revealed essentially a single component 
with similar chromatographic properties tothose of rat metabolite 
RT5B, previously identified as 5-hydroxy,8-cyano-5»6,7i8-tetrahydro- 
3-rnethylquinoline (Table VI.3)* A further 9% of total radioactivity 
in the hydrolysate was extracted into diethyl ether under acid 
conditions (pH 2) but was not characterized.
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DISCUSSION '
Limited studies on the metabolism of tiquinaraide in man have 
revealed that the processes involved (Fig. VI.2) were probably 
qualitatively similar to those observed in the rat andmonkey.
The major pathways involved were W-oxidation of the 3-methyl 
group and 3-kydroxylation, as in both rat and monkey. In addition, 
there was apparently a significant degree of aromatization of the 
3-carboxylic acid metabolite as observed in the rat but nob in the 
monkey. The extent of metabolic desulphuration of the thioaraide 
group in man could not be estimated on the basis of these studies.
The urinary end-products characterized were observed to be nitriles 
on the basis of a comparison of their chromatographic properties 
with those of corresponding compounds found in rat urine and 
identified by physico-chemical analysis. However, it is quite
e
possible that any thioamides present in urine would have undergone 
chemical degradation to the nitrile during the prolonged storage 
at -20°C and subsequent thawing. *
The indications from these results were that the metabolism 
of tiquinamide in man was not identical in every detail either with 
that in the rat or with that in the monkey, but shared some 
features with both these species (Table VIT4). Man excreted in 
24 h similar amounts (7-10%) of the fully aromatic 8-cyano-quinoline- 
3-carboxylic acid to the rat (9%)» v/hereas the monkey did not form 
this metabolite. However, in most other aspects, man resembled 
the monkey to a greater degree. Excretion of the partially 
saturated acid 8-cyano-5,6,7,8-tetrahydroquinoline-3-carboxylic 
acid was 17-25?° in man i.e. approximately three times that in the 
rat (7%) but ah) out half that in the monkey (38-477°). Excretion 
in 0-24 h urine of total acidic metabolites was 23-34% i.e. 1.5 
to' 2 times that in the rat (lo%) and approximately three-quarters 
that in the monkey (38-47?°)* At 17-27?° in man, the total material 
remaining on the origin and believed to represent primarily conjugates 
of 5-hydroxy,8-cyaiio-5,o,7,8-tetrahydro-3-methyl-quinoline, was 
greater substantially than in the 0-24 h rat urine (7%)i and possibly 
slightly greater than in monkey urine (16-19%). In that there was 
no evidence of free 5-hydroxy,8-cyano-5,6,7,8-tetrahydro-3-methyl- 
quinoline, man resembled the monkey in this respect more than the rat.
\
It is fairly well established that in general monkeys and 
other sub-human primates show greater similarities to man in terms 
of their drug-metabolizing activities than do other species 
(Williams, 1974; Smith, 19^7; Smith and Williams, 1974), although 
the different species of primate may vary among themselves and it 
is not always easy to predict in advance which will represent the 
best model for man. The rhesus monkey has been found to be most 
generally useful. Thus Smith and Caldwell (1977) found that for 
17/23 drugs, metabolism in the rhesus monkey was similar to that 
in man. The patas monkey, like the rhesus, is an Old World monkey 
and therefore perhaps similarly closely related to man in 
evolutionary terms. Though it has been less widely investigated, 
it might be anticipated that this species also would represent 
a good model for man. In the present studies on the comparative 
metabolism of tiqug-namide, this was found to be generally true in 
that the extent of W-oxidation and of 5-kydroxylation were of 
similar orders in patas monkey and man. However, man behaved quite 
differently from the monkey, but identically to.the rat, in carrying 
out the aromatization reaction which resulted in the formation 
of 8-cyano-quinoline-3-carboxylic acid. Species differences in 
the aromatization of quinic acid (Adamson et al., 1970a) and of 
cyclohexane carboxylic acid (Babior and Bloch, 1966) are known,but 
it is possible that the species difference in tiquinamide aromati­
zation has quite a different explanation, since it orobably occurs 
through a different mechanism (Chapter IV. p. 89).
Solvent system: Chloroform/methanol/acetic acid (18:2:1)
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% Dose
ML DM
HT1 17.2 27.1
- HT2 (11.2) (19.9)
ST3 6.8 * 9.7
HT4 16.6 25.4
Total % dose 
the bands
in 51.8 82.1
Total % dose 
0-24 h urine
in 6o,8 87.5
Figures in parentheses denote total percentage 
of dose within a diffuse area designated HT2
Table VI,1: Percentages of the administered dose present in each
of the major radioactive components in 0-24 h urine
l*fof male volunteers administered 30 mg C-tiquinamide 
5 orally
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Solvent Rf
Relative Rf values
THQ COOH
HT3 RT3 HT4- RT4
1 0.52 1.14- l.lb 1.30 1.30
2 0.09 3-34 3.00 3.00 3.00
3 0.05 • 3.24 3.24- 2.88 2.88
11 O.bO 1.22 1.22 1.16 1.19
12 0.24- 1.27 1.38 1.19 1.19
14- 0.17 1.29 1.32 1.38 1.33
Table VI.2: Comparative chromatographic properties of acidic end-
products of tiquinaraide in man and rat
Rf values for acidic end-products of tiquinamide are expressed 
relative to THQ COOH. Absolute Rf values for this reference 
compound are quoted for each solvent system.
Rf
Solvent HydrolysedHT1
Rat
metabolite RT5B.
k 0.07 0.07
5 o. 65 0.65
7 0.32 0.35
10 0.3.5 0.35
Table VI.3: Comparative chromatographic properties of the major
product of hydrolysis of HT1 with those of rat urinary
end-product RT5B 
Results are absolute Rf values.
PERCENTAGE DOSE PRESENT IN 0-24 H URINE
Female
Rat
Monkey Man
Mean
-SEM ^360 + 288 ML DM
8-cyano-quinoline* 
3-carboxylic acid
8.5
o76
ND ND 6.8 9.0
8-cyano-5,6,7*8-*
tetrahydroquinoline- 
3-carboxylic acid
7.4
076 37.8 46.6 16.6 23.6
8-cyano-5»6,7»8-*
tetrahydro-3-hydroxy- 
methylquinoline
0.9 ND ND ND ND
3-hydroxy-8-cyan0-* 
5,6,7,8-tetrahydro- 
3-methylquinoline
V
0.7
2.7 1.9 ND ND
8-cyano-5 ,7,8-tetra-* 
hydro-3-niethyl quinoline
V
o 7 i ND ND ND ND
Conjugates including* 
glucuronide of 5- 
hydroxy,8-cyano-5 ,7 *8- 
tetrahydro-3-methyl- 
quinoline
6.8 
■ 073 18.6 15.8 17.2 25.3
Unidentified
metabolites
12.1+•
0.6 31.0 22.6 20.2 30.4
Total 40.2+
272 90.1 86.9 60.8 87.5
Table VI.4: Percentages of the dose of ^C-tiauinamide HC1
excreted as individual metabolites in 0-24 h urine
of rats, patas monkeys and human volunteers
* Amounts of these nitrile metabolites may include their thioamide 
analogues
ND - not detectable
lbU
CHAPTER VII: PLASMA KINETICS OF TIQUINAMIDE AND ITS METABOLITES
IN RAT, PATAS MONKEY AND MAN
i d i
SUMMARY
Study of the plasma kinetics of tiquinamide and its metabolites 
in the rat and patas monkey revealed that the drug was quickly 
absorbed and rapidly eliminated in both species, but that there 
was a very pronounced species difference in rates of elimination 
of metabolites. Total drug-related products were very rapidly 
eliminated in the patas monkey but very slowly eliminated in the 
rat. Although unchanged drug was not assayed in human plasma, the 
kinetics of a toluene-soluble basic fraction which was assayed had 
been found in animal studies to be representative of those of unchanged 
tiquinamide. The kinetics of this fraction in plasma of human 
volunteers indicated once again both rapid absorption and elimination. 
The total metabolite fraction in human plasma was mostly eliminated 
quickly, as in the monkey, but there was some evidence of a slower 
elimination phase akin to that in the rat.
Kinetics of total metabolites in whole blood were similar to 
those in plasma and showed no evidence of a significant association 
of drug or metabolites with red cells.
Binding to plasma proteins was found to be moderate in all 
three species, with no significant species differences.
A fraction of drug-related products found in rat olasma 25 h 
after dosing was found apparently to contain a single component of 
different chromatographic properties from that of any major product 
isolated from 0-2*f h urine. Preliminary characterization suggested 
that it was of polar nature, and possibly a conjugate. Some possible 
structures are discussed.
The species difference in eliuvLnation of metabolites is discussed 
in the light of these findings and of knowledge of the identities 
of major metabolites and their physico-chemical properties.
t
INTRODUCTION
The plasma concentration-time profile of a drug and its 
metabolites provides information about the extent and rates of its 
absorption, and elimination from the body which represent fundamental 
parameters of the compound's behaviour in a mammalian system. The 
relevance of such information to the process of drug development 
and optimal clinical use has been discussed previously (Chapter I. 
p. 32 ).
Experiments were carried out-in animals and man in order to 
provide such fundamental pharmacokinetic information for tiquinamide 
as might facilitate decision-making during its development. Thus, 
for example, the time at which peak plasma concentrations occurred 
in man would be indicative of the intrinsic rate of absorption of 
tiquinamide. Determination of the rate of drug elimination in 
volunteers would be expected to aid the making of an informed 
decision about the frequency of dosing likely to offer maximum 
therapeutic benefit. Similarly, knowledge of the rate of elimination 
of total drug-related substances would show whether long-lived 
metabolites with a potentially increased risk of toxicity were likely 
to be a troublesome feature of this compound. Comparison of these 
parameters in man with those in the rat and patas monkey would 
establish whether the kinetic behaviour of the drug in these three 
species was sufficiently similar for chronic toxicity studies 
performed in the given animal species to be predictive of potential 
safety of tiquinamide on repeated administration to man.
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EXPERIMENTAL
(a) Plasma kinetics
Rats: Four male and four female rats received 10 mg/kg
14
C-tiquinamide HC1 orally as previously described (Chapter II 
p. 42 ). Blood was collected at various times after dosing 
(Fig. VII.1), over periods of 0-264 h in male rats and 0-292 h in 
females.
Radioactivity in aliquots of whole blood were determined by
scintillation counting after preparation of samples by a modification
of the Mahin and Lofberg perchloric acid digestion procedure
(Chapter II. p. 43)* Plasma was separated from red cells by
centrifugation. The toluene-soluble fraction of radioactivity in
plasma, containing unchanged drug, was determined after an in-vial
extraction, by liquid scintillation counting (Chapter II. p. 44 ).
Radioactivity in the residue was assayed by liquid scintillation
counting and concentrations of total radioactivity calculated.
The specificity of the toluene extraction procedure was determined
by chromatography of an extract. Plasma was collected as above from
a group of 10 female rats at 1-2 h after administration of 
14
C-tiquinamide HC1. It was made alkaline by addition of pH 9 
1M bicarbonate buffer and extracted with toluene ( 2 x 3  vols).
Stability of unchanged tiquinamide during the extraction 
procedure was ensured by loading the plasma to a concentration 
of 100 pg/ml with unchanged tiquinamide HC1. The extract was 
subjected to thin-layer chromatography in solvents 5* 6 and 19 *
In an additional experiment, to determine the kinetics of 
unchanged drug, groups of 4 female rats were killed at various 
times over a period of 0-8 h after dosing (Fig. VII.4) and exsanguin­
ated from the inferior vena cava whilst under ether anaesthesia. 
Plasma was separated from red cel3.s by centrifugation. A toluene 
extract of plasma was made as described above. Unchanged drug was 
separated from other components in toluene extracts by thin-layer 
chromatography in SoLvent 5 (Chapter II. p.38 ). Radioactive areas 
on plates were located by autoradiography. Bands corresponding to 
unchanged drug were scraped off, eluted with methanol/water (1:1) 
and quantitated by liquid scintillation counting. Absolute 
concentrations in plasma were calculated with reference to standard
amounts of C-tiquinamide HC1 added to control plasma and taken 
through the entire procedure. Kinetic analysis was performed as 
described previously (Chapter II. p. 4-7),
Patas monkeys: Two male and four female patas monkeys received
14
a 10 mg/kg oral dose of C-tiquinamide HC1. Blood was collected 
from the femoral vein at various times over a 0-48 h period after 
dosing (Fig. VII.5)• Total radioactivity in plasma and whole blood 
and toluene-soluble radioactivity in plasma were determined as for rats 
For the determination of the specificity in the patas monkey of the 
toluene extraction procedures, an experiment was performed in which 
a single animal was exsanguinated whilst under pentothal anaesthesia.
A toluene extract of plasma, prepared as previously described was 
subjected to thin-layer chromtography in solvents 5 and 6.
In another experiment, three female patas monkeys received a 
10 mg/kg oral dose of the drug and subsequently 10-15 ml portions 
of blood were removed from the.femoral vein at various times up to 
4 h after dosing (Fig, VII.7)* Monkeys were each administered 
6o*ml distilled water after the third blood sample had been taken, 
i.e. approximately 1.5 h after dosing, in order to compensate for 
the extensive fluid loss resulting from the removal of such large 
blood samples. Concentrations of total radioactivity were determined 
by liquid scintillation counting. Toluene extraction was performed 
and determination of unchanged drug carried out by the procedure 
described previously. Kinetic analysis was performed as already 
described (Chapter II. p. 47).
Man: Two male volunteers each received a dose initially of
14
20 mg containing 5 hCi C-tiauinamide EC1 and a week later a 
subsequent dose of 50 mg containing 50 pCi of radio-labelled drug.
On each occasion, blood was collected from the cephalic vein at 
various times after dosing (Fig. VII.8) up to 48 h in the first 
experiment and 98 h in the second.
Toluene-soluble and total radioactivity in plasma were 
determined by liquid scintillation counting as previously described. 
Kinetic.analysis was carried out according to the previously 
described method (Chapter II. p. 47).
(b) Plasma protein-binding
The extent of protein-binding of tiquinamide added at various 
concentrations to plasma of rat, patas monkey and man was determined 
by equilibrium dialysis. The dialysis was performed in cylindrical
perspex cells, each comprising twohalves separated by a dialysis
membrane (Spectrapor Grade 2, MSE Ltd., Sussex). Into one half-cell
was introduced 250 jul 0.1M pH 7*4 phosphate buffer and into the
14other an identical volume of a solution of C-tiquinamide HC1 at
concentrations of 100 ng/ml-5 Pg/ml (Fig. VII.10) in the same 
phosphate buffer or in plasma. Triplicate samples at each concen­
tration were prepared. Cells were mounted in a clamp, immersed 
in a water-bath at 57°C and shaken gently backwards and forwards for
2-3 h, a sufficiently long period for equilibration to be achieved.
At the end of the equilibration period, radioactivity in 200 /il 
aliquots taken from each half of the dialysis cell was determined 
by liquid scintillation counting. The percentage of drug bound to 
protein at each drug concentration could be determined as follows:
Percentage _ (Plasma radioactivity-Buffer radioactivity) x 100
protein binding ~ Plasma radioactivity
(where all concentrations of radioactivity are expressed as dpm/200 jul).
(c) Characterization of drug-related products in 25 h rat plasma 
Three female rats (circa 300 g) were administered
14
C-tiquinamide HC1 at 10 mg/kg orally and after 25 h were exsan­
guinated from the inferior venae cavae whilst under ether 
anaesthesia. Plasma was separated from red cells by centrifugation. 
Removal of protein from plasma was performed by ethanol precipitation. 
The chromatographic pattern of radioactivity in the ethanolic 
supernat*ant of plasma was compared with that in urine by t.l.c. 
in Solvent 1 on 0.25 mm silica plates with' pre-adsorbent zone.
Further chromatography of products in plasma was carried out 
in solvents 6, 8, 12, 15 and 18.
Tiquinamide and the related compounds Wy-24l46 (8-cyajio-5»6,7,8- 
tetrahydro-3-methylquinoline), Wy-24ll7 5»8,7,8-tetrahydro-3- 
methylquinoline-8-carboxamide were run for comparative purposes.
Aliquots of the ethanolic supernatant .(equivalent to j.,5 ml of 
plasma) were reduced to dryness and taken up in 1.5 ml portions of 
.^-glucuronidase/sulphatase (Helix pomatia Type HI, Sigma 
Chemical Co. Ltd., 20,000 units/inl in pH 4.5 0.1M acetate buffer) 
or in acetate buffer alone. The nature of the products in the 
incubation mixture were examined, after ethanolic precipitation 
of proteins, by t.l.c. in solvent systems 1 and 15.
For determination of a u.v. spectrum, material was isolated at
25 h after dosing from the plasma of 15 female rats (180-200 g)
14
administered C-tiquinamide HC1 at 100 mg/kg. Plasma proteins were 
precipitated with ethanol and the ethanolic supernatant subjected 
to a single t.l.c. step in solvent 12. The radioactive component 
was eluted with ethanol and the u.v. spectrum determined in
ethanolic solution at concentrations of 12 and 59 Mg equivalent
14 ,C-tiquinamide HCl/ml.
(d) Partition coefficients of tiquinamide and related compounds
between toluene and pH 7.4 phosphate buffer
Partition coefficients between toluene and pH 7.4 phosphate
buffer were determined for the following comoounds: tiquinamide,
8-cyano-5,8,7,8-tetrahydro-3-methylquinoline, 5-hydroxv,8-cyano-
5,6,7,8-tetrahydro-3-methylquinoline, 5,8,7,8-tetrahydro-3-methyl-
quinoline and 5,8 ,7,8-tetrahydroqu'inoline-3-carboxylic acid.
These were model compounds containing structural features
representative of the known tiquinamide metabolites. To duplicate
5 ml portions of a solution (25 MS/ml) of each compound in pH 7«3
0.1M K+ phosphate buffer in glass centrifuge tubes were added 5 ml
toluene ("Pronalys", May and Baker). Tubes were shaken gently for
30 min on a rotary shaker and toluene phases decanted. Concentration
of each compound remaining in the aqueous phase were determined
spectrophotometrically with reference to unextracted 5 Mg/ml
solutions. Absorbance was determined at 275. nm instead of the more
usual 270 nm (max for the 5,8,7,8-tetrahydroquinoline ring) in
order to avoid interference from an impurity back-extracted
from toluene and having an absorption maximum at 268 nm.
RESULTS
(a.) ' Plasma kinetics
Rats: After oral administration of a 10 mg/kg dose of
14
C-tiquinamide HC1 to rats, total radioactivity in plasma increased
slowly, only reaching its maximum concentration at 8-12 h after drug
administration (Fig. VII.l). Peak values were 8.3-9*2 jig equivalent 
14C-tiquinamide HCl/ral in males and 9*9-ll»5 MS equivalent in 
females. Subsequent elimination of radioactivity took place very 
slowly and apparently raonoexponentially, with mean half-lives of 
101 h and 85 h in males and females respectively (Table VII.l), 
so that concentrations were still as high as 1.1 Mg equivalent/ml 
.eleven days after dosing. Elimination was significantly slower 
in males than in females (p = 0.02-0.0.5, &s judged by Student’s 
t-test).
A toluene-soluble fraction of radioactivity extracted into 
aklalinized plasma (pH 9) represented approximately 60% of total 
radioactivity at 0.5 h after dosing, this toluene-soluble fraction 
achieved maximum concentrations of 2.I-3.4 ;ig equivalent/ml in male » 
rats and 2.1-3*9 MS equivalent/ml in female rats by 0.5-1 h after 
administration (Fig. VII.2). Thereafter, the concentration 
declined rapidly to 0.1-0.2 jag equivalent/ml in males and 0.2-0.5 Mg 
equivalent/ml in females by 12 h after dosing. Elimination was 
apparently monoexponential, with mean half-lives of 2.8 h and 3*7 h 
in males and females respectively (Table VII.l). Chromatography1” 
of the toluene-soluble fraction of alkalinized, rat plasma collected 
at 1-2 h after dosing revealed the nresence of four significant 
components (Fig. VII.3)» Only 12/ of radioactivity in the toluene- 
extract of rat plasma was unchanged tiquinamide. The most prominent 
component, representing 44/ of apnlied radioactivity was the nitrile 
derivative Wy-24l46 (8-cyano-5,6,7,8-tetrahydro-3-methylquinoline ) • 
Two unknown metabolites Containing 28/ and 6% of extracted radio­
activity were also present.
When an additional experiment was performed in order to measure 
concentrations of unchanged drug in groups of 4 rats exsanguinated 
at various times after dosing, the toDuene-soluble radioactivity 
achieved a maximum concentration of 4.3 Mg equiv/ml at 0.5 h after 
dosing, a similar order to that seen previously (Fig. VI1.4). The 
elimination half-life of this fraction, 2.0 h, was a little shorter
but still in the same range as that observed in the earlier
experiment. Unchanged drug reached a maximum concentration of 
14
2.7 Mg equiv C-tiquinamide HCl/ml at 0.5 h after dosing. Thereafter 
the concentration declined rapidly, so that the concentration was 
only 5 ng/ml at 12 h after dosing. After an initial rapid disposition 
phase lasting 1 h, elimination of tiquinamide from plasma proceeded 
monoexponentially with a half-life of 1.6 h, a similar order to that 
of toluene-soluble radioactivity.
The time-course of radioactivity in whole blood of male and
14-female rats following oral administration of C-tiquinaraide HC1 
was similar to that in plasma, although absolute concentrations 
were somewhat lower. There was no evidence of association of drug- 
related products with red cells.
14
' Patas monkey: After a 10 mg/kg oral dose of C-tiquinamide 
HC1 to patas monkeys, total radioactivity achieved'its maximum 
concentrations at 0.5 h after dosing in two male and two female
14
animals (Fig.' VII.5)• Values were 6-l4 jag equivalent C-tiquinamide 
HCl/ml, with no observed difference between males and females.
In a third female, the peak concentration (7»8 jag equivalent/ml) 
was at 1.5 h after dosing and in a fourth, the maximum value 
(4.8 Mg equivalent/ml) occurred as late as 3 h after drug 
administration.* In these two animals, the slower absorption 
apparently limited the rate of elimination which took place more 
slowly than in the other animals. In those animals in which 
absorption was rapid, most of the radioactivity (95/) was eliminated 
over a period of 0-6 h with a half-life of approximately 0.7 h 
(Table VII.2). The second phase of elimination was slower, having 
a half-life of 44 h, but accounted for a very small proportion of 
the radioactivity in plasma (5/).
A toluene-soluble fraction of radioactivity extracted from 
alkalinized plasma (pH 9) represented only 15-20% of total radio­
activity at 0.5 h after dosing. Times of maxima were somewhat 
variable, as for total radioactivity. In two male and two female
14
monkeys, peak concentrations of 1-2 jig equivalent C-tiquinamide HC1/ 
ml were observed at 0.5 h after drug administration (Fig. VII.5)•
In the other two females, however, maximum concentrations of 1.4 jag 
equivalent/ml and 0.5 MS equivalent/ml were not seen until resnectivel.y
1.5 h and 3 h after dosing. Once again, there was evidence of
slower, absorption rate-limited elimination in these animals.
In the rapid absorbers, elimination occurred rapidly and mono- 
exponentially, with a half-life of approximately 0.7 h (Table VII.2). 
Chromatography of a toluene-extract revealed the presence of four 
components (Fig. VII.6). Unchanged tiquinamide represented 40% of 
total radioactivity in this fraction. A further 20% was present 
as the nitrile derivative Wy-24l46 (8-cyano-5,6,7,8-tetrahydro-3“ 
methylquinoline). Two further unknown metabolites accounted for 
8% and 11%. '
Plasma concentrations of unchanged tiquinamide in three female
i T Ifmonkeys achieved maximum values of 1.1-2.4 pg equivalent ~ C-tiquinamide 
HCl/ml at 0.5 k after drug administration (Fig. VII.7)• They 
subsequently declined, fairly rapidly, such that at 1.5 k after 
dosing, values were 0.2-0.6 Mg equivalent/ml. A secondary peak 
was observed at 2 h after drug administration. This was particularly 
marked in one animal in which the observed concentration at this 
time was as high as 1,6 jug equivalent/ml i.e. two-thirds of the 
highest value seen. This secondary peeik followed administration at
1,5 h after dosing, 'of a 6o ml volume of water to compensate the 
animal for the fluid loss as a result of the relatively high volume 
of blood taken up'to this time. Since the rate of gastric emptying 
is dependent on the volume of gastric concents (Hunt and McDonald,
1954), it is possible that the sudden increase in this volume would 
have stimulated rapid emptying of any residual drug in the stomach 
and thus promoted more rapid absorption of this material than would 
normally have taken place. Subsequently, plasma concentrations 
again declined rapidly such that they were in the range 0.1-0.3 Mg 
equivalent/ml by 3 h after dosing. The half-life of elimination of 
unchanged drug from plasma in + 3&9 was 0*7 h. In the other two 
animals, the presence of the secondary peak made it difficult to 
determine meaningful elimination half-lives. However, with the 
exception of this irregularity, the general shape of the time-course 
was similar to that previously determined for the toluene-soluble, 
basic fraction of radioactivity.
The tirae-course of radioactivity in whole blood of male and
female patas monkeys following oral administration of 10 mg/kg 
14C-tiquinamide HC1 was similar to that in plasma. There was,
W \J
however, substantial association of radioactivity (27.7-56.0%
(Table VII.3) with red cells at 0.5 h after dosing, although t*he 
degree of association decreased markedly during the period of rapid 
elimination. Thus by 7»5 h after dosing, only 7-18% of radioactivity 
was associated with red cells.
Man: Following oral administration to two male volunteers of
14-capsules containing 20 mg C-tiquinamide EC1, the highest concentration
14of total radioactivity, 0.4 jug equivalent C-tiquinamide HCl/ml 
occurred at 1 h in subject DM and 2 h in subject ML (Fig. VII.8), 
Thereafter the concentrations declined at first relatively raoidly 
to 0.2 ug equivalent/ml by 12 h after dosing and then more slowly 
to 0.1 ug equivalent/ml by 48 h. After the 50 mg dose, the maximum 
concentration, 1.5 Mg equivalent/ml in subject DM and l.ljug 
equivalent/ml in subject ML occurred at respectively 1 and 3 h after 
drug administration. Hereafter, the concentration of radioactivity 
in both subjects was reduced to 0.6 pg equivalent/ml at 12 h and 
0.3 MS equivalent/ml at 98 h after dosing. Areas under the plasma 
cohcentration-tirae curve were proportional to the dose (Table VII.4), 
indicating an absence of dose-dependent kinetics. The decline of 
total radioactivity in plasma appeared to take place bi-exponentially.
In a first, more rapid, phase of elimination, lasting for about the 
first 12 h, 68.6 - 0.6% of the dose was»eliminated with a half-life 
of 3*7 - 0.5 h. The slower phase of elimination was more poorly 
defined. Estimates of its half-life after the 50 rag dose were of 
the order of l4o h (Table VII.5)»
The toluene-soluble, basic fraction represented approximately 
60/ of total olasma radioactivity at 0.5 h. Maximum values following 
the 20 mg dose were 0.2 jug/ml, at 0.5 h after dosing, and following 
the 50 rag dose were 0.4 pg/ral in subject ML and 0.6 pg/ml in subject 
DM, occurring at 1 h after drug administration • (Fig. VII.. 9) • This 
toluene-soluble fraction declined raonoexponentially with a half-life 
of 2 h (Table VII.5). As observed for total radioactivity, the areas 
under the plasma concentration-time curves were proportional to the 
dose (Table VII.4). The only difference in the kinetics of the two 
doses was the slightly later time of peak concentration after the 50 mg 
dose.
(b) Plasma protein binding,
In Fig. VII.10 are presented data describing the binding of 
tiquinamide to rat-, monkey and human plasma over a concentration
range of 0.1-5.0 jug/wl, which spanned the range of concentrations 
observed in plasma of these species in vivo.
In the rat, tiquinamide was bound to plasma proteins to the 
extent.of 50-60% throughout this concentration range. In the monkey, 
the degree of binding was somewhat higher at low plasma concentrations 
e.g. 7^ +% of 0.1 ;ig/ml, but at concentrations above 0.5 /ig/ml was of 
a similar order, aoproximately 50%. In man, the degree of protein 
binding was in the range 52-66% throughout the concentration range.
(c) Characterization of drug-related products in 25 h rat -plasma 
Plasma collected from rats 25 h after administration of
lif
10 mg/kg C-tiquinamide HC1 apparently contained a single component 
with a low Rf value (0.11 relative to 5 * 6,7*8-tetrahydroquinoline-3- 
carboxylic acid). This material did not correspond to any of the 
major components in 0-25 h urine (Fig. VII.11). It had different 
chromatographic properties from tiquinamide and from the reference 
compounds W,y-24l46 (8-cyano-5i6 ,7,8-tetrahydro-3-methylquinoline) , 
Vly-2kll7 (5,6,7»8-tetrahydro-3-methylquinoline-S-carboxaraide) and
5,6,7,8-tetrahydroquinoline-3-carboxvlic acid. Only in the polar 
solvent systems 12 and 15 did it move very far away from the origin 
(Table VII.6).
Treatment with molluscan (I -glucuronidase/sulphatase did not 
affect its chromatographic behaviour.
The u.v. spectrum of the material isolated from 25 h plasma 
was poorly defined. However, there was evidence of a peak at 
267-270 nm. approximating to the characteristic wavelengths of 
maximum absorption of the pyridine portion of the 5*6,7»8-tetrahydro- 
3-methylquinoline ring system.
(d) Partition coefficients of tiquinamide and related compounds 
between toluene and pH 7»^ phosphate buffer
Results of partition coefficient determinations (Table VII.7) 
on tiquinamide and several compounds serving as models for metabolites 
revealed that the unchanged drug, and its nitrile derivative, as well 
as 5*6,7i8-tetrahydro-3-methylquinoline, were all readily extracted 
ihto toluene. The hydroxyl-ated derivative, 5-bydroxy-5*6 ,7, 8- 
tetrabydro-3-methylquinoline was much less readily extracted. As 
expected, the acidic derivative 5»6,7,8-tetrahydroquinoline-3- 
carboxylic acid remained almost entirely in the aqueous phase at 
pH 7,4.
DISCUSSION
The generally rapid achievement of maximum plasma concentrations 
of unchanged tiquinamide and/or toluene-soluble radioactivity in the 
species studied implied that tiquinamide was normally quickly 
absorbed. In view of the absence of extensive gastric absorption 
in earlier experiments (Chapter III p. oO), it was probable that the 
rate of gastric emptying was the most important determinant of the 
absorption rate and that slow or delayed gastric emptying accounted 
for the slower absorption in some monkeys. Once in the small 
intestine, tiquinamide (pKa 5*2) would have been completely unionized 
and, being relatively lipophilic would, on the basis of the pH- 
partition hypothesis, have been expected to be rapidly absorbed 
(Chapter I p.19 ). %
The comparative pharmacokinetics in both rats and monkeys of 
unchanged tiquinamide and toluene-6oluble radioactivity demonstrated 
that the kinetics of the latter fraction were a good model for those 
of the unchanged drug, although it contained other components, 
including the nitrile derivative (Chanter II. p. kk) and thus its 
absolute concentrations were higher than those of tiquinamide.
Whilst the absolute bioavailability of tiquinamide could not 
be deduced without comparable data obtained after intravenous 
administration, there was some evidence that bioavailability was 
only moderate, in that quite high concentrations of metabolites were 
present in plasma even by 0.5 h after dosing. Thus in rats unchanged 
drug represented *f0% of total radioactivity in plasma at this time.
In monkeys, the proportion of unchanged drug was even lower at 
around 15%* Although concentrations of unchanged drug in human 
plasma were not determined, it is possible that bioavailability in 
man was closer to the rat than to the monkey, since concentrations 
of toluene-soluble radioactivity, which contained unchanged drug, 
represented 60% of total radioactivity at 0.5 h after dosing, a 
similar proportion to that in the rat but considerably greater than 
that in the patas monkey, only 15-20%.
Although there was a tendency to more rapid elimination in the 
patas monkey than in rat or man of tiquinamide and/or toluene- 
soluble radioactivity, the two to four times greater rate in the 
monkey was relatively unremarkable, in that elimination was raoid
in each of the species investigated. However, there was clear 
evidence of a species difference in the elimination of ‘total radio­
activity, which occurred with a half-life at least one-hundred-fold 
greater in the rat than that of the major phase in the monkey, with 
man occupying an intermediate position closer to the monkey than 
the rat.
The weak plasma-protein binding of tiquinamide was unlikely
to have influenced its disposition. Martin (1965) has suggested
that in this respect plasma-protein binding will have no effect
unless the association constant for the drug-protein complex 
kexceeds 1 x 10 . Such a drug would be 80-90% bound at concentrations 
^0.1 mM, compared with only 50-60% for tiquinamide.
There was no evidence of binding to red cells. Thus this 
process was not a significant factor in the disposition of tiquinamide
The material present in plasma 25 h after drug administration 
was apparently a single component not seen as a major product in 
0-25 h urine. It did, however, have a similar Rf value to an 
unidentified polar product in bile. Its uYv. spectrum was indicative 
of the pyridine portion of the tetrahydroquinoline ring system, but 
its chromatographic properties suggested that it was somewhat more 
polar than either tiquinamide-related bases or their corresponding 
5-carboxylic acid derivatives. Possible polar metabolites included 
pyridinium compounds substituted on the nitrogen atom of the tetra- 
hydroquinoline ring and various conjugates. There was a precedent 
for the formation of pyridinium compounds by methylation of the 
pyridine nitrogen atom in the N-methylation of nicotinic acid, which 
is subsequently excreted as K-methylnicotinamide (Reddi and Kodicek, 
1953).
The most likely conjugates were those of the basic metabolites.
As discussed previously (Chapter V p.122), the 3-carboxylic acids 
and resulting conjugates would have been rapidly excreted in urine.
Glucuronide conjugates were excluded because the chromatographic 
behaviour of the compound was not altered by treatment with molluscan 
P> -glucuronidase/sulphatase. However, a sulphate conjugate remained 
a possibility because the sulphatase component of the enzyme 
preparation was an aryl sulphatase which may not have hydrolysed 
sulphates of alcoholic hydroxyl groups such as present in 5-hydroxylat 
or 3-hydroxymethyl metabolites of tiquinamide. Alternative
possibilities included conjugates of the tetrahydroquinoline nitrogen 
atom with a sugar. An N-riboside has been identified for 2-hydroxy- 
nicotinic acid (Schwartz et al., 1973) and a conjugate with an 
unidentified pentose, probably ribose, for pyrazole (Clay, Watkins 
and Murphy, 1977)« Similarly, a N-glucoside of 3-(^-pyrimidinyl)-5- 
(*f-pyridyl)-l,2,4 triazole is known (Duggan et al. , 197^)» However, 
such a conjugate of a tiquinamide metabolite, by analogy, with these 
compounds, would only be formed after an initial 2-hydroxylation, 
allowing the subsequent possibility of enol-keto tautomerism so that 
the tetrahydroquinoline nitrogen acquired partially the character 
of a secondary nitrogen atom. Since there was no evidence for
2-hydroxylated metabolites of tiquinamides this was perhaps the 
least likely possibility.
Whatever the identity of this metabolite, in view of its polar 
nature it seemed unlikely that it was, itself, poorly eliminated. 
However, it could have represented the product of further metabolism 
of a compound in the basic metabolite fraction, the disposition of
which controlled the overall rate of elimination.
Considerations on the consequences for elimination of tiquinamide 
metabolites
The rates at which drugs and their metabolites are eliminated 
from the body are influenced predominantly by the ease with which 
they are excreted in urine and bile. They are also affected by the 
extent to Y/hich the compounds are taken up into tissues and by the 
affinity of any binding to tissue constituents such as proteins,
nucleic acids or pigments. Re-cvcling of compounds by gastric
secretion and intestinal reabsorption and by entero-hepatic circulation 
tend to slow elimination. As discussed previously (Chapter I" p.20 ), 
these processes vary in their significance from compound to compound 
as a function of the physico-chemical and structural properties* 
of the molecule.
As discussed in Chapter I (p. 20 ), lipophilic bases of lov; pKa 
which are largely unionized at physiological pH’s have a tendency 
to be readily taken u p into tissues and to be Poorly excreted in 
urine, the latter as a result of extensive renal reabsorntion.
In contrast, polar compounds in the ionized state are rapidly 
extreted in urine without significant ‘tissue uptake because they 
are relatively water-soluble and will not easily traverse lipoidal 
membranes e-
The identified metabolites of tiquinamide fell into two groups, 
one basic and more lipophilic, the other acidic and polar. The 
ease with which the various metabolites were excreted in urine 
would thus have been largely influenced by these properties.
The first group of basic metabolites comprised principally 
5-hydroxy,8-cyano-5$6»7,8-tetrahydro-3-methylquirioline (rat RT5B 
and monkey MT4) and 8-cyano-5»6»7,8-tetrahydro-3-hydroxymethyl- 
quinoline (rat RT5A), but also contained small amounts of toluene- 
soluble metabolites which included unchanged tiquinamide and its 
nitrile derivative. These compounds shared the pKa of tetrahydro­
quinoline nitrogen i.e. 5*2 and therefore would have been extensively 
unionized at pH of plasma and urine. The lipophilicity of tiquinamide 
was of a similar order to other weak bases such as aniline (pKa 5*0) 
and aminopyrine (pKa 5»0) which are known to readily traverse 
biological membranes (Mayer, Maickel and Brodie, 1959; Brodie,
Kurz and Schanker, i960). Thus partition coefficients' for the drug 
between heptane, benzene or chloroform and pH 7.^ buffer were 
respectively 0.1?) 5-5 and 17*3 compared with published values of 
0.55) 0.90 and 17 for aniline and 0.15t 0.40 and 73 for aminopyrine. 
Similar partition coefficients for the metabolites are not available. 
However, results of an experiment to investigate the effects of 
various functional groups on the partition coefficient of 5,6,7i&- 
tetrahydro-3-niethylquinoline between pH 7 •*+ 0.1M phosphate buffer 
and toluene showed that 8-nitrile substitution increased the 
lipophilicity, partition coefficients of respectively 8.6 and 16.9 
being recorded, Y/hereas the thioamide was apparently somewhat less 
lipophilic, with a corresponding partition coefficient of 5*8. 
5-Hydroxylatiofi apparently made this molecule considerably less 
lipophilic, reducing the partition coefficient to 0.56. However, 
comparisons kith the data of Mayer, Maickel and Brodie (1959) using 
the comparable solvent benzene suggested that the lipophilicity of 
the metabolite 5-hydroxy,8-cyano-5i& )7,8-tetrahydro-3-methylquinoline 
would still have been sufficiently high to permeate biological, membranes 
fairly rapidly, especially given that the presence of the 8-nitrile 
group would have increased the lipophilicity compared to the
5-hydroxylated base. For examole, in their experiments amidopyrine, 
with a partition coefficient of only 0.^ -0 between benzene and pH 7 
buffer, achieved a ratio of 1 between plasma and cerebro-soinal
fluid within 10 min. As a consequence of the tendency of the basic 
metabolites of tiquinamide to be unionized in plasma and.urine 
and as a result of their relatively high lipophilicity it is possible 
that they would have been subject to a significant degree of renal 
reabsorption as well as to extensive uptake into tissues. Thus 
they would not have been expected to be rapidly excreted in urine.
The second group, the acidic metabolites, contained two types
of compound. Firstly, there were the 3-carboxylic acids 8-cyano-
5,6,7,B-tetrahydroquinoline-3-carboxylic acid (rat RT^ f, monkey MT3,
human ET^O and 8-cyano-quinoline-3-carboxylic acid (rat RT3 and
human HT3)> as well, possibly, as some thioamide analogues of these.
Secondly, there were the polar conjugated metabolites (rat RT1,
monkey MT1 and human HT1) which comprised wholly or partly the
glucuronide conjugate of 5-hydroxy-8-cyano-5»6,7,8-tetrahydro-3-
methylquinoline. In contrast to the basic metabolites all these
e
acidic compounds would have been extensively ionized both in plasma 
and urine. 3y analogy with nicotinic acid, the 3-carboxylic acids 
would have possessed carboxyl groups of pKa around 2.0 (Wade, 1977) 
and hence would have been virtually completely ionized in plasma 
and urine. Furthermore, the partition coefficient of. 5«6,7»8- 
tetrahydroquinoline-3-carboxylic acid into toluene at pH was 
very low (0.04), suggesting that acids related to this structure 
would permeate lipoid&l membranes very poorly. These properties 
would have promoted rapid urinary elimination as well as predisposing 
against uptaKe into tissues. Support for this view comes from the 
literature concerning the elimination kinetics of related carboxylic 
acids. Thus nicotinic acid had a half-life of 1 h in rats 
(Fumagalli, 1971)* Similarly, following oral administration of
6-chloropicolinic acid to rats, the compound was eliminated from 
plasma with a half-life of 1.1 h (Ramsey et al., 197^ -).
3-Methyl-pyrazole-3-carboxylic acid had half-lives of 1.0 h, 1.8 h 
and 1.9 h in rat, dog and man respectively (Smith, Wagner and 
Gerritsen, 1967). Similarly, glucuronide conjugates are usually 
very water-soluble molecules of pKa 3-^» fully ionized at urinary 
pH, and as such do not readily cross biological membranes but are 
rapidly excreted in urine (Smith and Williams, 1966). There is 
no reason to suppose that the glucuronide metabolite of tiquinamide 
would not have been similarly rapidly eliminated in urine.
It follows from the above considerations that the proportions 
of basic and acidic metabolites formed in the different species may 
have been a major contributing factor in determining how rapidly 
eliminated was the total metabolite fraction. In the rat, it was 
true that the majority of the identified metabolites excreted during 
the first 2k h were acidic compounds. However, it must be remembered 
that only k0% of the dose was excreted in rat urine in this period 
(Chapter IV. p. 78). Since the identified acidic compounds would 
have been rapidly eliminated, it follows that the 28% of the dose 
excreted as acidic metabolites comprising 3-carboxylic acids and 
glucuronides in the first 2k h probably represented the sum total 
■ of these compounds formed in the rat. This conclusion is confirmed 
by the absence of the known 3-carboxylic acids and of the known 
glucuronide conjugate in the 25 h plasma. By comparison, at.least 
60% of the dose in the patas monkey and 4-0-60% in man was excreted 
either as 3-carboxylic acids or as polar conjugates during the first 
2k h. More extensive formation in primates than in rats of
3-carboxylic acids and more complete conjugation of 5-hydroxy,8-cyano
5,6,7,8-tetrahydro-3-methylquinoline would have contributed to this 
difference. In contrast, the excretion of free hydroxylated bases 
in the rat (3% of dose) raised the possibility that, as a result of 
renal reabsorption of these compounds, greater amounts.had been 
retained in the body.
The existence of conjugated metabolites added the further 
possibility that entero-hepatic circulation following biliary 
* secretion of these compounds could have contributed to the slow 
elimination in the rat. However, in view of the slow biliary 
excretion observed, representing only 5-13& of the dose in 6 h 
(Chapter IV. p. 84), it was unlikely that this process made a 
major contribution.
The high polarity of the metabolite found in 25 h plasma would 
have predisposed it to rapid excretion. It therefore seems unlikely 
that the formation of this product was itself responsible for the 
slow elimination. more probably, it was the rate of formation of 
this product which determined the rate of elimination.
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Fig.VII.2:
Toluene extractable  rad io ac t iv ity  in male rat 
plasma fo llowing oral administration of 14C
Wy 24081  HCI at 10 m g/kg bodyweight
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.Fig.VEL9: Toluenersoluble radioactivity in plasma 
of two male volunteers following oral 
administration of 20 or 50  mg doses 
of l4C -tiqu inam ide HCI.
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Fig.VII.10: Protein binding of1i>tiquinamide in plasma 
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Time after 
dosing (h) M294 M2 9 5
F296 F297
0.5 27.7 28.4 31.7 56.0
1.0 21.4 - 22.0 29.0 17.3
2.0 59.2 30.5 37.6 26.8
3.25 22.9 NS 17.5 15.5
4.50 21.0 12.4 19.0 31.9
5.50 19.3 6.5 6.3 11.3
.6.50 10.6 NS 0.4 14.3
7.50 6.8 ND 14.4 17.5
11.75 HD HD ND 6.7
24.0 15.3 11.3 5.2 11.6
31.5 • 11.2 ND 12.0 2.2
48.0 8.3 ND 2.2 1.8
NS = No sample
HD = Mo detectable association
Results are expressed as percentage total radioactivity in whole 
blood which was associated with red cells
Table VII.3- Association of radioactivity with red cells 0-48 h
following 10 mg/kg oral administration of 
14C-Wy 24o8 l HCI to natas monkeys
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Compound PartitionCoefficient
Tiquinamide 5.8
Wy-24146 16.9
3-methyl,5,6,7,8-tetra- 
hydro-3-methylquinoline 8.6
5 -hydroxy,5,6,7,8-tetra- 
hydro-3-methylquinoline 0.56
5,6,7,8-tetrahydro-quinoline 0.04
3-carboxylic acid
Table VII.7: Partition coefficients (Toluene/pH 7.4 0.1M 
potassium phosphate buffer) of tiquinamide 
and some related compounds
CHAPTER VIII: TISSUE DISTRIBUTION OF TIQUINAMIDE AND ITS 
METABOLITES IN RAT AND PATAS MONKEY
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SUMMARY
Studies of the tissue distribution of tiquinamide-related 
products in the rat and patas monkey revealed that the major site 
of accumulation was in the stomach and its contents, and, to a lesser 
extent, in other regions of the gastrointestinal tract. This 
observation was a reflection of gastric secretion. Elimination 
from the stomach took place slowly, at a rate identical to that 
from plasma, but there was no evidence that the stomach constituted 
a depot site limiting the overall rate of elimination from the body. 
However, gastric re-cycling may have contributed to the slow 
elimination.
In addition, there was evidence of localization in the nasal
turbinal region in the rat. Otherwise, there was generally even
* -
distribution in a wide range of tissues. There was no evidence of 
localization in the thyroid, a potential accumulation site for 
thioamides. Nor was there very marked uptake into the lung, a 
common site of localization of basic drugs.
The tissue distribution of tiquinamide-related products is“ 
discussed with reference to the nature of the major identified 
metabolites and their anticipated physico-chemical properties.
The gastric re-cycling and re-distribution from the tissues of 
basic metabolites are implicated as factors in the slov; elimination 
from the rat.
INTRODUCTION
The tissue distribution of drugs and their metabolites may be 
an important factor both with respect to their general disposition 
and their potential toxicity.
The binding of drugs to tissues can severely limit the rates 
of their elimination from the body. Thus, for example, binding of 
aniline mustard to nucleic acids in the kidney resulted in a half- 
life of 1-2 days for the bound material (Warwick, 19&9)• Similarly, 
the poor elimination by the rat of the sulphonamide drug sulphadi- 
methoxine, only 16% in the first 2k h, was attributed to strong 
• tissue binding (Adamson et al ., 1970b).
Furthermore the accumulation of high concentrations of compounds 
at specific sites can result in toxic lesions. Thus the retino­
pathies caused by phenothiazines and chloroquine may be related to 
the high concentrations achieved in the uveal tracts of pigmented 
animals as a result of binding to melanin (Potts, 19&2; Bernstein 
et al., 1963).
Therefore it was of interest to examine the tissue distribution 
of tiquinamide and its metabolites both as part of the safety 
evaluation of the drug and in order to assess its significance in 
relation to the species difference in elimination.
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EXPERIMENTAL
(a) Tissue excision studies
Rat: Four male (^10-^70 g) and four female rats (280-320 g)
were fasted overnight before dosing and administered a 10 mg/kg 
Ik
dose of C-tiquinamide orally by gastric intubation. The animals 
were killed by ether anaesthesia at 12 h after dosing, the previously 
determined time of maximum plasma concentrations of total radio­
activity. Small portions (30-100 mg) of a comprehensive range of 
tissues (Fig. VIII.1) were taken in triplicate for digestion by the 
method of Mahin and Lofberg (Chapter II. p. ^3). Total radioactivity 
was then determined by liquid scintillation counting.
Major organs (heart, brain, lung, liver and kidney) were removed 
for assay of toluene-soluble radioactivity. Each organ was.homogenized 
in 9 nil distilled water. Duplicate samples (0.5 ml) were basified 
with pH 9.2 1M bicarbonate buffer (0.3 ml) and subjected to in-vial 
extraction with toluene-scintillant (Chapter II. p. kk) followed by 
liquid scintillation counting.
Patas monkey: One male and one female patas monkey, weighing
2.3 and 2.0 kg respectively received a 10 mg/kg oral dose of 
1^C-tiquinamide HCI. At 0.3 h after dosing, when plasma radio­
activity was maximal, animals were killed by an intravenous injection 
of pentothal (250 rftg/kg). Samples (80-100 mg) of a range of tissues 
(Fig. VIII.2) were subjected in triplicate to acid digestion by the 
method of Mahin and Lofberg. Total radioactivity was determined 
by liquid scintillation counting.
(b) Whole body autoradiography
Whole body autoradiography was performed by Dr. P. Nicholls 
and Dr. D. K. Luscombe (Denartment 'of Pharmacology, University of 
Wales Institute of Science and Technology, Cardiff). One male and 
one female rat were killed under‘chloroform anaesthesia at each of 
the following times after administration of a 10 rag/kg oral- dose of
Ik
C-tiquinamide EC1: 0.5» 12 and 2k h. Cutting of sections and 
subsequent preparation of autoradiography was described in Chapter II. 
(p. **?)•
(c) The accumulation of drug-related products in rat stomach wall 
and contents
Groups of five male rats, weighing aooroximtely 200 g each, 
v/ere fasted overnight before dosing and administered 30 mg/kg
C-tiquinamide HCI by subcutaneous injection as a solution in 
saline (2.5 ml/kg). Two hours before each rat was due to be killed, 
its stomach was ligated under halothane anaesthesia, according to the 
method of Shay, Sun and Gruenstein (195*0 • Animals were sewn-up 
and allowed to recover. Gastric juice was collected in the ligated 
stomach for two hours. At the end of this period, rats were killed 
by ether anaesthesia, bled from the inferior venae cavae, stomachs 
removed and contents ejected. Times of sample collection were at 
various times after dosing as detailed in Fig. VIII.6.
Toluene-soluble and total radioactivity in plasma were measured 
by the previously described method (Chapter IL p. kk). Gastric 
contents were centrifuged to remove mucus and solid debris and 
toluene-soluble and total radioactivity determined similarly.
Each stomach was washed in saline and divided longitudinally into
two portions. One half was dissolved in SHT solubilizer (NaOH,-f
80 g; methanol, 300 ml;_ Triton-X-*+05» 100 ml; in one litre, made 
up with water) according to the method of Dent and Johnson (197*+) 
as described previously (Chapter II. p. *+*+). The other half was 
frozen in liquid nitrogen, powdered with pestle and mortar and 
homogenized, 'with the aid of a Potter homogenizer, in pH 9*3 
bicarbonate buffer to yield a 10% homogenate. Aliquots (0.5 ml) 
of the homogenate v/ere subjected to in-vial extraction with toluene- 
based scintillant (10 ml) and total and toluene-soluble radioactivity 
determined by liquid scintillation counting as described previously 
(Chapter II. p. *+5).
(d) The elimination of drug-related products from rat plasma
and stomach wall over a 0-21 day period
Female rats, weighing 180-200 g, fasted overnight before dosing,
Ik
received a 10 mg/kg oral dose of C-tiquinamide HCI. At various 
times up to 21 days after dosing, as detailed in Fig. VIII.7$ rats 
v/ere killed by ether anaesthesia and bled from the inferior venae 
cavae. Stomachs were removed and washed free of contents. Total 
radioactivity in plasma was assayed by liquid scintillation counting. 
Stomachs v/ere digested in SHT solubilizer and total radioactivity 
determined by liquid scintillation counting.
RESULTS
(a) Tissue excision studies
Rat: Tissue excision studies in rats carried out at 12 b after
1 if
administration of a 10 rag/kg oral dose of C-tiquinamide HCI 
revealed that the outstanding feature of the tissue distribution 
was the accumulation of drug or metabolites by the stomach and. its 
contents. Stomach wall contained about four and six times the nlasma 
concentration in male and female rats respectively (Fig. VIII.1). 
Stomach contents contained approximately seven times the plasma 
concentration in males and fifteen times in females. Although 
the concentrations of radioactivity in stomach and its contents 
were very high, the total material contained in this organ represented 
only 3% and 7% of the dose respectively in males and females.
In the skin/fur of male rats but not females, radioactivity 
e
was present at approximately twice the concentration in plasma.
In no other tissue sampled did the total radioactivity 
concentration exceed that in plasma. There was, however, widespread 
even distribution. In most tissues, radioactivity concentrations 
were in the range 20-60% of those in plasma. With the exception 
of the greater accumulation in the stomachs of female and of male 
animals, there was apparently no other difference in tissue 
distribution between male and female rats.
The mean tissue concentration (- SEM) calculated from values 
for all tissues exceot gastrointestinal and excreting organs were
4.3 - 0.8 pg/g and 3.6 i 0.4 pg/g in males and females respectively. 
Since a 10 mg/kg dose distributed evenly throughout the animal 
would have resulted in concentrations of 10 pg/g in all tissues, 
the implication v/as that approximately 30-40% of the dose was 
generally distributed throughout the somatic tissues of rats at 12 h 
after dosing. By comparison, only about 4% was in the plasma, 
assuming a plasma volume for the rat of 41.3 ml/kg (Soector, 1956).
Toluene-soluble radioactivity represented a low proportion 
( 14%) of the total radioactivity in any of the major organs
investigated (Table VIII.l).
Patas monkev: Tissue excision studies in monkeys, carried out  _ . _ _ — <— v
at 0.5 h after administration of a 10 mg/kg oral dose, reveal.ed 
high concentrations of radioactivity in stomach wall and kidney,
representing respectively four times and three to four times plasma 
concentration (Fig. VTII.2). Slightly higher concentrations of 
radioactivity were achieved in liver than in plasma. No other 
tissue extensively accumulated radioactivity,. As in the rat, most 
tissues contained 20-60% of the concentration of radioactivity in 
plasma.
The mean tissue -concentration (- SEM) calculated from all 
tissues except gastrointestinal and excreting organs were 4.8 - 
0.5 pg/g for the male monkey and 6.5 - 0.5 Pg/g for the female.
Thus by an analogous argument to that used for the rat, the proportion 
of the dose distributed throughout the somatic tissues of the monkey 
at 0.5 h after dosing was of the order of 50-60%. 3y comparison, 
approximately 7% of the dose was to be found in plasma, based on the 
assumption of a plasma volume in the monkey of 45 ml/kg (Spector, 
1956). - '
Bile collected from the gall-bladder contained concentrations 
five to six times those in plasma.
(b) Whole body autoradiography
Data gathered from whole body autoradiographic studies confirmed 
ana extended the results of the tissue excision studies.
Whole body autoradiography at 0.5 h after dosing showed very 
high concentrations of radioactivity in the stomach and small 
intestine. High concentrations were also observed in the liver, 
kidney, bladder and nasal turbinal region. (Figs. VIII.3»
VIII.4). There was general distribution of radioactivity throughout 
other tissues but no marked accumulation.
At 12 h after dosing, whole body autoradiography confirmed 
the results of the tissue excision studies, demonstrating the 
presence of high concentrations of radioactivity only in the stomach 
and its contents, in the large intestine and in faecal pellets 
in the rectum. Again, distribution in other tissues was widespread, 
but.at much lower concentration than in the gastro-intestinal 
tract.
At 24 h after drug administration, the distribution pattern 
was very similar to that at 12 h, with high concentrations of radio­
activity being evident only in the stomach and large intestine. 
Enlargement of autoradiographs of the stomach revealed that radio­
activity had begun to disappear from the gastric lumen by this time, 
but was concentrated in the gastric mucosa (Fig. VIII.5).
13,5
(c) The accumulation of drug-related, products in rat stomach wall
and contents
The subcutaneous administration of a single 30 mg/kg dose of
Ik
C-tiquinamide HC1 to male rats resulted in extensive gastric 
secretion of radioactivity and in uptake by the stomach wall 
(Fig. VIII.6).
The toluene-soluble, basic fraction containing unchanged 
tiquinaraide achieved its maximum concentrations in plasma, stomach 
wall and gastric contents at the same time, 3 h after dosing.
This observation was indicative of rapid equilibration between plasma 
and gastric contents. Once the oeak value had been achieved, 
concentrations of this fraction declined rapidly.
Total radioactivity, similarly, achieved maximum concentrations 
in plasma and stomach wall at 3 h after dosing. Thereafter a flow 
of drug-related products between plasma and stomach wall was evident, 
since plasma concentrations began to decline, whereas those in 
gastric contents continued to rise until 5 h after drug administration, 
before they too began to fall. Concentrations in stomach wall remained 
constant for up to l^ f h once the peak value had been achieved.
There was a marked concentration gradient increasing from plasma 
to gastric contents, so that at the time of maximum plasma con­
centration (k7 pg equiv/ral), the concentration in stomach wall was 
2.8 times this value and that in gastric contents was already 5*3 
times as much. The maximum concentration* in gastric contents,
5kk jug equiv/ml at 5 h, represented 37 times that occurring 
simultaneously in plasma.
The much more rapid elimination of the toluene-soluble fraction 
than of total radioactivity meant that radioactivity accumulated 
in the stomach wall and secreted into gastric contents was not 
predominantly toluene-soluble. In stomach wall, toluene-soluble 
basic radioactivity, which would have included unchanged drug, 
represented only 30/c of total radioactivity at 2 h after dosing and 
only 8*> at k h. in gastric contents, this fraction represented 
"2k % of total radioactivity at 2 h and only at k h after dosing.
(d) The elimination of drug-related products from rat plasma and
stomach wall over a 0-21 day period
/ ">kFollowing oral doses of 10 mg/kg C-tiquinamide HC1 to groups 
of female rats, the maximum Plasma total radioactivity concentration 
was observed between 5 h and 12 h after dosing. The highest value
of the mean concentration (- SEM) was at 5 h (11.2 i 0.8 jig- 
equivalent ^C-tiquinamide HCl/ml), but a higher standard error in 
the 12 h value (9*3 - 1*2 jig equivalent/ml) reflected some inter­
animal variation in the time of the peak concentration (Fig. VIII.7)• 
Plasma concentration of total radioactivity subsequently declined 
monoexponentially with a half-life of 89 h.
The concentration of radioactivity in stomach wall achieved 
its maximum value, k3 jig equivalent/g at 12 h after drug administration, 
after which it declined monoexponentially with a half-life of 9k h 
(Fig. VIII.7).
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DI3CUSSX0M
A significant feature of the tissue distribution of tiquinamide
and its metabolites in rats and monkeys was the extensive accumulation
of radioactivity in the stomach and contents and to a lesser extent
in the other regions of the gastrointestinal tract. Thus in this
respect, whole body autoradiography resembled those following
administration of weak bases such as nicotine (Andersson, Hansson
and Schmiterlbw, 19&5) and mepivicaine (Kristerson, Hoffmann and
Hansson, 19^5)• As for these drugs, such accumulation in the stomach
and its contents must have resulted primarily from gastric secretion,
since absorption of unchanged drug has been shown to be complete
within 0.5-1 h after dosing (Chapter VII. p. 157, lo2), but high
concentrations of radioactivity persisted in the stomach until 12 h
and 24 h after an oral dose, when concentrations of unchanged ^rug
in plasma were negligible.- Furthermore, very high concentrations of
radioactivity were evident in the stomach and contents after a
14subcutaneous dose of C-tiquinamide HC1. Gastric secretion of basic 
compounds into the acidic medium of the contents is a well-known 
phenomenon established by Shore, Brodie and Hogben (1957)*
Bases are ionized at acidi-c pH’s and unionized under more 
alkaline conditions. Because of the much lower pH (1-.3) in the 
gastric contents than in plasma (pH 7*4), basic drugs of pKa ^  4 will 
be very extensively ionized in the gastric contents, but extensively 
unionized in plasma unless their pKa values exceed about 8. Therefore, 
if such a compound is supplied to the stomach in the bloodstream there 
will always be a large concentration gradient of unionized drug 
between plasma and gastric contents and if the compound is also 
lipid-soluble diffusion into gastric contents will be rapid.
Once in the gastric contents drug is retained there by ionic trapping
until emptied via the pylorus into the small intestine. Back
• I
diffusion into plasma is not usually possible because of the generally
poor lipid solubility of ionized drugs.
Other examples of basic, lipid-soluble drugs which are rapidly 
secreted into gastric contents include aniline and aminooyrine 
(Shore, Brodie and Kogben, 1957)* These compounds were found to be 
so readily gastrically secreted that the ratio of their concentrations 
in gastric contents and-plasma was limited only by the rate of blood
flow through the gastric epithelium. Tiquinamide has very similar 
physico-chemical properties to these bases, as discussed previously 
(Chapter VII. p. 163). It has also been deduced that the hydroxylated 
basic metabolites would have been sufficiently lipophilic to have 
traversed lipoidal membranes. It follow*? that the rapid gastric 
secretion of tiquinamide and its basic metabolites was to be 
predicted on the basis of their known physico-chemical properties.
The very even distribution of radioactivity in the majority 
of tissues except those of the gastrointestinal tract suggested 
entry by passive diffusion. The range of concentrations, 20-60% 
of plasma radioactivity, reflected to some degree the vascularity 
of the tissues concerned, in that the more highly vascular organs 
such as liver, kidney and lung tended to contain somewhat highef* 
concentrations than did those less well perfused. The higher 
concentration of radioactivity in plasma than in tissues probably 
represented the containment within the plasma compartment of acidic 
metabolites not readily distributed into tissues. The basic, lipid 
soluble compounds on the other hand may have been present at higher 
concentrations in tissues than in plasma.
In one respect, the distribution of tiquinamide was atypical 
of a basic drug in that drug or metabolites were not localized in 
lung at concentrations in excess of those in plasma. Extensive 
uptake of basic drugs into the lung is quite common, as indicated 
in a recent review by Brown (1974). The mechanism of this uptake 
has been ascribed by some authors to ionic trapping as a result of 
th'e lower pH in the pulmonary extravascular space (pH 6.7) compared 
to that in pulmonary plasma (pH 7*4) (Effros and Ghinard, 19^9; 
Waddell, 1973)• The failure of tiquinamide or its metabolites to 
localize in the lung was consistent with this hypothesis in that 
it reflected the low pKa (5.2) of this drug. The drug would have 
been virtually completely unionized even at p H 6.7 arid thus the 
difference in pH between lung and plasma would not have significantly 
affected the distribution of the drug between them.
A further significant feature of the tissue distribution of
tiquinamide was the absence of any apparent accumulation of the 
14drug or its C-labelled metabolites by the thyroid. This was a
possible consequence of the thioamide character of the drug, in 
view of the known thyroid accumulation of a number of thioureas and 
thiouracils active as anti-thyroid agents e.g. thiourea (Maloof 
and Soodak, 19&5) thiouracil (Maloof and Soodak, 1957), 
propylthiouracil (Marchant et al., 1971) and methimazole (Marchant 
and Alexander, 1972). In addition, the thioamide anti-tubercular 
compound ethionamide has been shown to exert an anti-thyroid effect 
at high doses (Moulding and Fraser, 1970). The fact that tiquinamide 
was found in practice not to be accumulated in this organ may be 
a reflection of the extent of its metabolism to desulphurized products 
and to acidic derivatives not readily distributed into tissues.
The evidence for above average concentrations of radioactivity 
in the skin/fur.of male rats was not strong enough to suggest 
substantial secretion of drug or metabolites in sweat. The
possibility of contamination of the fur with urine could not be-
$excluded. Furthermore, in this respect the results of whole body 
autoradiography were unreliable since photographic artefacts can 
result in.the appearance of accumulation of radioactivity in skin/fur.
The apparent high concentrations of radioactivity in the bile 
of monkeys reflected the rapid elimination occurring at the time 
the animals were, killed. The significance of the extent of biliary 
excretion will be discussed more fully in Chapter IX.
Considerations on the significance of the tissue distribution of 
tiquinamide metabolites with respect to their slow elimination in 
the rat
Although very high concentrations of tiquinamide-related „ 
products were achieved in the stomach and its contents, the total 
amount of material present in this organ at 12 h after dosing 
represented only 3“7% of the dose in rats. Thus the slow 
elimination of tiquinamide metabolites in the rat was not the result 
of slow release from a depot in the stomach. However., it was 
evident that gastric secretion was extensive and that concentrations 
of drug-related products in the stomach remained many times those 
in plasma for a very long period. Thus it was possible that gastric 
re-cycling, involving re-absorption of gastrically secreted material 
was a contributory factor.
The total proportion of the dose present in rat plasma at
12 h after dosing was only about 4%. It was therefore unlikely that
plasma-protein binding of metabolites played a significant role.
It has been calculated that for a compound which is 90% bound by
plasma proteins, the amount of drug retained in the plasma will
be 38% of total drug in the body (Butler, 1971). Therefore the
percentage binding of tiquinamide metabolites in plasma would have
been considerably less than 90%. As previously discussed (Chapter VII
P*163), Martin (19&5) ^as suggested that plasma protein binding of
a compound will not seriously affect its disposition unless it has
4
an affinity constant 10 * under which circumstances more than 85% 
of total drug concentration in plasma will be in the bound form.
The largest proportion of the material remaining in the rat at
12 h after dosing, representing some 30-40% of the dose, was found 
to be distributed throughout the tissues. In view of the absence 
of evidence for either extensive plasma-protein binding or entero- 
hepatic circulation of tiquinamide metabolites, it follows that 
it must have been the re-distribution and/or further metabolism of 
the tissue-distributed material which represented the major rate- 
limiting step in elimination. Possibly some binding to tissue 
components contributed to the slow re-distribution from tissues.
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CHAPTER IX: EXCRETION OF TIQUINAMIDE AND ITS METABOLITES IN
RAT, PATAS MONKEY AND MAN
SUMMARY
The extent of urinary and faecal excretion and the kinetics 
of urinary excretion of drug-related products in rat, patas monkey 
and man were studied. . The rate of biliary excretion of drug-related 
products in the anaesthetized rat was also investigated.
Results showed that radioactivity was rapidly and completely 
excreted in the patas monkey almost entirely in the urine. In rats, 
a fraction of metabolites was raoidly excreted, but the majority 
was slowly eliminated at a rate equivalent to that of elimination 
from plasma. In man, the majority of radioactivity was rapidly 
eliminated in urine. Faecal excretion occurred to a significant 
extent only in the rat. Biliary secretion in this species occurred 
to an extent commensurate with that of faecal excretion with no 
indication of entero-hepatic circulation.
The species difference in the i?ate of urinary excretion is 
discussed with respect to the species difference in metabolism.
INTRODUCTION
The main reason for investigating the rate of excretion of a 
potential drug substance and its metabolites is to ensure that they 
are relatively quickly eliminated from the body and thus to avoid 
the risk of residues of potentially toxic substances remaining in 
the tissues for long periods after termination of a course of treat­
ment. In addition, it is necessary to know the rate of elimination 
of a drug in order to determine the most satisfactory frequency of 
dosing. Furthermore, one important criterion by which to judge 
whether animal species are suitable for chronic toxicity studies for 
evaluation of the potential safety of a given drug in man is whether 
it is excreted at similar rates and by the same routes in these 
animals as in man. The relative importance for the compound of 
different routes of excretion needs to be known also so that the 
implications for drug excretion of changes in the relevant physio­
logical processes resulting from disease, pregnancy etc. can be 
assessed.
Investigations of the plasma kinetics and metabolism of 
tiquinamide had indicated that metabolism constituted the major 
route of elimination of the drug. Thus the excretion of unchanged 
tiquinamide was quantitatively of relatively little significance. 
However, the rate of excretion of its metabolites was of interest 
because any drug-related substance which remains in the body for 
a long period constitutes a potential hazard. Plasma kinetic 
studies (Chapter VII) had revealed that tiquinamide metabolites were 
very slowly eliminated in the rat, but very quickly eliminated in 
the patas monkey and that man showed a g'reater similarity to the 
monkey in this respect but did have a significant slow phase of 
elimination. Studies of the rates of excretion of drug-related 
substances from the body were expected to confirm the existence of 
such a species difference. In combination with the information 
already obtained about the nature of the excreted metabolites, the 
results of such studies might also have cast some light on the 
reasons for the slow elimination in the rat.
EXPERIMENTAL
(a) Excretion kinetics in rats
Urine, faeces and expired air: Four male and four female rats
housed individually in all-glass metabolism cages as previously
described (Chapter II p. 43 ) each received a 10 mg/kg oral dose of
■^C-tiquinamide HCI (8.82 jiCi/mg). Urine and faeces were collected
at various intervals, as indicated in Fig. IX.1 over a period up
to 7 days after drug administration. Total and toluene-soluble
radioactivity in urine v/ere assayed by liquid scintillation counting
as previously described (Chapter II p. 44 ). Total radioactivity
in faeces was assayed by liquid scintillation counting after
perchloric acid digestion (Chapter II p. 44 ). The kinetics of
urinary excretion of radioactivity were analysed by the sigma-minus
method of Martin (1967), as previously described (Chapter II p. 47 )•
In a further experiment, two female rats were individually
housed in all-glass metabolism cages equipped, for the collection
14of expired air (Chapter II p. 43 ). C-Tiquinamide HCI was 
administered as above. Expired air was collected by absorption 
into 33 Vo ethanol for a period of 24 h and urine am faeces ior 7 days 
at intervals outlined in Table IX.1. At the end of this period, 
the rats were killed by ether anaesthesia and residual radioactivity 
in carcasses assessed by liquid scintillation counting after alkaline 
digestion in SET solubilizer (Chapter II p. 44'),
Bile: Biliary excretion was studied in three bile-duct 
cannulated rats maintained under halothane anaesthesia and
14
administered C-tiquinamide HCI (2-4 p.Ci/mg) at 10 mg/kg orally.
Bile was collected over hourly intervals for periods of 6 h. Radio- 
activity in bile was assayed by liquid scintillation counting.
(b) Excretion kinetics in patas monkeys
Urine and faeces: Two male and two female patas monkeys v/ere
administered C-tiquinamide HCI (2.21 ;uCi/mg) at 10 mg/kg orally. 
Urine and faeces were collected until 7 da.ys after dosing at 
intervals specified in Fig. IX .3* Total and toluene-soluble radio­
activity in urine were, assayed by liquid scintillation counting.
Total radioactivity in faeces was assayed by liquid scintillation 
counting after perchloric acid digestion (Chapter II p. 44 ). The 
kinetics of urinary sxcretion of radioactivity were analysed by the 
sigma-minus method of .Martin (19^7) (Chapter II p. 47 )•
(c) Excretion kinetics in man
Urine and faeces: Two male volunteers (ML and DK) received
14C-tiquinamide HCI at a dose of 20 mg (containing 5 juCi) orally 
by capsule. Urine and faeces were collected for 3 days at intervals 
as in Fig. IX.4. Seven days after the first dose, the same 
volunteers received a second dose of 50 mg (containing 50 jiiCi) in 
an identical fashion. Urine and faeces were again collected for 
5 days at intervals as in Fig. IX.4. Total and toluene-soluble 
radioactivity in urine was assayed by liquid scintillation counting. 
Total radioactivity in faeces was assayed by liquid scintillation 
counting after perchloric acid digestion (Chapter II p. 44 ).
.RESULTS
(a) Excretion kinetics in rats
Urine, faeces and expired air: After a single administration 
of a 10 mg/kg dose to % animals of each sex, tiquinamide and its 
metabolites were excreted primarily in the urine of rats, a mean 
of 57/o of total radioactivity being eliminated by this route in 
males and 50% in females in 7 days after dosing. Faecal excretion 
was evident, but was less pronounced than elimination by the urinary 
route, representing 15% of the dose in males and 22% in females 
(Fig. IX.1). The total recoveries of radioactivity in urine and 
faeces of these animals over a 0-7 day period were lower than might 
have been expected * comprising 72% of the dose in both sexes.
In a further experiment, in 2 additional female rats, to examine the 
reasons for this low recovery, the total percentages of the dose 
accounted for v/ere 8%.%% and 89*9% (Table IX. 1)'. Urine and faeces 
contained 56-58% and 13-20% respectively i.e. similar amounts to 
those observed in the first experiment. Elimination of radioactivity 
in expired air was low (1.9% and 3*0%). When these animals were 
killed 7 days after drug administration, however, substantial 
proportions of the dose (12.%% and 10.8%) we re founcl to be still 
resident in the carcasses. This observation provided an adequate 
explanation for the somewhat low recoveries in excreta observed 
previously.
There was a trend towards somewhat more extensive elimination 
of radioactivity in urine of male rats compared with females.
However, the difference was fairly small, so that when the mean
at 0-7 days for male animals (56.9 - 2.7%; n = %) v/as compared by
Student’s t-test with that for all females (52.1 - i.6%; n = 6),
the difference was not significant at the 5% level (t = 1.6%1,
p= 0.1-0.2). Conversely, faecal excretion was apparently slightly
greater at 0-7 days in females than in males (20.% - 1.7% and
15.0 - 1.8% respectively but again the difference was not statistically
significant (t = 2.11%, p = 0.05-0.1).-
Negligible amounts of unchanged tiquinamide were excreted in 
urine. Only 2.5% 01 the dose was recovered from basified urine as 
toluene-soluble radioactivity, which would have included unchanged 
drug.
£  JLtS
Analysis of the kinetics of urinary excretion of total radio­
activity by the sigma-minus method of Martin (1967) required allowance 
>for the fact that excretion was incomplete at 7 days. It could be 
deduced from the results of total balance studies in two female 
rats (Table IX.1) that 85% of the dose should ultimately be recovered 
from urine and faeces. The proportion of radioactivity eliminated 
by each route in the*post-7 day period were deduced from the mean 
daily faecal/urinary elimination ratios (post-%8 h), which were 
0.5 - 0.1 and 1.3 - 0.1 in male and female animals respectively.
The sigma-minus analysis revealed two exponential phases. In the 
first, more rapid phase of elimination having half-lives of about 
% h in males and 3 h in females, approximately %3% and 38% of the 
dose respectively v/ere excreted (Table IX.2). In the second, slower 
phase of half-life 122 h and 98Dh respectively, 22% and 18% of the 
dose were eliminated.
Bile: Excretion of radioactivity in bile following 10 mg/kg
1%oral administration of G-tiquinamide to three halothane-anaesthetized, 
bile duct-cannulated female rats totalled 5-13% in a 6 h period 
(Fig. IX.2).
(b) Excretion kinetics in patas monkeys
TJrine ana faeces: Excretion of radioactivity by 2 male and
Ik2 female patas monkeys, administered C-tiquinamide HCI by the oral
route, occurred orincipally in the urine. The proportion excreted
by this route in a period 0-7 days after drug administration amounted
to 70-95% of the dose. Faecal excretion was low, representing only *
3-7% of the dose (Fig. IX.3). The total recovery of radioactivity,
77-100% of the dose, represented a very satisfactory recovery from
monkeys, since the unclean habits of these animals e.g. rubbing
excreta into fur tend to lead to lower recoveries than would be
acceptable in rats. The sex of the monkey did not significantly 
• * •
affect the amount of the dose excreted in urine or faeces.
Not more than 1.5-3 •£'% of the dose was present in urine as 
unchanged drug, as represented by the basic toluene-soluble fraction 
of radioactivity.
Urinary excretion of tiquinamide metabolites was extremely 
rapid. Analysis of excr'etion kinetics of total radioactivity in 
urine by the sigma-minus method of Martin (19o7) revealed -two
exponential phases* The majority of radioactivity, 68-93% of the 
dose, was 'excreted in the first very rapid phase of half-life 1 h. 
Only 2-3% of the dose was eliminated in the slower phase of half- 
life 31-50 h (Table IX.2-5.
(c) Excretion kinetics in man
14Urine and faeces: After oral administration of C-tiquinamide 
HCI to two male volunteers, excretion of radioactivity occurred 
mainly in the urine. Following the 20 mg dose, 69-77% of the dose 
was excreted in urine in 4 days and after a 50 nig dose 66-92%
(Fig. IX.4). Faecal excretion of radioactivity was Tow. After the 
20 mg (5 ^Ci) dose the amounts of radioactivity detected in faeces 
were largely below the level of sensitivity of the assay, 2-3% of 
the dose in up to 4 days. After t}je 50 mg (50 juCi) dose, 6-8% of 
the radioactivity was eliminated by the faecal route in 5 days.
The total recovery of radioactivity from urine and faeces was 
71-100%.
Excretion of unchanged tiquinamide in urine was low. Only 2% 
of the administered dose was excreted in the basic, toluene-soluble 
fraction of urinary radioactivity.
Sigma-minus analysis could not be performed satisfactorily, 
because recoveries of radioactivity were not sufficiently complete 
nor the collection period sufficiently long to make possible the 
certain conclusion that the slower phase of elimination had ceased 
by the termination of the experiment. However, it could be safely 
concluded that the. majority of radioactivity was excreted rapidly, 
since 66-73% the dose appeared in the 0-24 h urine after the 
20 mg dose and 61-88% after the 50 mg dose.
DISCUSSION
It was clear from these studies that there was a marked species 
difference in the excretion of tiquinamide and its metabolites with 
regard to both the rate of urinary elimination of radioactivity and 
the importance of the faecal route. An initial rapid phase of urinary 
excretion was observed in all species. However, whereas this 
constituted the most important phase in monkeys and man (approximately 
80% and 70% of dose respectively), it was of lesser importance in 
the rat (circa 40%). A slower urinary excretion phase was more 
important in the rat (about 20%) than in monkey (3%)» This phase 
could not be properly delineated in man, but at least 3-4% of the 
dose was excreted more slowly in the post 24 h period. -In addition, 
faecal elimination in the rat (20%) was of the order of 3-4 times 
that in either of the other species (5% and 7% approx. respectively 
in monkey and man). In accordance with the slow elimination of-the 
compoiind in the rat about 10% of the dose remained in the carcass 
7 days after dosing.
The findings of the excretion kinetic studies generally confirmed 
those of plasma kinetic studies in'demonstrating much slower 
elimination of tiquinamide metabolites in the rat than in the other 
species. However, the results also demonstrated that even in the 
rat there was an initial rapid phase of urinary excretion which was 
not evident from the results of plasma kinetic studies. This 
observation implied that metabolites eliminated in this initial 
phase v/ere so readily excreted that their rate of formation was the 
rate-limiting factor in their elimination and they, therefore, never 
achieved high concentrations in plasma. 3y the time the peak 
concentration of radioactivity in plasma had been achieved at 8-12 h 
after dosing (ChapterVII p.157) "the rapid phase of urinary elimination 
was virtually complete. Thus the slow elimination from plasma 
observed after the maximum concentration of radioactivity had been 
achieved corresponded to the slower phase of urinary excre tion.
Closer 'analysis of the kinetics of urinary excretion and 
comparison with those of elimination from plasma revealed that in 
the rat and monkey the half-life of the rapid phase of urinary 
excretion of total radioactivity was of very similar order to that 
of elimination from plasma of the basic, toluene-soluble fraction
containing unchanged drug, i.e. approximately 3-4 h in the rat and 
1 h in the monkey (see Chapter VII p. 157)• Whilst the rapid phase 
of elimination in human urine could not be accurately delineated, 
inspection of sigma^minus plots revealed that the half-life for 
this phase would have been of the order of 3 h, again not very 
different from the half-life for elimination from plasma of the 
basic, toluene-soluble fraction. Since the proportion of toluene- 
soluble basic compounds excreted in urine was very low, this 
observation implied that it was the rate of metabolism of these 
compounds which controlled the rate of the fast phase of urinary' 
elimination. Thus it seemed clear that there was a group of 
metabolites which, once formed, were very quickly excreted in 
urine. In view of the considerations discussed previously, in 
Chapters VII and VIII, it was most likely that it comprised 
3-carboxylic acids and glucuronides. Comparisons of the proportion 
of the dose found as such acidic metabolites with the proportions 
excreted in the rapid phase of urinary excretion seemed to generally
t
bear out this conclusion. Thus in the female rat, a total of 23% 
of the dose was found as acidic metabolites, compared with 37% excreted 
in the fast phase. In the monkey, these values were respectively 
62% and 80% and in man 58% and 70%.
In contrast, the half-life of the slow-phase of .urinary 
elimination greatly exceeded that* of the toluene-soluble basic 
fraction. Material eliminated in this phase may have constituted 
the products of further metabolism of the basic group of metabolites 
which included 5-hydroxy, 8-cyano-516,7,8-tetrahydro-3-methyl 
quinoline and 8-cyano-5*6,7,8-tetrahydro-3-hydroxymethyl quinoline.
It has been suggested in Chapters VII and VIII that these compounds 
may have been poorly eliminated as a result of extensive tissue 
uptake and gastric re-cycling. There existed the additional 
possibility that, being extensively unionized in urine as a result 
of the low pKa of the tetrahydroquinoline nitrogen (pKa 5.2), they 
may also have been subject to renal reabsorotion, which would have 
limited their direct urinary excretion.
14
The excretion of 5-13% of a 10 mg/kg dose of C-tiquinamide HCI 
in bile within 6 h of dosing the compound to female rats was broadly 
consistent with the observed extent of excretion of drug-related 
products in faeces (9% in 24 h). It did not suggest a significant 
entero-henatic circulation. If such a process had constituted a
major factor in the slow elimination of tiquinamide metabolites, 
the hypothesis demanded that when toluene-soluble basic metabolites 
disappeared from plasma with a half-life of 3 h, the 70% of the dose 
which did not appear in the urine as acidic metabolites should have 
been predominantly excreted in the bile. Thus something of the 
order of 30% of the dose should have appeared in bile v/ithin a 6 h 
period. Since the observed biliary excretion was much lower and 
consistent with the known extent of faecal excretion, there was no 
evidence that tiquinamide metabolites v/ere substantially re-absorbed 
from bile. It followed that entero-hepatic circulation of metabolites 
could not have significantly contributed to the slow elimination 
in this species.
The rate of biliary secretion was not measured directly in
species other than the rat. However, on the basis of concentrations
of radioactivity found in gall-bladder bile of monkeys killed at
0.5 h after dosing for tissue excision studies (Chapter VIII), it
could be calculated that a maximum of k-7% of the dose would have
been excreted in bile. These calculations assumed- that concentrations
in bile at this time, when the rate of excretion in this species
was at its most rapid, were maintained over the period of 6 h during
which most of the drug-related products v/ere in fact excreted in
urine. This estimate was consistent with the appearance of around
3% of the dose in monkey faeces. In man, the recovery of only 7%
£
of the dose in faeces was presumed to reflect a similarly low extent 
of biliary secretion. The greater extent of biliary excretion in 
the rat than in the other two species was consistent with the lower 
molecular weight threshold for biliary secretion in this species.
The threshold value for biliary secretion of organic anions in the 
rat has been found to be of the order of 325 - 50, whereas the value 
in rhesus monkey and man is believed to be similar to the value 
found for the rabbit i.e. ^75 - 50 (Millburn, Smith and' Williams,
1967; Aziz et al., 1971; Smith, 1973)* As discussed in Chapter I 
(p. 22), on this basis tiquinamide itself had too low a molecular 
weight (206) to be extensively biliary excreted in any of these 
species. However, conjugated metabolites such as, for example, the 
glucuronide of 5-hydroxy-8-cyano-5 »7, S-tetrahydro-3-niethylquinoline 
(MW 383) would have been sufficiently large to be excreted to a 
significant extent in the bile of the rat but not of monkey or man.
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Percentage recovery 
- administered dose
of
Rat 9 Rat 10
Expired Air 1.88, 2.99
Car ca'ss 12.4, 10.8
Urine 57.6, 55.6
Faeces 12.6, 20.5
Total 84.4, 89.9
e
Table IX:1: Recovery of radioactivity from urine, faeces«
expired air and carcasses of female rats 0-7 days
following oral administration of 10 mg/kg 
14C-tiquinamide HC1
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CHAPTER X: DISCUSSION
DISCUSSION
At the outset of the present work, the objective was to define 
the metabolism and disposition of tiquinamide in the soecies of 
interest and to apply this knowledge to the development of the drug 
as a gastric anti-secretory agent. During the course of the work 
a species difference in elimination of metabolites was discovered 
and it became pertinent to understand this difference in terms of 
the known routes of metabolism of the compound.
The absorption of tiquinamide
Investigations of the plasma kinetics of tiquinamide have 
revealed that the drug is rapidly absorbed, as might be predicted 
of a weakly basic, lipophilic compound. Whilst results of studies 
to determine the extent of gastric absorption have upheld the 
preliminary case that tiquinamide could be absorbed from the stomach 
under conditions of elevated gastric pH and inhibited gastric 
emptying, they have also suggested that absorption from this site 
would not be predominant under normal physiological conditions.
This finding is consistent with others suggesting that the small 
intestine may be the more inrnortant site of gastrointestinal 
absorption even for compounds which can potentially be absorbed 
from the stomach, for exaraole the weak acids sulphaethidole and 
barbital (Crouthamel et al., 1971). It is the relative rates of 
absorption from the two sites and the rate of gastric absorption 
relative to that of gastric emptying which wil*l determine how 
significant is the total extent of gastric absorption in conscious 
animals with normal gastric emptying. The vastly greater surface 
area of the small intestine than that of the stomach tends to favour 
absorption from the former site and it would seem that this factor 
can be more important than considerations about the degree of 
ionization which might ostensibly favour the latter site.
The metabolism of tiquinamide
Study of the metabolism of tiquinamide in rat, patas monkey 
and man has defined four major routes of Phase I biotransformation 
and one significant conjugation pathway. The 3-methyl substituent 
underwent £a) -oxidation to give rise to 8-cyano-5»6,7,8-tetrahydro- 
3-hydroxymethylquinoline and 8-cyano-5 *6 ,7 ,8-tetra.hydroquinoline- 
3-carboxylic acid. The reaction pathway was analogous to that for 
p-nitrotoluene worked out by Gillette (1959). On this basis it was
likely that the oxidation to the intermediate alcohol was carried 
out by a microsomal raono-oxygenase. Further oxidation would have 
been performed by a soluble alcohol dehydrogenase, giving rise to 
an undetected aldehyde intermediate which would have been oxidized 
by a soluble aldehyde dehydrogenase to the carboxylic acid.
The tetrahydroquinoline ring was'hydroxylated at an allylie 
position, yielding 5-hydroxy,8-cyano-5,6,7,8-tetrahydro-3-methyl- 
quinoline, which subsequently underwent glucuronide conjugation.
The hydroxylation reaction resembled that undergone by hexobarbital 
and known to be catalysed by a microsomal mono-oxygenase (Cooper 
and Brodie, 1955 and 1957).
Desulphuration of tiquinamide and its metabolites occurred
chemically during their isolation and thus it was impossible to
ascertain the precise degree to which this reaction occurred in
vivo. However, it is almost certain that it represented an additional
e.
route of metabolism consistent with the behaviour of other thioamide 
compounds such as 2 ,6-dichlorothiobenzamide (Griffiths et al.,
19oo). It was not clear whether the metabolic desulphuration 
involved a reductive loss of hydrogen sulphide similar to that 
proposed for l-phenyl-2-thiourea (Smith and Williams, 19&1) or a 
sulphoxidation analogous to that of ethionamide (Johnston, Kane 
and Kibby, 19^7) with subsequent degradation of the unstable 
tiquinamide sulphoxide to the corresponding nitrile.
Aromatization of the tetrahydroquinoline ring was also observed 
to take place, resulting in the fully aromatized 8-cyano-quinoline- 
3-carboxylic acid. The mechanism of this reaction was unclear.
Differences between the three species studied were observed with 
respect to both the routes and rates of metabolism. Thus 60 -oxidation 
represented the major route of metabolism in the patas monkey and 
man, accounting respectively for 38-47?* and 23-3^% of the dose in 
the 0-24 h urine in the form of 3-carboxylic acids. Among products 
recovered from rat urine, however, only 16,8% of the dose could be 
unequivocally attributed to the products of tj -oxidation. Although 
only detected in relatively small amounts (circa 1% of the dose), 
the intermediate compound 8-cyano-5»o ,7,8-tetrahydro-3-hyaroxy- 
methylquinoline was present in this species but not in patas monkey 
or man. The more complete oxidation through to the carboxylic acids 
in the two primate species studied than in the rat was attributable 
to the greater activity of liver alcohol dehydrogenase in these 
species (Krebs and Perkins, 1970; Von v'artburg and Schlirch, 1971).
The total 5-hydroxylated products excreted in 0-24 h urine of 
patas monkeys and man, respectively 18-21% and 17-27% of the dose, 
were greater than that excreted over the same period in the rat 
(11.3%)* However, it has been suggested (Ch.apter IV p. 86) that 
these values may not have truly represented the total extent of 
formation of 5-hydroxylated metabolites. The 0-24 h urinary excretion 
accounted for the majority of the dose in patas monkey and man, but 
for only 40% of the dose in the rat and it was more likely on 
physico-chemical grounds that the basic metabolites, which included 
5-hydroxy,8-cyano-tetrahydro-3-methylquinoline, were poorly eliminated 
than that this was true of the 3-carboxylic acids. The extent of 
conjugation with glucuronic acid was lower in the rat than in the 
other two species. Thus 40% of total 5-hydroxylated products 
excreted in 0-24 h of this species was unconjugated, compared to 
only 10% in the patas monkey and negligible amounts in man.
With respect to the aromatization of the tetrahydroquinoline 
ring, the rat showed greater similarity to man than did the patas 
monkey. In the former two species the proportions of the dose detected 
as 8-cyano-quinoline-3-carboxylic acid were 8.5% and 7-10% respectively 
whereas in the latter species the aromatization reaction was not 
observed.
There was evidence that desulphuration occurred to a greater 
extent in the rat than in the patas monkey, despite the uncertainties 
regarding the occurrence of this reaction in vivo. Thus in the rat 
there was nothing to suggest that thioamides were excreted and 
subsequently degraded chemically in spite of estimates that at least 
one-third of any thioamide-metabolites excreted in this species would 
have been detectable in the chromatographic pattern of urinary 
products. In the patas monkey, however, a metabolite which formed 
a substantial proportion of the 50% of the dose excreted in urine 
in the 0-2 h period was found to subsequently degrade to 8-cyano- 
5,6,7,8-tetrahydroquinoline-3-carboxylic acid. Circumstantial 
evidence suggested that it was the thioamide analogue of this acid.
The excretion of this compound in the patas monkey but not the rat 
probably reflected the more rapid U) -oxidation in the former species. 
Thus it is envisaged that 3-carboxylic acid formation proceeded 
more rapidly than desulphuration and because these acids were so 
readily excreted in urine a mixture of sulphur-containing and
desulphurated products appeared. In the rat, however, deslphuration 
evidently occurred more rapidly thanW -oxidation, so that the two 
carboxylic acid metabolites excreted were both nitriles. No evidence 
was obtained concerning the extent of metabolic desulphuration in man. 
The relationship between the metabolism and disposition of tiquinamide
The factors which affect the disposition of molecules have 
been discussed fully in Chapters I, VII, VIII and IX. Briefly, the 
most important factor is perhaps the relative lipid/water solubilities 
of the ionization state most prevalent at pH’s pertaining to plasma, 
tissues and urine, for example. Water-soluble, acidic molecules 
extensively ionized under these physiological conditions tend to be 
poorly taken up into tissues and rapidly excreted in urine. Conversely, 
lipophilic bases which are largely unionized are more likely to suffer 
widespread tissue distribution and retarded elimination resulting 
from'renal reabsorption and re-cycling processes such as gastric 
re-cycling.
Entero-hepatic circulation can substantially delay excretion
of molecules which af*e relatively lipophilic themselves but which
form polar conjugates of high molecular Weight which are extensively
excreted in bile but subsequently hydrolysed .by the action of bacteria
in the large intestine and re-absorbed. Factors which promote the
extensive localization of molecules in particular tissues thereby
retard their elimination. Thus, very lipid-soluble molecules which
accumulate in fat depots will be poorly eliminated, as will molecules
*
predisposed to high affinity binding either to plasma proteins or 
to proteins, nucleic acids, pigments or other macromolecules in 
tissues.
Study of the metabolism of tiquinamide has revealed why the 
majority of the products in patas monkey and man were rapidly excreted 
in urine and why this was not so in the rat. Two important routes 
of metabolism in all species studied involved U>-oxidation to 
3-carboxylic acids and 5-hydroxylation with subsequent glucuroniae 
conjugation. In the patas monkey and in man, the predominance of 
these reactions resulted in the majority of the dose being excreted 
in an acidic fraction comprising 3-carboxylic acids end glucuronides. 
Because such compounds are poorly taken up into tissues, are fully 
ionized at physiological pH's, and are very water-soluble, they were . 
rapidly excreted in urine. This constituted virtually the only
route of excretion of these compounds because even the glucuronide 
conjugate resulting from tiquinamide was of too low a molecular 
weight to exceed the relatively high molecular weight threshold for 
biliary excretion believed to exist in primates. In the rat, the 
lower extent of 6a) -oxidation and the lower proportion of 5-hydroxylated 
products which were subsequently conjugated resulted in a smaller 
proportion of total metabolites than in the other two species being 
present in the acidic fraction. Consequently, in the rat the phase 
of rapid urinary excretion was of lower significance than in the 
patas monkey or man.
. What is less clear is the reason for the slow elimination of 
the alternative products in the rat. .The only known metabolites 
suspected of being slowly eliminated were in the basic fraction 
containing unchanged drug, its nitrile derivative, and the 5-hydroxy- 
and 3-hydroxymethyl analogues. It is suggested that this fraction 
was more pronounced in the rat than in the other two species because 
oxidation to the carboxylic acids was less extensive and the degree 
of conjugation of the 5-hydroxylated metabolite was lower. These 
basic compounds could have been poorly excreted in urine because 
their low pKa values and relatively high lipophilicity predisposed 
them to renal reabsorption. In addition, these same properties 
would have promoted uptake into tissues and gastric secretion of 
these compounds. Tissue distribution studies in the rat have revealed 
a widespread evep distribution of drug-related products without 
evidence" of a depot tissue from which metabolites were slowly 
leached out. It seems likely that the material distributed in 
the tissues included the basic metabolite fraction. Gastric 
secretion resulted in the stomach and its contents being the major 
site of accumulation and it is probable that the basic metabolite 
fraction was involved. Although drug-related products were found 
to be eliminated from this site at a slow rate identical to that 
from plasma, at no time were the concentrations* in this organ high 
enough to constitute a depot controlling the rate of elimination.
It was more likely that continued gastric re-cycling following 
re-absorption' of these compounds from the small intestine 
contributed to their slow elimination.
A metabolite different from any of the major urinary end-products 
was found circulating in rat plasma at a time when the rapid phase 
of urinary elimination had ceased. This was a polar product of
similar chromatographic properties to a metabolite seen to the extent 
of 2-3% of the dose in 0-6 h bile. It was the predominant component 
in plasma at 25 h, but in view of its high polarity, it was unlikely 
that it was itself slowly eliminated. Possibly it represented the 
product of further metabolism of a compound in the basic fraction 
of tiquinamide metabolites.
The extent of biliary secretion of tiquinamide metabolites in 
the rat was approximately consistent with the amounts of drug-related * 
material appearing in the faeces. Thus there was no evidence that 
entero-hepatic circulation contributed substantially to the slow 
elimination in the rat. Whilst faecal excretion in the rat was a 
relatively minor route of excretion, it occurred more extensively 
than in the patas monkey or man. This was believed to reflect more 
extensive biliary secretion in the rat as a result of the lower 
molecular weight threshold for biliary secretion i.n this species 
than in primates (Millburn, Smith and Williams, 19^7; Aziz et al.,
1971; Smith, 1973).
In conclusion, it can be said that the greater extent of formation 
of 3-carboxylic acids by Ui -oxidation and the greater extent of 
conjugation of 5-hydroxylated products in the monkey and man comnared 
to the rat promoted more rapid elimination in these species.
Conversely the greater amounts of unconjugated basic metabolites 
in the rat may have hindered the elimination of drug-relzted 
material as a result of renal readsorption, tissue uptake and gastric 
re-cycling.
The biological significance of the metabolism and disposition of 
tiquinamide
Oral bioavailability: The limited amount of data available on the
oral bioavailability of tiquinamide suggested that it was of a 
moderate order and probably somewhat, less than that of- cimctidine. 
Although rapidly absorbed, tiquinamide was found to be rapidly and 
extensively metabolized. k substantial proportion of metabolism 
probably occurred during the first-pass, since the toluene-soluble 
fraction of basic compounds, which included the unchanged drug, 
in man represented maximally 60% of total radioactivity in plasma, 
at the time of peak plasma concentration, around 0.5. h after dosing.
It was possible that the true bioavailability was even less than this 
value, since it is known, at least in rats and monkeys, that this
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fraction contained other metabolites apart from unchanged tiquinamide* 
By comparison, cimetidine undergoes a relatively low degree of • 
metabolism, being excreted predominantly unchanged in urine (Taylor, 
Creewell and Bartlett, 1978) and has an oral bioavailability as 
high as 72% (Griffiths, Lee and Taylor, 1977)* It seems, however, 
that the lower bioavailability of tiquinamide is more than offset 
by its higher intrinsic^potency, since, as discussed previously 
(Chapter I p. 15 ), -75 mg tiquinamide elicited 60-70% inhibition 
of acid secretion in man, whereas this order of inhibition was only 
achieved after a 200 mg dose of cimetidine (Burland et al., 1975).
Site of gastrointestinal absorption: Investigations into the 
predominant site of absorption of tiquinamide did not demonstrate 
substantial gastric absorption of the drug in normal conscious
animals. However, there was an indication that the compound had •
• « • oa potential for gastric absorption if the pH conditions promoted
the presence of the unionized drug. Administration of a loading 
dose as a buffered tablet or in combination with an antacid might 
conceivably promote gastric absorption which would be repeated after 
subsequent doses once gastric secretion came under effective control 
by. .the drug. Gastric absorption of tiquinamide might improve on the 
availability at its presumed site of action in the gastric mucosa 
by delivering the drug there directly and thus avoiding initial first- 
pass metabolism.
The relationship between plasma concentration of drug and its anti- 
secretory* effect: Although a clear relationship between plasma 
concentrations of the drug and the intensity and duration of its 
pharmacological effect has not been established, there is circum­
stantial evidence to suggest that the drug rather than its metabolites 
is primarily responsible for its anti-secretory activity. Experiments 
to examine the time-course of inhibition of acid secretion by 
tiquinhmide in pylorus-ligated rats c^ fter 30 mg/kg subcutaneous 
dose had shown that the effect on gastric secretory volume was 
maximal (SQ-90% inhibition) until approximately 7 h after dosing, 
and remained statistically significant (p <0.01) until 13 h after 
dosing. The effect on acid concentration persisted a little longer, 
until 2b h after, drug administration (Beattie et al., 1979*0. 
Simultaneous studies on the time-course of the drug and metabolites 
demonstrated that the decline of the toluene-soluble fraction of
CSC
radioactivity in plasma and stomach wall occurred rapidly over the 
same time-scaJLe as the decline of anti-secretory activity 
(Chapter VIII. Fig. VIII.6. 3y contrast, total metabolites in plasma 
declined slowly and, more significantly, those in the stomach wall 
remained constant at least until l^ f h after dosing. It was thus 
likely that the primary anti-secretory agent v/as a constituent 
of the toluene-soluble basic fraction. It has been established 
(Chapter II. p. b5 ) that this fraction contains the unchanged drug 
and has a similar time-course in plasma (Chapter VII. p.lo2).
The significance of the plasma half-life of tiquinamide for the 
control of nocturnal acid secretion: It was postulated in Chapter I 
(p. 33 ) that an ideal plasma half-life for a gastric anti-secretory 
compound v/ould be determined by the need to maintain effective 
control of nocturnal acid secretion. Thus a half-life of 
approximately 8 h, equivalent to the average period of sleep, would 
be useful. In this respect, the half-life of tiquinamide, Ground 
2 h in man, was somewhat short but was no worse than that of cimetidine 
(Griffiths, Lee and Taylor, 1977; Bprland et al. , 197.5)»
The pharmacological properties of tiquinamide metabolites: The major
identified metabolites of tiquinamide were found difficult to 
synthesize and thus their pharmacological properties have not been 
evaluated. However, the anti-sepretory properties of one metabolite, 
the nitrile derivative of tiquinamide (8-cyano-5»7,8-tetrahydro- 
3-methyl quinoline) have been studied. This compound was found to 
be only weakly active (Beattie et al., 1977).
Furthermore, studies of structure-activity relationships amongst 
a number of related compounds have suggested that although the 
thioamide group may be substituted, for example by an alkyl group, 
its presence is very important to the manifestation of anti-secretory 
activity by this class of substituted'5 , 7 ,8-tetrahydroquinoline 
compounds (Beattie et al., 1977). This requirement for the thioamide 
group and an additional one for a heterocyclic nitrogen in close 
proximity were consistent with the findings of other workers with 
respect to so me substituted thioacetamide compounds active as anti- 
secretory agents (Malen, Danree and Pascaud, 1971; » Phillips
and Sause, 1972).
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Thus it seems unlikely that metabolites of tiquinamide identified 
as nitriles contributed significantly to the anti-secretory effects.
In view of the possibility that metabolites of tiquinamide existed 
which retained an intact thioamide group, some contribution by 
these compounds to the pharmacological activity cannot be excluded. 
Thioamide containing 3-carboxylic acids would perhaps be less useful 
as anti-secretory agents than the parent drug since their physico­
chemical properties would not promote uptake into the acidic 
environment of the stomach, but would rather lead to rapid urinary 
elimination. However, thioamide-containing 5-hydroxylated or 
3-hydroxymethyl compounds may have had significant anti-secretory 
activity in their own right. Taking all these considerations into 
account, it would appear that unchanged tiquinamide was the largest 
contributor to the anti-secretory activity, but that thioamide- 
containing metabolites, when present, may have played a part.
Whilst the cardiovascular properties of the majority of the 
known metabolites could not be evaluated because of the difficulties 
associated with their synthesis, there was indirect evidence to 
implicate the unchanged drug-in the tiquinamide-induced tachycardia. 
Firstly, the nitrile derivative of tiquinamide had no significant 
effect on blood pressure or heart rate (Waterfall, 1978). This 
nitrile was a. known metabolite of tiquinamide and one which was 
likely to represent an intermediate between the drug and the 5- 
hydroxylated compounds and 3-carboxylic acids which represented 
the major products of further metabolism. Therefore the absence 
of nitrile-induced tachycardia directly implicated the thioamide 
group. Methyl substitution of the thioamide group in tiquinamide 
and two related compounds was found to abolish the tachycardia, 
confirming the link between the cardiovascular properties of these 
compounds and the stereochemistry around the thioamide group. 
Furthermore the unchanged drug was found to cause relaxation, of 
vascular smooth muscle in vitro in the isolated, perfused rat 
mesentery preparation. This finding suggested a possible mechanism 
for the tachycardia involving a reflex response to the lowering 
of blood pressure, mediated by the baro-recentors.
A possible role for the 3-carboxylic acid metabolites of 
tiquinamide in its cardiovascular properties was considered because 
nicotinic acid is a. peripheral vaso-dilat or, though, fairly weak
(Goodman and Gilman, 1975) and because the structurally related 
compounds fusaric acid and picolinic acid are known to decrease blood 
pressure and induce tachycardia (Antonaccio, Cote^and Cavaliere,
1976). However, this possibility had to be excluded because Wy-23995 
(5,6,7,8-tetrahydroquinoline-8-thiocarboxamide) was a more potent 
inducer of tachycardia in the rat than was tiquinamide. This compound 
could not form 3-carboxylic acid metabolites because it contained no 
aromatic methyl substituent. On the same grounds, 3-hydroxymethyl 
metabolites could not have been implicitly involved.
Thus the available evidence suggested that the unchanged drug . 
could cause the tachycardia without the need for a prior metabolic 
step. Thioamide-containing metabolites may, however, have contributed 
to this effect when present.
The acute toxicity of tiquinamide metabolites: The desulphuration of 
tiquinamide in vivo had potential implications for the acute toxicity 
of the compound because it raised the question of whether hydrogen 
sulphide was generated in tissues as a by-product. Hydrogen sulphide 
is a very toxic gas, inducing symptoms ranging from headache, fatigue 
and respiratory tract irritation at lower concentrations to death 
by respiratory failure at higher levels (Milby, 1962). It has an
value in rats as low as 0.3-0.5 mg/kg when administered 50 •
intravenously. Furthermore, its generation in tissues as a result
t
of metabolic desulphuration had been, implicated in the high acute 
toxicity of mono-substituted aryl thioureas such as phenylthiourea 
(LD,_q 5 mg/kg in rats; Scheline, Smith and williams, 19^1). However, 
tiquinamide was found to have a remarkably low acute toxicity in 
animals. LDP va3r.es in rats and mice were as high as 163^ mg/kg
D ' - i
and k-00 mg/kg respectively after oral administration (West-Watson, 
197*0. Thus if hydrogen sulphide was liberated in tissues, the 
rate of generation was not sufficiently fast to exceed the rate of 
its subsequent elimination. Alternatively, the desulphuration may 
have proceeded by an oxidative route, via the sulphoxide, with 
subsequent degradation to the nitrile, as discussed -previously 
(Chapter IV. p. 87 )•
The low acute toxicity of tiquinamide also implied that the 
nitrile metabolites were innocuous. This was consistent with their 
stability to further metabolic alteration. In this respect they
2 35
resembled aryl cyanides rather than alkyl cyanides which have a
high acute toxicity as a result of rapid hydrolysis to the corresponding
amides with consequent release of hydrogen cyanide (Williams, 1959h).
The choice of rat and patas monkey as snecies for chronic toxicity 
studies: The results of the comparison of metabolism and disposition
of tiquinamide in rat and patas monkey with those in man confirmed the 
usefulness of both these species in evaluating the potential long­
term toxicity of the drug. Whilst the patas monkey was overall a 
better model for man, the absence of the fully aromatized 8-cyano- 
quinoline-3-carboxylic acid in this species meant that the toxico- 
logical properties of this compound would have been overlooked if 
the patas monkey alone had been used to evaluate the long term 
toxicity of tiquinamide. The additional use of the rat, which, like 
man, did form this metabolite provided full compensation for the 
omission.
The extremely slow elimination of some metabolites in the rat
apparently had no serious toxicological consequences. The most
significant abnormality observed after repeated daily administration
of tiquinamide at doses up to *f00 mg/kg for 26 weeks was an effect
on serum cholesterol concentrations, which were elevated by up to
60% in a non-dose related fashion (Paterso^ (197*0. However,
there was a similar trend to elevated serum cholesterol levels in 
«
patas monkeys. Although values for this parameter in the monkey 
did not fall outside the normal range for this species (Paterson,
1975), the percentage elevations over control values (38% in males 
and kS% in females after doses up to 250 mg/kg daily for 2k weeks) 
were not markedly lower than those in the rat (Paterson, (1975))*
Thus the species difference in elimination did not result in any 
clear soecies difference in toxicity.
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A mixed isotope method for the study of gastric absorption of drugs
D. M. P ie r c e *, R. A. F r a n k l in , Wyeth Laboratories, Huntercombe Lane South, Taplow, Maidenhead, Berks., U.K.
The most widely used method for studying gastric 
absorption of drugs is that devised by Shanker, Shore 
& others (1957), which involves the measurement of 
the decline in concentration of drug in the pylorus- 
ligated stomach. In the absence of adsorption to the 
stomach wall, this provides a means of studying the 
potential for gastric absorption of a drug in relation 
to its lipophilicity and pKa and for comparing this 
potential with those of other drugs. However, the 
method is subject to certain limitations. Firstly, it does 
not permit evaluation of the significance of gastric 
absorption in the presence of normal gastric emptying. 
Secondly, the presence of an anaesthetic as an 
accessory to the pylorus ligation may itself influence 
the course of gastric absorption by altering gastric 
motility and blood flow to the stomach. Hence if the 
significance of gastric absorption of a particular drug 
under normal physiological conditions is to be 
properly evaluated, the measurement of the rate of 
this process should be performed in animals with a 
functioning pylorus and an allowance made for 
disappearance of drug from the stomach by gastric 
emptying.
Several workers have described the use of non­
absorbable markers in absorption studies to make an 
allowance for loss of drug by gastric emptying and also 
for dilution of stomach contents by gastric secretion. 
For example, Cooke & Hunt (1970) used the marker 
phenol red when studying the gastric absorption of 
acetylsalicylic acid in man. The method relies on the 
principle that changes in drug concentration due to 
gastric emptying and dilution of stomach contents 
parallel similar changes in the concentration of the 
marker. Any additional decline in drug concentration 
in gastric contents must then result from gastric 
absorption. In previously reported studies, the non­
absorbable marker was unlabelled and was determined 
spectrophotometrically by an assay separate from that 
used to measure concentrations of drug in stomach 
contents. The low sensitivities of the assay methods 
necessitated the use of relatively high concentrations 
of non-absorbable markers. Under these conditions, 
the method is subject to the criticism that the marker 
itself may influence the absorption of the drug 
(Beerman, Groschinsky-Grind & Rosen, 1976).
The present communication describes a modification 
which simplifies the procedure when radiolabelled drug 
is available. The ratio of concentration of a r e ­
labelled drug to that of a 3H-labelled marker is used 
to make automatic compensation for effects of volume 
changes and gastric emptying without the need for 
separate assays. The ratio of 14C/3H in gastric contents
* Correspondence.
remains constant, despite gastric secretion and gastric 
emptying, unless drug is absorbed from the stomach. 
In this case, the 14C/3H ratio declines at a rate equal to 
the rate of gastric absorption of the drug. Further­
more, simultaneous determination of the gastric 
emptying rate allows calculation of the total percentage 
of the dose absorbed from the stomach.
The drug chosen for study of gastric absorption by 
this method was [14C]salicylic acid, since Shanker & 
others (1957) had shown it to be well-absorbed from 
the pylorus-ligated stomach of the rat, and not signifi­
cantly adsorbed to stomach wall. The marker was 
[3H]inulin, an inert substance negligibly absorbed from 
the gastrointestinal tract (Miller & Schedl, 1970), and 
not subject to significant exchange of tritium with 
water under physiological conditions (Marlow & 
Sheppard, 1970). The animals used were one male 
and two female patas monkeys (Shamrock Farms 
Ltd., Brighton, Sussex), 3-0-3-5 kg, fasted overnight. 
The dose (0'5 mg kg-1) of salicylic acid was admini­
stered by oral intubation such that each animal received 
5 ml kg-1 of a solution containing 100/xgmL1 [14C]- 
salicylic acid and 1 jug ml-1 [3H]inulin (The Radio­
chemical Centre, Amersham, Bucks) in isotonic saline. 
Immediately after dosing and subsequently at 10 min 
intervals for 1 h, aliquots of approximately 1 ml of 
gastric contents were aspirated and after the hour the 
entire stomach contents were aspirated. At the end of 
the period of serial sampling, stomach contents were 
aspirated so that the amount of remaining [3H]inulin 
could be assayed. Because of the possibility of incom­
plete recovery of stomach contents in the final gastric 
wash, the efficiency of this recovery was checked by 
introduction of [14C]polyethylene glycol (PEG 4000) 
(14C-PEG) (The Radiochemical Centre).
14C-PEG (8-15 p. Ci) was administered by oral intuba­
tion of 20 ml of a 12 /xg ml-1 solution in isotonic saline, 
and was recovered within 3 min of dosing by washing 
out with 3 x 50 ml isotonic saline. Radioactivity ad­
ministered as 14C-PEG 4000 was in large excess over 
that of any remaining [14C]salicylic acid, which thus did 
not interfere with the determination of the 14C-labelled 
marker. Mixing of 14C-PEG 4000 and [3H]inulin in 
stomach contents was assumed to have been achieved by 
the regular contractions of the stomach and by subse­
quent washes. Three 50 ml portions of isotonic saline 
were introduced into the stomach and the gastric con­
tents aspirated after each wash. Recoveries of 14C-PEG 
4000, determined in 2 animals only, were 90 and 101 %. 
Consequently no compensation for loss of gastric con­
tents was considered necessary. Samples of gastric 
contents and the pooled gastric washes were centri­
fuged to precipitate any solid particles. Tritium and 
14C concentrations in suitable aliquots were assayed
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by liquid scintillation counting under conditions in 
which the two isotopes could be separately determined.
The half-life of gastric absorption was calculated 
from the slope of the regression line relating logx0 
14C/3H ratio to times after dosing. The gastric emptying 
half-life was determined from the amount of [3H]- 
inulin not emptied from the stomach in the 60 min 
after dosing. The calculation assumed monoexponential 
gastric emptying, as established by Hunt & MacDonald 
(1954) from studies in man. The method of calculation 
used the formula:
Gastric emptying t1/2 ==
0-301 t 
logio (Xo)
(Xt)
The total percentage of the administered dose 
absorbed from the stomach was calculated from the 
rate constants for gastric absorption and gastric 
emptying, kas and kge respectively, as follows:
Percentage dose
kas +  k:
x 100 %, where k =
ge
0-693 
11/2
As illustrated in Fig. 1, the ratio of [u C]salicylic acid 
to [3H]inulin declined monoexponentially with time 
(correlation coefficient =  —0-996), indicating that 
substantial gastric absorption of salicylic acid had 
taken place. The mean gastric absorption half-life 
(db s.e.m.) was 12-8 ±  1-8 min. The mean gastric 
emptying half-life ( ±  s.e.m.) was 37-3 ±  9-0 min, in 
good agreement with the value of 30 min previously 
reported by Franklin (1975). The mean percentage of 
the administered dose absorbed from the stomach 
(±  s.e.m.) was 69-0 ±  6-1 %.
Thus, this mixed isotope ratio method provides a 
simple means of determining the rate of gastric 
absorption of a drug without recourse to artificial 
preparations involving surgical ligation of the pylorus. 
Whilst there are existing methods to compensate for
o
o
10-
x
CO
O
6020
Time (m in)
F ig . 1. The gastric absorption of [14C]salicylic acid 
(0-5 mg kg-1) in patas monkeys. One male and two 
female animals each received by oral intubation 
5 ml kg-1 of a solution of 100 fig ml-1 [14C]salicylic 
and 1 fig ml-1 [3H]inulin. The ratio of 14C to 3H in gastric 
contents was measured at intervals from 0-60 min 
after dosing and values were expressed as a percentage 
of the ratio in the dose before administration. Each 
result is the mean ±  s.e.m. of determination in the 3 
animals.
changes in drug concentration resulting solely from 
gastric secretion and gastric emptying, this method 
confers the greater convenience of a single assay by 
comparison with the more usual determination of drug 
and non-absorbable marker by separate specific assays. 
Finally, the method incorporates the determination of 
gastric emptying simultaneous with that of absorption, 
thus permitting a simple assessment of the total extent 
to which gastric absorption occurs under conditions 
of unimpaired gastric emptying.
The authors gratefully acknowledge the skilled 
technical assistance of Mr S. Meacham in the collection 
of samples of gastric contents.
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. 'en pimozide at doses of 8, 6 and 4 mg daily 
^  successive days. All five improved. As shown 
Table 1, pimozide, in contrast to  fenfluramine, 
oduced a marked reduction in the manic 
^ jn ten t of the patient’s speech and euphoria; it 
iso  improved behaviour w ithout leading to 
sedation. Subsequently there was a tendency to 
relapse on the fixed dose of pimozide (4 mg) 
daily, but increasing the dose in two patients up 
to  8 rag twice daily was successful in controlling 
their manic symptoms.
While our findings confirm the earlier report 
(Pearce, 1973) that fenfluramine improves manic 
symptoms, we consider that it did so by 
producing sedation accompanied by a reduction 
in m otor activity, rather than by lowering mood 
or manic ideation. The biochemical basis for this 
sedative effect o f fenfluramine is uncertain. It is 
known tha t fenfluramine releases 5-HT and 
blocks its reuptake in the CNS (Garattini & 
Samanin, 1976), and such an action might 
potentiate the activity of those 5-HT neurones of 
the median raphe nuclei which are thought to  be 
involved in slow wave sleep (Jouvet, 1972). This 
interpretation runs counter to the view that 
mania is due to  over-activity of 5-HT pathways 
and that blockade of 5-HT receptors with 
methysergide is a specific treatm ent for mania 
(Dewhurst, 1969). Unfortunately for this view 
Coppen, Prange & Whybrow (1969) failed to 
confirm that methysergide had any anti-manic 
activity, on the contrary it seemed to make 
m atters worse.
In contrast to the general sedative action of 
fenfluramine, pimozide appeared to affect the 
core symptoms of mania more directly. This 
finding is consistent w ith the idea that mania 
results from over-activity o f DA pathways.
J. COOKSON & T. SILVERSTONE
Academic Unit o f  Human Psychopharmacology, Medical 
Colleges o f  St. Bartholomew’s and The London 
Hospitals, The German Hospital, Ritson Road, London 
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PHARMACOKINETIC STUDIES ON TIQUINAMIDE, 
A NOVEL INHIBITOR OF GASTRIC ACID SECRETION
Tiquinamide (3-m ethyl-5,6,7,8-tetrahydroquino- 
line-8-thiocarboxamide, Figure 1) is a new com­
pound having po ten t effects as an inhibitor of 
gastric acid secretion in a variety of animal species 
(Curran, Crossley & Hill, 1976). It inhibits basal 
acid secretion and has a wide spectrum of activity 
against chemical stim ulants of acid secretion e.g. 
pentagastrin, histamine and the cholinergically- 
mediated stimulant, carbachol. Studies in our 
laboratories (Beattie, personal com m unication)
have shown tha t it is not a classical anticholinergic 
drug, as dem onstrated by its lack o f activity in the 
guinea-pig isolated ileum preparation at concen­
trations up to  1 0 - 4 M. It does have weak histam ine 
H2-receptor antagonist activity, but this is 
probably a relatively minor feature o f its pharm a­
cological profile, since it is substantially more 
potent in inhibiting basal acid-secretion than  the 
established H2‘-receptor antagonists, m etiam ide 
and burimamide. Preliminary studies in four
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Figure 1 Structural formula of tiquinamide, with 
asterisk denoting location of 14 C-radiolabel.
hum an volunteers have indicated approxim ately 
50% inhibition of pentagastrin-induced acid 
secretion after a single 40 mg oral dose 
(Lancaster-Smith, personal com m unication).
The pharm acokinetics and metabolism of 
[ 14C]-tiquinam ide have been investigated after 
adm inistration to  two healthy male volunteers. In 
one study, each subject ingested a gelatin capsule 
containing 5 uCi of radio labelled tiquinam ide HC1 
in a to ta l dose of 20 mg. In a second study, the 
dose was 50 mg containing 50 ^Ci of the radio­
labelled drug. Blood was sampled from the 
cephalic vein at frequent intervals up to  48 or 72 h 
after dosing. Urine was collected over short 
intervals during the first 24 h after drug adminis­
tration , and subsequently daily. Faecal samples 
were collected daily.
Radioactivity in plasma and urine was assayed 
by liquid scintillation counting. Faecal samples 
were homogenised and small portions digested by 
the m ethod of Mahin & Lofberg (1966). Aliquots 
o f plasma and urine were extracted w ith toluene. 
Extracted radioactivity contained unchanged 
tiquinam ide, but would also have included some
non-polar metabolites. The chromatograph', 
pattern  of metabolites was investigated in 0*24 ^  
urine from  one subject who had received t l  
50 mg dose. Urine was applied to  a column 
XAD-2 Amberlite resin and eluted w ith methano^ 
Methanolic extracts were hydrolysed by molluscari 
/3-glucuronidase/sulphatase (Sigma Chemical Co. 
L td) and subjected to  silica gel thin-layer chroma­
tography in the following solvents:
(a) diethyl e th e r-e th a n o l—am monia (60:40:10)
(b) dim ethylform am ide—diethylam ine—ethanol— 
ethyl acetate (1 :1 :6 :12)
(c) ethyl acetate—m ethanol—water (65:10:5) 
Chromatograms were scanned by a Panax radio­
chromatogram scanner.
Absorption was very rapid, as indicated by the 
appearance of the  peak concentrations of toluene- 
soluble radioactivity in plasma at 0.5-1 h after 
dosing (Table 1). Furtherm ore the low  faecal 
recovery of radioactivity, together with the high 
recovery of urine constitute evidence that 
absorption was extensive (Table 2).
Elimination of toluene-soluble radioactivity, 
from plasma occurred rapidly in a m onoexponen­
tial fashion, having a half-life o f 2.2 ± 0.2 h. This 
represented the maximum plasma half-life of 
unchanged tiquinamide. Total radioactivity was 
eliminated somewhat more slowly from plasma. 
Peak concentrations were attained within 1-3 h 
after dosing, and declined to  25-35% of these 
maxima by 48 h after adm inistration.
Excretion o f radioactivity occurred quickly and 
almost entirely in the  urine. In the first 24 h after 
drug adm inistration, 61-88% of the dose was 
eliminated by this route. These figures had risen to 
66-92% by 4 days after dosing. Not more than 2%
Table 1 Toluene-soluble and total radioactivity in plasma of two male volunteers following oral administration 
by capsule of [I4 C] -tiquinamide HCI (20 and 50 mg)
Subject
20 mg 50 mg
ML DM ML DM
Time after 
dosing (h)
pg f 14 C]-tiquinamide HCI equivalents/ml plasma
0.5 0.29 (0.19) 0.34 (0.20) 0 .22 (0 .13 ) 0.88 (0.46)
1 0.37 (0.18) 0.45 (0.19) 0.74 (0.38) 1.46 (0.64)
2 0.38 (0.15) 0.37 (0.11) 1.02 (0.38) 1.16 (0.34)
3 0 .36(0 .10) 0.30 (0.06) 1.09 (0.33) 1.08 (0.27)
4 0.31 (0.07) 0.28 (0.05) 1.01 (0.22) 0.99 (0.19)
6 0.26 (0.04) 0.21 (0.02) 0.84 (0.12) 0.87 (0.12)
8 0.24 (0.02) 0.20 (0.01) 0.72 (0.05) 0.76 (0.07)
12 0.19 (0.01) 0.16 « 0 .0 0 8 ) 0.57 (0.02) 0.59 (0.02)
24 0.13 (<0.008) 0.13 « 0 .0 0 8 ) 0.43 « 0 .0 0 3 ) 0.50 « 0 .0 0 3 )
48 0.12 (<0.008) 0.11 « 0 .0 0 8 ) 0.37 « 0 .0 0 3 ) 0.40 « 0 .0 0 3 )
72 NS (NS) NS (NS) 0.34 (<0.003) 0.39 « 0 .0 0 3 )
96 NS (NS) NS (NS) 0.32 « 0 .0 0 3 ) NS (NS)
Values in brackets represent toluene-soluble radioactivity. 
NS = No sample
Br. J. clin. Pharmac. (1976 ), 3 LETTERS TO THE EDITORS 945
T a b le  2  Cumulative urinary and faecal excretion of radioactivity in two male volunteers following oral 
administration by capsule of [14 C] -tiquinamide HCI (20 mg and 50 mg)
20 mg 50 mg
Subject ML DM ML
Total
DM
Time after % o f radioactivity in administered dose
dosing (h) Urine Faeces Urine Faeces Urine Faeces Urine Faeces
3 33.8 37.5 12.7 11.0
6 48.4 — 39.8 50.6
9 59.6 60.2 NS 55.0
12 66.3 NS 56.9 78.0
24 73.0 <1.6 66.0 <2.1 60.8 NS 87.5 0.8
48 75.2 <0.2 68.2 <2.7 63.3 4.1 90.6 4.0
72 76.3 2.4 68.7 <2.7 64.6 5.2 91.6 7.6
96 76.8 NS 69.1 1.7 65.7 5.6 92.0 NS
120 NS NS NS NS NS 5.9 NS NS
I 76.8 2.4 69.1 1.7 65.7 5.9 92.0 7.6
d total 79.2 70.8 71.6 99.6
NS = No sample
of radioactivity in urine was unchanged tiquin­
amide. Only 2-8% of the dose was excreted in 
faeces in 4 days.
The presence of at least two major metabolites 
was detected in urine after hydrolysis w ith 
|3-glucuronidase/sulphatase. Neither of these 
metabolites had values corresponding to  those 
of the nitrile, which would have resulted by loss of 
hydrogen sulphide from the thiocarboxam ide 
group. The chrom atographic properties of one 
metabolite were similar to, though not identical 
with, those of 3-m ethyl-5,6,7,8-tetrahydro- 
quinoline 8-carboxylic acid, the expected product 
of hydrolysis o f the thioam ide group of 
tiquinamide. Furtherm ore, it could be extracted 
into diethyl ether from  acidified urine (pH 2), and 
hence is acidic in  nature. A more detailed study of 
the nature of the major metabolites is in progress 
and will be reported separately.
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SALIVARY ANTIPYRINE HALF-LIFE: 
A USEFUL MEASURE OF HEPATIC DRUG METABOLISM
The rate of disappearance of antipyrine from 
plasma after a single oral dose has been shown to  
be a useful indicator in man of the drug meta­
bolising capacity of the liver (Vessell & Page, 
1968). With the proliferation of new drugs and the 
increasing interest in the effect o f these agents on 
bodily functions, newer m ethods of examining the 
drug metabolising capacity of man have been
discovered, such as the urinary excretion of 
D-Glucaric acid and plasma glutam yl transpep­
tidase activity (Davidson, M cIntosh & Ford, 
1974). However, despite these new  m ethods, 
measurement o f plasma antipyrine half-lives 
remains a reliable m ethod for assessing hepatic 
drug metabolism. The problem  w ith m easurem ent 
of the plasma antipyrine half-life is th a t frequent
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blood samples are required over a 24 h period, 
which makes study of outpatients difficult. 
Recently, concentrations of a num ber of drugs 
(Huffman, 1975), including antipyrine (Vessel, 
Passananti, Glenwright & Dvorchik, 1975), have 
been measured in the saliva and we decided to  see 
if salivary antipyrine half-lives could be correlated 
with the disappearance rate of antipyrine from 
plasma, thus allowing us to  carry out drug 
metabolism studies on outpatients as well as 
inpatients.
Antipyrine in a dose of 10 mg/kg was given to  
six subjects (three normal volunteers and three 
patients with rheum atoid arthritis). Blood was 
collected 6 h, 12 h, 20 h and 26 h after ingestion. 
At the same tim e as blood was taken, saliva (3 ml) 
was collected in a container and centrifuged to  
remove debris. Blood was centrifuged at 2,000 
rev/min, and the  resultant plasma and saliva stored 
at 4° C until antipyrine estim ation was carried out, 
using the m ethod of Brodie, Axelrod, Soberman & 
Levy, 1949). A fter a period of at least 4 days, 
salivary antipyrine half-lives were repeated using 
the same dose of oral antipyrine.
From  Table 1 it can be seen tha t there is no 
significant difference between the plasma and 
salivary antipyrine half-lives. The mean plasma/ 
saliva ratio for antipyrine concentration in these 
patients was 0.839 ± 0.09 s.d.). Regression analysis 
showed tha t the  correlation coefficient for 
antipyrine plasma v saliva half-lives was 0.76 and 
that for saliva (1) v saliva (2) half-lives was 0.98.
The advantage of measuring antipyrine in the 
saliva is tha t drug metabolism studies can be 
carried out in outpatients. Subjects can be given an 
oral dose of antipyrine and instructed as to  when
Table 1 Antipyrine half-lives (mean ± s.e. mean) in
six individuals
Ty2 (h)
Plasma 13.7 + 2.06
Saliva (1) 12.8 + 2.8
Saliva (2) 12.7 ± 4.0
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and how saliva samples are to be collected. 
Samples can be stored in the refrigerator aiid 
posted back in an envelope, thus negating another 
visit to  the clinic.
The m ethod shows a high degree of reproduci­
bility and the collection of adequate am ounts c/ 
saliva did not pose too  great a problem in this 
study, despite the fact tha t three of the patients 
were elderly females with rheum atoid arthritis and 
would perhaps have been expected to have less 
saliva than normal.
The m ethod is far more acceptable to  patients 
because blood sampling is no t required, though it 
was found to  be less aesthetically pleasing to  the 
medical and technical staff handling the saliva 
samples.
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